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  9   Introduction 
1. Introduction 
 
1.1 Haematopoiesis   
 
   The haematopoietic system is responsible for the production and maintenance of all 
types of blood and immune cells. It contains a supply of a range of different lineages: 
lymphoid cells, including B-lymphocytes, T-lymphocytes and nature killer cells; myeloid 
cells, including granulocytes, monocytes and macrophages; red blood cells (erythrocytes) and 
platelets (thrombocytes) (Figure 1.1). These mature blood cells have only limited life spans 
ranging from less than a day for granulocytes, to longer than 4 months for erythrocytes and up 
to several years for thrombocytes or memory T-cells (Abkowitz et al., 1996; Gunsilus et al., 
2001). Hence, a source of cells is needed which is preserved throughout an individual’s entire 
life. This source of cells is the multipotent haematopoietic stem cells (HSCs), and the process 
of continuous formation of blood cells is known as haematopoiesis. In adults, the dynamic 
process of haematopoiesis takes place in the bone marrow (BM), providing the 
haematopoietic cells with necessary supplies for survival, proliferation and differentiation 
(Kondo et al., 2003). The amount of active BM is about 2600 g, with roughly 1.3 × 10
12 
marrow cells. Every day, the HSCs are responsible for the formation of an estimated 1 trillion 
(10
12) mature blood cells of different lineages (Figure 1.1). These terminally differentiated 
blood cells are required for a variety of important functions, such as the transportat of oxygen 
and CO2 by the red blood cells, fighting infections (killing of pathological microbes e.g. by 
granulocytes and macrophages), immune surveillance (B- and T-cells) and stopping bleeding 
by the platelets. In addition to the great productivity, haematopoiesis is remarkably stable, i.e. 
even in periods of extraordinary demand, blood cell production normally never becomes 
exhausted throughout life. 
 
1.1.1 Haematopoietic Stem Cells 
 
Haematopoiesis is generally regarded as an irreversible hierarchy with just a few 
HSCs at the top of the tree. These HSCs can give rise to early progenitors committed to the 
myeloid and the lymphoid lineages that proliferate and progressively differentiate into fully 
mature blood cells (Weissman et al., 2000) (Figure 1.1). The existence of HSCs was 
established in the early 1950s (Cole et al., 1952; Lorenz et al., 1951) and the first candidate 
HSC, the colony-forming unit-spleen (CFU-S), was described by Till and McCulloch in 1961. 
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With this historic experiment, the early haematopoietic progenitors were identified and their 
clonogenic nature was detected, in that they are capable of forming colonies (CFU-S) post-
transplantation in the spleen of ablated mice, as well as repopulating the ablated recipients 
(Till et al., 1961). Becker and colleagues first reported the clonal origin of mouse BM HSCs 
in 1960 (Becker et al., 1963). However, in the late 1970s, data from different groups indicated 
that the CFU-S cells do not represent the most primitive HSCs (Hodgson et al., 1979; Jones et 
al., 1990; Jones et al., 1996; Ploemacher et al., 1989). Later, evidence of the presence of 
HSCs was obtained by in vivo tracking of progeny from foetal liver cells marked with 
retroviruses in transplanted mice (Jordan et al., 1990). A turning point in the search for HSCs 
came in 1988, when the Weissman group used a combination of monoclonal antibodies 
against cell surface markers to successfully characterise and isolate murine HSCs by 
fluorescence activated cell sorting (FACS) (Spangrude et al., 1988). This led to rapid 
developments in the identification of HSCs. However, the exact identity of stem cells is still 
not known. At present, the definition of a HSC depends on three unique and important 
functional requirements, as described by Kondo and Weissman (Kondo et al., 2003). First, 
HSCs have the ability to self-renew, i.e. they can divide into two daughter cells, of which at 
least one remains identical to the parental cell. Second, HSCs can differentiate into all 
haematopoietic blood cell lineages, therefore, they are multipotent. Third, HSCs can 
reconstitute long-term and thereby rescue an ablated recipient.  
In the murine haematopoietic system, HSCs can be divided into the more primitive 
long-term repopulating (LT-HSC) and the less primitive short-term repopulating (ST-HSC) 
stem cells based on their function in transplantation (Morrison et al., 1994; Kondo et al., 
2003) (Figure 1.1). Both types of HSCs are derived from multipotent stem cells, which can be 
isolated from various tissues in foetal and adult animals. Multipotent stem cells are tissue 
specific and include, among others, HSCs, neuronal stem cells and hepatic stem cells (Kondo 
et al., 2003). During the progressive development of haematopoiesis from LT-HSC to mature 
blood cells, the self-renewal ability of the cells decreases, while their differentiation capability 
increases. 
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CLP CMP
Erythrocytes
Platelets
Granulocytes
Macrophages
MPP
LT-HSC
ST-HSC
GMP MEP
Pro-T NK -progenitor Pro-B
CFU-Meg  BFU-E
Megakaryocyte CFU-E
CFU-M  CFU-G 
T cells B cells NK cells
 
Figure 1.1: A schematic demonstration of the haematopoiesis of an adult mouse. The pluripotent HSC 
gives rise to multipotent progenitors that in turn give rise to committed progenitors with the final output 
being the mature, functional blood cells. Not all of the linear relationships in this figure have been proved. 
In the human haematopoiesis tree, the CMPs can directly give rise to CFU-Eo and CFU-Basso which yield 
the mature eosinophilic and basophilic cells (schematic presentation modified from Kondo et al., 2003). 
Abbreviations: CLP, common lymphoid progenitors; CMP, common myeloid progenitors; CFU, colony 
forming unit; GMP, granulocyte-macrophage progenitors; BFU, burst-forming unit erythroid; MEP, 
megakaryocyte-erythrocyte progenitor; MPP, multipotent progenitors. 
 
1.1.2  Identification of HSCs and Progenitor Cells 
 
HSCs and their progenitor cells have been extensively identified and enriched through 
size fractionation with density-gradient centrifugation, the use of cell-cycle active drugs, such 
as 5-FU (5-fluorouracil), and FACS. Presently, FACS analysis based on cell surface markers 
is the most commonly used method for identifying HSCs. The most important cell surface 
markers of murine haematopoietic stem and progenitor cells are shown in Table 1.1 (Kondo et 
al., 2003). All HSCs lack the expression of lineage-specific cell surface markers found on 
differentiated blood cells (lineage negative; Lin
–) but express the stem cell antigen-1 (Sca1) 
and show low or negative expression of the differentiation marker Thy-1 (Uchida et al., 
1992). These Lin
–/Sca1
+/Thy-1
lo/– (LST)
 stem cells fulfil all stem cell criteria and allow long-
term repopulation in lethally irradiated mice (Spangrude et al., 1988; Spangrude et al., 1990; 
Uchida et al., 1992). In addition, numerous other cell surface antigens have also been used in 
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an effort to isolate a more primitive HSC. For example, the co-selection of c-kit further 
enriches for HSCs. c-kit
+ murine BM progenitors were found to possess high haematopoietic 
potential. Hence, many researchers have utilised Lin
–/Sca1
+/c-kit
+ (LSK) cells as a source of 
murine HSCs (Ikuta et al., 1992; Orlic et al., 1993). Single Lin
–/Sca1
+/Thy-1
lo/–/c-kit
+ HSC 
cells give rise to complete long-term multilineage reconstitution and self-renewal in irradiated 
mice (Smith et al., 1992; Wagers et al., 2003). However, recent studies in mice and humans 
have provided evidence indicating that very early pluripotent HSCs display only low 
expression of c-kit (= c-kit
lo, phenotypically c-kit
–, with c-kit still detectable by RT-PCR) 
(Ikehara et al., 2000; Gunji et al., 1993; Katayama et al., 1993). The expression pattern of 
surface markers like Thy1.1 and Flk2 allow different cell types to be distinguished e.g. mature 
HSCs from a population with extensive self-renewal potential (Thy1.1
lo/Flk2
–) or a 
multipotent progenitor population with limited self-renewal ability (Thy1.1
–/Flk2
+) 
(Christensen et al., 2001). 
The human HSC has not been dissected as scrupulously as the mouse HSC due to the 
lack of an optimal stem cell assay. Human LT-HSCs express CD34 but not the surface marker 
CD38, and therefore exist within the CD34
+/CD38
– cell population (Morrison et al., 1995). In 
contrast, mouse LT-HSCs express CD34 at negative to low levels (Osawa et al., 1996). 
However, the stem cell pool is most likely a heterogeneous population and recent data 
demonstrate that candidate human HSCs can also be found within the CD34
– population 
(Zanjani et al., 1998; Bhatia et al., 1998). Furthermore, the murine HSC has a reversible 
CD34 expression depending on its activation status (Ogawa et al., 2002). 
The downstream progeny of murine HSCs have also been characterised based on the 
expression profile of cell surface markers. Thus lineage-restricted oligopotent progenitor cells 
for lymphoid (common lymphoid progenitor, CLP) and myeloid (common myeloid progenitor 
cells, CMP), and granulocyte-monocyte progenitor (GMP), and megakaryocyte-erythrocyte 
progenitor (MEP) lineages have been identified and are listed in Table 1.1 (Kondo et al., 
1997; Na Nakorn et al., 2002). 
Purification and isolation of murine and human HSCs is not an easy task because of 
the limited frequencies of these cells. For example, the frequency of long- and short-term 
repopulating cells in BM is roughly 1 in 10,000 and 1 in 2,000, respectively (Reya, 2003). 
Most isolation strategies rely on the expression of specific cell surface antigens, as described 
above. However, other properties of HSCs can also be utilised to isolate these primitive cells. 
The majority of HSCs are believed to be in a quiescent, non-cycling state (Ogawa et al., 
1993). Based on this theory, sorting for HSCs residing in the G0/G1 cell cycle phase with low 
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levels of RNA, measured with different stains like the DNA stain Hoechst 33342, can be used 
to purify these cells (Goodell et al., 1996). 
 
Cell type  Cell surface marker 
Multipotent LT-HSC 
ST-HSC 
MPP 
Lin
–, Sca1
+, c-kit
+, Thy-1
lo, IL-7Ra
–, FLK2
–, CD34
–/lo  
Lin
–, Mac1
lo, Sca1
+, c-kit
+, Thy-1
lo, IL-7Ra
–, FLK2
+, CD34
+ 
Lin
–, Mac1
lo, Sca1
+, c-kit
+, Thy-1
–, IL-7Ra
–, FLK2
+, CD34
+
Oligopotent CLP 
 
CMP 
Lin
–, Sca1
lo, c-kit
lo, Thy-1
–, IL-7Ra
+, FLK2
+, CD24
lo, CD27
+, 
CD34
+, CD43
+, TdT
+
Lin
–, Sca1
–, c-kit
+, Thy-1
–, IL-7Ra
–, CD34
+, FcϒRII/III
lo
Single 
lineage 
Pro T 
 
NK progenitor 
Pro B 
GMP 
MEP 
Meg progenitor 
Lin
–, CD4
lo/–, CD25
–, CD44
+, c-kit
+, Thy-1
–, IL-7Ra
+, FLK2
+, 
CD34
+
NK1.1
–, IL-2Rß
+
B220
+, CD19
–, CD24
–, CD43
+, AA4.1
+, IL-7Ra
– 
Lin
–, Sca1
–, c-kit
+, Thy-1
–, IL-7Ra
–, CD34
+, FcϒRII/III
+ 
Lin
–, Sca1
–, c-kit
+, Thy-1
–, IL-7Ra
–, CD34
–, FcϒRII/III
lo 
Lin
–, Sca1
–, c-kit
+, Thy-1
–, IL-7Ra
–, CD34
lo, FcϒRII/III
lo, CD9
+
 
Table 1.1: Cell surface markers of murine HSCs and progenitor cells. The different cell surface 
markers that have been identified from undifferentiated stem cell to differentiated lineage cells. Most 
abbreviations are explained in the main text (modified from Kondo et al., 2003). 
 
So far, the primary source of murine or human HSCs for therapeutic applications has 
been the adult bone marrow (BM). In human stem cell transplantation studies, the preferred 
cell source is BM cells from the peripheral blood (PB) after mobilisation of progenitor and 
stem cells from the BM to the PB through treatment with cytokines such as granulocyte-
colony stimulating factor (G-CSF). These mobilised cells can then be harvested by blood 
aphaeresis. Additionally, there is an increased number of short-term-repopulating-HSCs (ST-
HSCs) in this population, and these cells are reported to contribute to the transplantation 
efficiency (Korbling et al., 2001). Another source for human HSCs is umbilical cord blood 
(CB). These cells are potentially the best source for transplantation since they have been 
demonstrated to have a competitive advantage over BM cells (Holyoake et al., 1999), but the 
collected cell numbers are limited. 
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1.1.3  Functional Assays for Haematopoietic Stem and Progenitor Cells 
 
A continuum of cells with altering phenotype and properties is produced in the 
haematopoietic system during the progression from stem to differentiated cells. A variety of 
in vitro and in vivo assays have been developed for murine and human cells in order to 
measure quantitative and qualitative properties of primitive haematopoietic stem and 
progenitor cells (Figure 1.2). These assays are based on the high proliferative and clonogenic 
characteristics of primitive haematopoietic cells separating them from the more mature cells 
that possess a narrower haematopoietic potential.  
 
Undifferentiated
Stem cells
Primitive 
progenitor
Lineage 
restricted 
progenitor
Differentiated
In vitro colony asseays
In vitro liquid culture
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LTRC husheep-RC
CRU huSRU?
huCRU?
MRA
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CLP hE-LTC-ICM
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CFU-Ly-My
CFU-blast
HPP-CFC
CFU-GEMM
CFU-GM iBFU-E
mCFU-proB  mBFU-E BFU-MK
mCFU-NK  CFU-M, CFU-G
CFU-E, CFU-MK
 
 
Figure 1.2: Categorisation of distinct classes of haematopoietic stem and progenitor cells in in vitro 
and in vivo assays. According to the type of assay, 3 methodological families can be distinguished: in vivo 
transplantation assay (left), in vitro long-term culture assay (middle) and in vitro short-term colony assay 
(right). The cells are aligned on the vertical axis based on their maturation stage, from undifferentiated stem 
cells to differentiated lineage-restricted progenitors. “hu” designates cells identified solely in human tissues 
and “m” indicates murine assays (adapted from Coulombel, 2004). 
 
1.1.3.1   In Vitro Assays 
 
So far, no perfect in vitro assay is available which allows analysis of all the 
haematopoietic characteristics of HSCs. Nevertheless, for the routine analysis of early 
haematopoiesis, a few assays for primitive progenitors “correlating” to the numbers of the 
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HSCs have been developed. These comprise short-term in vitro colony assays based on semi-
solid media such as methylcellulose and long-term in vitro assays including LTC-IC (long-
term culture-initiating cells) and CAFC (cobblestone area-forming cells). These are performed 
in the presence of feeder cells which are necessary for the long-term culture of HSCs.  
In human HSC colonies, several types of progenitors, e.g. erythroid, granulocytic, 
macrophagic and megakaryocytic can be distinguished on the basis of their sensitivity to 
cytokines, the time required to produce differentiated cells and their size, colour and 
composition (see web page www.stemcell.com). For murine cells, however, it is more 
difficult to discriminate the colour and appearance of the different colonies. Several classes of 
multipotent progenitors, e.g. colony-forming unit granulocyte-erythroid-macrophage-
megakaryocyte (CFU-GEMM), blast progenitors and lymphomyeloid progenitors, have been 
identified (Ash et al., 1981; Leary and Ogawa, 1987; Lacaud et al., 1998) because of the 
presence of more than one lineage of differentiated cells and/or progenitors in a single colony. 
Nevertheless, the lifespan of the viscous medium is too short (no more than 3 weeks) to allow 
the detection of more immature progenitors with this method. For long-term in vitro assays, 
both human and mouse, two different cell types have been identified: LTC-IC (or human 
ELTC-IC) and CAFC. LTC-IC are obtained by culturing the cells for a long time of about 5–8 
weeks (about 12 weeks for ELTC-IC) on an irradiated stroma layer, during which mature 
cells die and a selection for the most primitive cells occurs. Further committed cells present in 
the input populations will not survive culture. The haematopoietic ability of surviving 
primitive cells can then be measured by their colony forming ability in methylcellulose 
cultures. The CAFC assay is another measurement for primitive haematopoietic progenitors 
based on a similar principle to the LTC-IC assay. The CAFCs integrate in an adherent layer of 
feeder cells and form a cobblestone area, which is defined as a group of flattened, optically 
dense cells tightly associated with the adherent feeder cells (Breems et al., 1994; Ploemacher 
et al., 1989). Murine CAFCs are counted on day 28–35 after plating.  
 
1.1.3.2   In Vivo Assays 
 
The in vitro assays described above are important for measuring certain functions of 
haematopoietic progenitor cells. However, in vitro assays characterise an artificial system that 
can not take into account the effects from stimuli and other environmental surroundings found 
in vivo. Hence, the final assessment of HSC capacity is the ability to repopulate a recipient. 
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This method can be most easily performed when using the murine system. Here three 
transplantation assays have been established (Coulombel, 2004):  
 
•  Short-lived cell assay, such as day 12 CFU-S (colony forming unit-spleen). The CFU-
S assay was the first to be described for assessing murine HSC activity in vivo. 
Macroscopic colonies visible on the spleen 8–12 days post-transplantation were shown 
to contain cells which contributed to the rescue of lethally irradiated mice (Till et al., 
1961). However, experimental data demonstrated that long-term reconstituting HSCs 
(LTR-HSCs) could not be found in CFU-S colony forming units (Na Nakorn et al., 
2002).  Currently, the CFU-S assay is used mainly for measurements of primitive 
multipotent myeloid progenitors but not as an assay for true HSCs. 
•  Pre-CFU-S and marrow-repopulating activity (MRA) assay. Two weeks post-
transplantation, BM cells of recipients are re-transplanted into secondary recipients. 
The ability to produce CFU-S in secondary recipients is analysed (Hodgson et al., 
1979; Lord et al., 1993). 
•  Identification and quantification of long-term reconstituting cells (LTRCs) based on 
the competitive repopulating unit (CRU) assay. This assessment is the most stringent 
assay for murine LTR-HSCs and can be performed in a competitive transplantation 
with a limiting dilution approach, thereby measuring the repopulating capability of a 
single stem cell (Harrison, 1980; Harrison et al., 1993; Szilvassy et al., 1990). 
 
The murine transplantation assay allows systematic analysis of short-term (<6 weeks) 
and long-term (3–4 months) engraftment with the option of serial transplants into secondary 
or tertiary recipients as the ultimate test for LTR-HSC activity. Importantly, transplantation 
experiments also determine the homing ability of HSCs to the BM, a feature not accessible in 
in vitro assays (Szilvassy et al., 2001). For human HSCs, similar transplantation studies have 
been established using xenograft models in immune-deficient mice, such as the non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mouse model (Vormoor et al., 
1994). 
 
1.1.4  HSCs as Targets for Gene Therapy 
 
Based on their capability to self-renew and to give rise to all haematopoietic lineages, 
HSCs are an attractive and well-studied target cell population for gene therapy of 
haematopoietic disorders like chronic granulomatous disease (see chapter 1.2), severe 
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combined immunodeficiency (X-SCID) and others. These cells are easily isolated from 
haematopoietic tissues. They can be concentrated, enriched and readily delivered back to the 
patients by autologous transplantation methods which have been routinely performed for over 
40 years. As mentioned earlier, HSCs are long-lived, have repopulation potential and are 
pluripotent. They could contribute to the correction of defects in all haematopoietic lineages 
and probably non-haematopoietic cell lineage via transdifferentiation (Vollweiler et al., 2003). 
A primary focus of studies in the field of gene transfer to HSCs is targeting primitive 
stem cells without losing their unique stem cell properties during the ex vivo transduction 
period. Various cytokine combinations have been considered preclinically for their ability to 
improve gene transfer efficiency and to expand primitive HSCs while maintaining their 
repopulating capability in model systems (Laneuville et al., 1988; Dick et al., 1991; Nolta et 
al., 1996; Bhatia et al., 1997). Different cytokines, such as stem cell factor (SCF), Flt-3 ligand 
(Flt-3), thrombopoietin (TPO), megakaryocyte growth and development factor (MGDF), 
interleukin-3, -6 and -11 (IL-3, IL-6, IL-11) have been used in many gene transfer protocols 
for murine and human HSCs (Table 1.2). SCF has been demonstrated to have a critical role in 
haematopoiesis and its maintenance, both in human and murine system (Broudy, 1997), and 
Flt-3 can induce the expansion of haematopoietic cells based on stimulation of tyrosine kinase 
activity (Gilliland and Griffin, 2002). The utilisation of IL-3 in the ex vivo-expansion of HSCs 
has been considered as an attractive possibility (Ivanovic, 2004), although it has been reported 
that IL-3 could be associated with a diminished repopulating ability in mice (Yonemura et al., 
1996; Wognum et al., 2000). It has been suggested that a combination of cytokines including 
IL-3, IL-6 and SCF may be more beneficial for improving gene transfer efficiency, and may 
preserve the characteristic properties of target HSCs (Kiem et al., 1997; Van Beusechem et 
al., 1997; Ivanovic 2004). However, many combinations of cytokines with activity on early 
haematopoietic stem/progenitor cells have been utilised for ex vivo stem cell transduction and 
expansion. So far, no consensus on the optimal combination has been reached (Horn et al., 
2004). The optimal combinations of cytokines are dependent on the vector type, cell type and 
experimental goal. It is commonly agreed that SCF, TPO Flt-3 and IL-3 are the optimal 
cytokine combination for clinical trials for gene therapy of diseases such as X-CGD (see 
below), X-SCID and adenosine deaminase deficiency (ADA).  
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Origin of HSCs  Cytokine combination  Reference 
SCF, Flt-3, TPO 
Schilz et al., 2000 
Schiedlmeier et al.,2000 
SCF, Flt-3, IL-3, TPO 
Cavazzana-Calvo et al., 2000 
Bruno et al., 2001 
SCF, Flt-3, IL-6, TPO 
Hossle et al., 2002 
Piacibello et al., 2002 
SCF, Flt-3, IL-3, IL-6 
Demaison et al., 2002 
Schilz et al., 2000 
SCF, G-CSF, TPO 
Hanenberg et al., 1997 
Leurs et al., 2003 
Human 
SCF, Flt-3, IL-3, IL-6, G-CSF 
Hennemann et al., 1999 
Conneally et al., 1998 
SCF, Flt-3, G-CSF, MGDF  Kiem et al., 2002 
SCF, G-CSF, MGDF  Horn et al., 2002  Baboon 
Il-3, IL-6, SCF  Kurre et al., 2001 
SCF, Flt-3, 
IL-11 
Mackarehtschian et al., 1995 
Miller et al., 1990 
SCF, IL-3, IL-6  Mikkola et al.,2000 
SCF, IL-3, IL-6, Flt-3, TPO  Moreau-Gaudry et al., 2001 
SCF, IL-6 
Dinauer et al., 1999 
Hara et al., 2004 
SCF, Flt-3, IL-3, IL-11  Li et al., 2003 
SCF, TPO, IL-6, Flt-3  Kurre et al., 2004 
Murine 
 
 
 
SCF, Flt-3, IL-6  Schwickerath et al., 2004 
 
Table 1.2: Summary of cytokine combinations established in various studies to maintain the 
properties of HSCs. 
 
1.2  Chronic Granulomatous Disease  
 
Chronic granulomatous disease (CGD) is a rare inherited disorder of phagocyte 
function, based on a genetic defect in 1 of four genes encoding the subunits of the 
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase, which is required 
for superoxide (O2
–) production. The disease is characterised by an increased susceptibility to 
bacterial and fungal infections. The incidence of CGD is about 1 in 200,000 all over the world 
(Winkelstein et al., 2000). However, it is likely that this disease continues to be under-
diagnosed, which would explain discrepancies in incidence. About 70% of CGD patients 
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inherit the disease as a characteristic sex-linked defect in the recessive gene found on the X-
chromosome from the mother (Rae et al., 1998). 
 
1.2.1  Clinical Features and Diagnosis of X-linked CGD 
 
The symptoms of this disorder do not appear until 3 months of age. In the UK, the 
median age of patients at the time of diagnosis is 3 years (Jones, 2002). Patients with X-linked 
CGD (X-CGD) suffer from recurrent infections with certain bacteria, such as Staphylococcus, 
Salmonella and Pseudomonas or fungi, such as Aspergillus. Staphylococcus aureus is most 
frequently isolated from CGD patients, but it is also reported that the most common causes of 
death are pneumonia and/or sepsis due to infection with Aspergillus or Bacillus cepacia 
(Winkelstein et al., 2000). Some bacteria and fungi generate their own hydrogen peroxide, 
which phagocytes can use to kill the microbes themselves. Other invaders quickly destroy any 
hydrogen peroxide they produce so that the scavenger cells that lack NADPH oxidase can not 
do their job. Although these bacteria and fungi can lead to infections anywhere in the body, 
they most often target the lung, lymph nodes, skin, liver, gastrointestinal tract, nostrils, mouth 
or bones in the arms and legs (Winkelstein et al., 2000). Recurrent chronic inflammations lead 
to the development of characteristic tumour-like masses called granulomas, which can cause 
serious problems by preventing the passage of food through the oesophagus, stomach and 
intestine, as well as by blocking urine flow from the kidneys and bladder. 
CGD is diagnosed by the demonstration of absent or markedly deficient respiratory 
burst activity in phagocytes. The oldest and most widely used assay is the nitroblue 
tetrazolium dye reduction (NBT) test (Ochs et al., 1973). This assay assesses the ability of 
activated neutrophils to produce superoxide, which reduces the water-soluble, yellow NBT 
dye to insoluble, blue formazan. The test is useful for the identification of female carriers 
having a mixed population of NBT-positive and -negative cells. Usually, the presence of as 
few as 2–5 % of normal neutrophils is sufficient to maintain a mild clinical phenotype, an 
aspect of great importance for any gene therapeutic approach (see chapter 1.3.3). The 
dihydrorhodamine (DHR) assay (Vowells et al., 1995) is a quick and convenient assay based 
on flow cytometric analysis. This test assesses the ability of stimulated phagocytes to produce 
superoxide that can oxidize dihydrorhodamine to rhodamine. Rhodamine releases a 
fluorescent signal that can be detected by a flow cytometer. A lack of fluorescence confirms 
the clinical diagnosis of CGD. The most widely used quantitative measurement of superoxide 
production is the superoxide dismutase (SOD)-inhibitable reduction of ferricytochrome c 
(Babior et al., 1973). In addition, a chemiluminescent-based assay has been developed which 
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involves the SOD-inhibitable reduction of lucigenin or catalysed peroxidation of luminol 
(Porter et al., 1992). This assay is less quantitative but has greater specificity for determining 
NADPH oxidase activity. Conformation of the molecular defect can be obtained by 
sequencing the relevant gene (Roos et al., 1996).  
 
1.2.2  Molecular Background of CGD 
 
The NADPH oxidase is a phagosomal and plasma membrane-associated enzyme 
complex. In resting neutrophils, it is dormant and its components are localised in different 
parts of the cell. The active enzyme complex is rapidly assembled following neutrophil 
activation by a variety of inflammatory stimuli, e.g. by the binding of microorganisms to cell 
surface receptors. It has been demonstrated that oxidase activation needs at least five different 
protein factors (De Leo et al., 1996). During neutrophil stimulation, the cytosolic factors 
p47
phox, p67
phox/p40
phox and GTPase Rac1/2 translocate to the plasma membrane and associate 
with cytochrome b558, which consists of p22
phox and heavily glycosylated gp91
phox subunits.
 
The gp91
phox subunit is the redox centre of the oxidase and contains two heme prosthetic 
groups in the hydrophobic N-terminus of the protein embedded within the membrane. The C-
terminus contains a flavoprotein domain with binding sites for flavin and NADPH (Babior et 
al., 1999). A schematic representation of the inactive and active NADPH oxidase complex is 
displayed in Figure 1.3.  
CGD patients lack NADPH oxidase activity as a result of the absence of one of its 
components. If one of the components is defective, the activity of NADPH oxidase is 
significantly decreased, which also results in the CGD phenotype (Jurkowska et al., 2004). X-
CGD cases result from defects in the CYBB gene that encodes the gp91
phox subunit. The 
remaining cases are autosomal recessive and caused by defects in the CYBA, NCF-1 or NCF-
2 genes (Table 1.3).  
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Figure 1.3: Schematic representation of the inactive and active NADPH oxidase complex. The 
membrane assembly of activated NADPH oxidase occurs upon stimulation. The known functional 
components involved in activation are shown: the integral membrane cytochrome b558 consisting of the 
gp91
phox and p22
phox subunits; the cytosolic components p47
phox and p67
phox/p40
phox, and the Rac2 GTPase 
in complex with the regulatory protein GDP dissociation inhibitor (GDI). Multiple phosphorylations of 
p47
phox are depicted by attached p groups. The wavy line on Rac2 indicates the C-terminal geranylgeranyl 
isoprenyl group and associated polybasic domain (modified from Lekstrom-Himes and Gallin, 2000). 
 
Gene Protein  Cellular 
localisation 
Assembling 
domains 
Aberrant in CGD 
(%) 
CYBB gp91
phox membrane -  ~  65 
NCF1 p47
phox cytosol  two proline-rich, two SH3 motifs  ~ 25 
NCF2 p67
phox cytosol  one proline-rich, two SH3 motifs  ~ 5 
CYBA p22
phox membrane  one proline-rich motif  ~ 5 
NCF4 p40
phox cytosol  one SH3 motif  - 
 
Table 1.3: Characteristics of NADPH oxidase components of CGD patients. The genes most 
commonly mutated in CGD patients are given. An internationally maintained database, the CYBB 
base (see web page http://www.uta.fi/imt/bioinfo/CYBBbase/), lists 304 different mutations within 
this gene (adapted from Jurkowska et al., 2004). 
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1.2.3  Treatment and Prognosis of CGD 
 
The most important principles for treatment of CGD patients are prevention and 
aggressive treatment of infections, usually through antimicrobial chemoprophylaxis, such as 
with cotrimoxazole, and antifungal prophylaxis, such as with itraconazole (Petropoulou et al., 
1994; Gallin et al., 2003). It has also been reported that interferon-gamma (IFN-γ) can restore 
NADPH oxidase activity in a small number of patients with X-CGD (Ezekowitz et al., 1988); 
however, this is not a routine treatment. Topical and systemic steroids are major components 
of therapy for the inflammatory complications of CGD, but unfortunately, a significant 
number of patients become dependant on these drugs. In cases where patients are resistant to 
conventional treatments, neutrophils from leukophoresed donors can be administered, with 
similar drawbacks as those described for BM cell transplants below. 
For over 40 years, allogeneic haematopoietic stem cell transplantation (HSCT) has 
been used to treat a wide range of primary immunodeficiencies, haematological disorders and 
metabolic conditions. It can also be performed for the treatment of CGD patients (Seger et al., 
2002). Nevertheless, high rates of morbidity, mortality and graft failure limit the broad usage 
of this method. Morbidity and mortality result on the one hand from the high degree of 
immunosuppression required to achieve engraftment, and on the other hand from graft versus 
host disease (GvHD). Despite modern tissue typing techniques and prophylaxis, GvHD 
remains one of the major complications of allogeneic HSCT, with a rate of about 25%. 
Additionally, the limited availability of matched donors has restricted the application. 
Attempts are being made to reduce toxicity related to conditioning and to use stem cells 
derived from CB as an alternative source with a significantly lower rate of GvHD (Han et al., 
1995; Risdon et al.,  1995). The better immunological tolerance of this source of 
haematopoietic progenitor cells (HPC) has permitted an expansion of the donor pool, and 
wider representation for ethnic minorities, who have a much smaller pool of possible donors 
for BM transplants. CB offers additional advantages over BM in unrelated transplantations, 
such as a low transmission rate of infectious diseases and the immediate availability of the 
product. However, the major current barrier to a wider use of CB transplantations is the 
limited cell dose of CB units, especially for adults (Benito et al., 2004).  
Altogether, there is currently no cure for CGD with drug treatment and HSCT is 
limited due to severe drawbacks, another alternative method like gene therapy could be an 
option for the treatment of X-CGD patients (see chapter 1.3.3). 
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1.3  Gene therapy  
 
Principally, gene therapy can be defined as the transfer of genetic material into cells in 
order to treat or prevent a disease, or to slow its progression (Mountain, 2000; Somia and 
Verma, 2000; Pfeifer and Verma, 2001). This novel therapeutic strategy has been regarded as 
a potential revolution in medicine. The reason for this is that gene therapy aims to treat or 
correct the source of a genetic disease. A mutated gene could be replaced by its normal 
functional counterpart, rather than treating the effects of the defective gene product, as many 
drugs do (Friedmann, 1989; Mountain, 2000). Gene therapy was originally conceived as a 
possible treatment option for hereditary single gene defects. Today, it has been demonstrated 
that many complex diseases, such as cancer (Cristiano, 1998), cardiovascular diseases (Isner, 
2002), neurodegenerative disorders (Baekelandt et al., 2000) and infectious diseases like 
AIDS (Bunnell and Morgan, 1998), could also be targeted via gene transfer. In this technique, 
a defective gene is replaced or supplemented by a functional, normal gene using recombinant 
DNA technology. The functional gene copy provides the corrected enzyme or protein and the 
cause of the disease is consequently eliminated. Different strategies for gene therapy have 
been developed (Driskell et al., 2003):  
 
•  Gene replacement: A normal gene is inserted into a non-specific location of the 
genome. This strategy is currently the standard approach in gene therapy, due to its 
relative simplicity. 
•  Gene repair: Mutated sequences in the genomic DNA are directly repaired or replaced 
by a normal gene. This method is considered as the ultimate goal of gene therapy, but 
even today the efficiency of gene repair techniques is so low that clinical applications 
are not realistic. 
•  Gene reprogramming: A functional correction of the defect is reached by modification 
of endogenously encoded mutated RNA transcripts. Unfortunately, this is also equally 
inefficient at this time. 
 
To date, gene replacement is the most common type used in clinically approved gene 
therapy trials, and it is used in the current study. In all of these trials, the genes of interest 
were transferred into somatic cells. In principle, there are three techniques that can be used, 
based on the mode of delivery of the gene to the target tissue (Anderson, 1998): 
 
   Indirectly, ex vivo: Cells are modified in culture and then transplanted back into the 
patient. 
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   Directly, in situ: Gene delivery vectors are injected or infused into the target tissue. 
   In vivo: Gene transfer vectors are directly injected into the bloodstream. 
The ex vivo method has been proposed for gene therapy of haematopoietic diseases such as 
CGD and SCID. 
A number of factors may influence a successful gene therapy approach, such as the 
identification of a suitable therapeutic gene, targeting the tissue associated with the disease 
and a delivery system that can transfer the gene efficiently into the host genome in a locus 
that does not disturb other gene functions or, most importantly, lead to insertional 
oncogenesis. 
 
1.3.1  Retroviral Gene Transfer Vector Systems 
  
Two types of vector system, i.e. non-viral and viral, are used for gene therapy 
applications. Non-viral methods involve either the direct introduction of naked DNA into 
target cells, or the use of liposomes or other molecules that can transport DNA into cells. 
However, most of these approaches suffer from inefficient delivery and transient expression 
of the gene. Transiently expressed cDNA plasmids are usually lost or degraded by the 
targeted cell itself. Viral vectors are more effective, delivering genes into the target cells with 
high efficiency, due to their natural infectious properties. Promoting integration into the host 
cell genome also provides the opportunity for long-term expression (Walter et al., 2000; 
Gardlik et al., 2005).  
There are also drawbacks in the use of viral gene therapy vectors, such as 
immunogenicity, the problem of specific targeting, and the duration and level of gene 
expression in the cells. Nevertheless, the progress of viral vectors into clinical trials has been 
eased through current advances in vector design, pseudotyping of viruses with envelopes 
specific for certain cell types, the use of target cell-specific promoters, the development of 
viral packaging cell lines and the incorporation of reagents to improve transduction 
efficiencies. In gene therapy studies, different vectors are chosen based on their properties and 
the experimental goal. A summary of various viral vectors and their properties is given in 
Table 1.4. Gammaretroviral vectors based on the murine leukaemia virus (MLV) and 
lentiviral vectors based on the human immunodeficiency virus (HIV) are attractive tools for 
gene therapy due to their large packaging capacity, high transduction efficiency, long-term 
expression of the transgene and to the possibility of pseudotyping the vector with a range of 
envelopes.
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Table 1.4: Summary of properties of viral vectors used for gene transfer 
 
Features            Gammaretroviral Lentiviral HSV-1 Adenoviral AAV
Genetic material  RNA          RNA dsDNA dsDNA ssDNA
Maximum insert size  8 kb  8 kb  40 kb  ~ 30 kb  <5 kb 
Tropism  Dividing cells only  Broad  Strong for neurons  Broad  Broad with possible 
exception of HSC 
Vector  
genome form 
Integrated           
         
   
Integrated Episomal Episomal Episomal (>90%)
Integrated (<10%) 
Duration of  
expression in vivo 
Long Long Short Short Long
Immunological 
problems 
Not immunogenic  Few  Extensive  Extensive  Few 
Pre-existing host 
immunity 
Unlikely  Unlikely except AIDS patients  Yes  Yes  Yes 
Other  
advantages 
Can be tissue specific 
Stable expression 
Tissue-specific 
Stable expression 
High titre (10
10 p.f.u./ml) 
Transduce non-dividing cells  High titre 
High transduction efficiency 
Stable expression 
Wild type integrates at 
specific site 
Problems Possible  insertional
mutagenesis 
Silencing of LTR 
promoter 
Possible insertional 
mutagenesis 
Ethical considerations 
Lytic replication 
Transient expression 
Low titre 
Possible hepatotoxicity 
Transient expression 
Lack of tissue specificity 
Vector immunogenicity 
Loss of specific 
integration 
Difficult to purify vector 
Low titre 
Possible insertional 
mutagenesis 
 
(Adapted from Merma and Somia et al., 1997; Thomas, Ehrhardt and Kay, 2003; Tendeloo et al., 2000)
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1.3.1.1   Gammaretroviral Vectors 
 
One of the first classes of viral vectors to be developed were those based on 
gammaretroviruses, previously known as oncoretroviruses. These viral vectors have been the 
most widely used in clinical trials so far, particularly for ex vivo transduction of HSCs. 
Gammaretroviral vectors are derived from different simple type C murine retroviruses, such as 
MLV, spleen necrosis virus and Rous sarcoma virus. MLV-based vectors are most frequently 
utilised (Kootstra and Verma, 2003). These vectors have been modified for safety and to 
generate space for carrying the therapeutic gene. Important features of gammaretroviral vectors 
include: 
 
   First, for reasons of safety, the endogenous viral genes necessary for viral 
replication and budding from the cell are removed.  
   Second, viral genes can be replaced by a therapeutic gene and expressed under 
the control of the long terminal repeat (LTR) promoter.  
   Third, the natural viral envelope can be replaced e.g. by those from the gibbon 
ape leukaemia virus (GALV Env) and the vesicular stomatitis virus (VSV-G) 
(pseudotyping).  
 
Retroviral vectors have also been modified to incorporate an internal promoter to increase 
specificity of transgene expression and to improve vector safety. The minimal cytomegalovirus 
(CMV) promoter, a very strong promoter sequence, was one of the first promoters used in 
haematopoietic cells. However, it was observed that this promoter could not provide high 
transduction efficiency and long-term expression of the transgene because of gene silencing 
(Sutton et al., 1998; Uschida et al., 1998; Case et al., 1999). An alternative promoter element is 
derived from the polycythemic strain of the spleen focus forming virus (SFFV). This contains a 
potent murine retroviral enhancer sequence important for gene expression in myeloerythroid 
haematopoietic cells (Baum et al., 1995). Numerous studies have demonstrated high levels of 
transgene expression and low levels of gene silencing in haematopoietic cells transduced with 
gammaretroviral vectors incorporating the SFFV promoter (Grez et al., 1990; Danno et al., 1999; 
Hildinger et al., 1999; Flasshove et al., 2000). In addition, the development of self-inactivating 
(SIN) vectors further reduced the possibility of vector mobilisation and recombination with 
defective retroviruses in the target cells (Yu et al., 1986; Kraunus et al., 2004). Figure 1.4 shows 
a comparison of the wild type MLV genome and a retroviral vector developed for gene transfer 
into mammalian cells.  
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A: Proviral structure of MLV genome (8,8 Kb)
B:  Structure of a gammartrovital vector for gene therpy
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Figure 1.4: Schematic presentation of the proviral structure of the MLV genome (A) and a modified 
gammaretroviral vector (B). In the MLV provirus, gag, pol and env coding regions are flanked by LTRs. The 
LTR contains three regions, U3, R and U5. These regions are necessary for reverse transcription, proviral 
integration and transcriptional activation. ψ indicates the packaging signal. In the recombinant vector (B), the 
genomic RNA is transcribed using the 5’U3 or an internal heterologous promoter. The primer binding site 
(PBS) is indicated in the figure (schematic diagram modified from Hu and Pathak, 2000; Pages et al., 2004; 
Kootstra and Verma, 2003). 
 
Retroviral vectors are packaged into infectious particles from so called packaging cell 
lines. Such a cell line contains the necessary structural genes gag, pol and env (Tendeloo et al., 
2001). The gag (group specific antigen) gene encodes the viral core proteins and the pol (RNA-
dependent DNA polymerase) gene encodes the viral replication enzymes. These two genes are 
expressed as a Gag/Pol fusion glycoprotein, which is cleaved by a viral protease. The env 
(envelope) gene encodes the viral envelope glycoprotein, which is subsequently cleaved by 
cellular proteases into the external envelope glycoprotein and transmembrane protein. The 
constructs encoding these genes lack the packaging signal (ψ) which normally allows the viral 
RNA to be distinguished from other RNA in the cell. The recombinant vector containing the 
gene of interest lacks the structural genes gag, pol and env, but has retained the LTR sequences, 
which are required for viral integration and transcription, and the packaging signal. The 
packaging signal ψ is located downstream of the 5’-LTR in the construct incorporating the 
therapeutic gene. This ensures that only the viral genomic RNA encoding the therapeutic gene is 
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packaged (but not the gag, pol and env genes) into virions to be transferred to the target cells (see 
Figure 1.5). Once it has been established, the packaging cell line can provide a continuous source 
of high titre vector (Verma and Somia, 1997; Hu and Pathak, 2000; Buchschacher and Wong-
Staal, 2000; Vollweiler et al., 2003; Tendeloo et al., 2001). 
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Figure 1.5: Principles of the function of the retroviral packaging cell line and transduction of target 
cells. The eukaryotic expression plasmid encoding the therapeutic gene (e.g., gp91
phox for X-CGD), lacking the 
essential genes for replication (gag, pol and env) but containing a packaging signal ψ, LTR promoter 
sequences and enhancer regions, is introduced into the packaging cell line by calcium phosphate transfection. 
The packaging cell line is constructed such that the viral core proteins (gag), envelope (env), and polymerase 
and reverse transcriptase (pol) are constitutively expressed and therefore provided in trans. These trans-acting 
factors are needed for the packaging of expressed vector RNA into retroviral particles. After transduction of 
target cells, the transferred vector RNA is reverse-transcribed into double-stranded DNA for random 
integration into the cell’s genome and subsequent expression of the transgene (adapted from Hossle, Seger and 
Steinhoff, 2002). 
 
For the pre-integration complex to gain access to the chromatin and for efficient 
transduction, gammaretroviral vectors are strictly dependent on the disruption of the nuclear 
membrane that occurs during mitosis (Miller et al., 1990). This prevents their application for the 
transduction of quiescent cells, such as HSCs, muscle, brain, lung and liver cells. For this reason, 
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there has been considerable interest in the development of vectors such as those based on HIV 
type 1 (HIV-1), which are able to infect non-dividing cells. 
 
1.3.1.2   Lentiviral Gene Transfer 
 
In contrast to gammaretroviruses, lentiviruses have a more complex genome and, 
consequently, a more complex replication cycle. Besides the structural proteins Gag, Pol and 
Env, HIV-1 encodes two regulatory proteins, Tat and Rev, essential for efficient viral expression, 
and four accessory proteins termed Vpr, Vpu, Nef and Vif (Figure 1.5). The Rev protein interacts 
with a region of viral RNA known as the Rev-responsive element (RRE). This element controls 
the amount of spliced RNA and promotes the transport of viral RNA from the cell nucleus to the 
cytoplasm (Kondo et al., 1995). Modification of the HIV genome with the aim of developing 
lentiviral vectors started over 15 years ago (Page et al, 1990). Great efforts have been directed 
towards improving the biological safety of the vectors to minimise the possibility of replication-
competent lentivirus production. Similar in design to gammaretroviral vectors, lentiviral vectors 
are produced by separating the sequences required in cis for packaging (packaging signal, psi), 
reverse transcription (primer binding site) and transcriptional control (LTR) from those encoding 
viral structural and enzymatic proteins (Miller et al., 1993). In addition, the RRE is included in 
the transfer vector. Three generations of lentiviral vector system have been developed with the 
view of improving biosafety while retaining properties essential for efficient gene transfer. The 
first and second generation of packaging constructs still contained tat and rev genes, and all or 
some of the accessory elements, although the U3 regions of the 5’- and 3’-LTRs were replaced 
with a minimal CMV promoter and a polyadenylation signal from the insulin gene, respectively, 
and part of the packaging sequence was replaced with 5’ splice donor and acceptor sites. At this 
stage, the HIV accessory proteins were demonstrated to be critical fir HIV pathogenesis (Cullen 
et al., 1998). In order to improve the safety of lentiviral vectors, a so-called third generation of 
lentiviral packaging systems were constructed. These are devoid of all accessory genes not 
essential for transduction (except gag, pol and env) in order to prevent viral recombination. In 
the absence of a functional HIV-LTR and with expression of the transgene being driven by an 
internal promoter, the presence of tat was no longer necessary (Dull et al., 1998; Zufferey et al., 
1997 and 1998). Furthermore, the rev gene was also deleted from the packaging plasmid and 
incorporated in a separate construct, generating a four-plasmid expression system (Dull et al., 
1998). At the same time, SIN lentiviral vectors were developed to further increase biosafety 
(Miyoshi et al., 1998, Zufferey et al., 1998). In these vector constructs, the 3’-LTR contains a 
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133 bp deletion which is transferred to the 5’-LTR during reverse transcription and integration, 
resulting in elimination of expression from the HIV-1-LTR and allowing expression from an 
internal promoter. This inactivation design significantly improves the safety of HIV-derived 
vectors, as it reduces the risk of the formation of replication-competent lentiviruses and hinders 
recombination with wild type HIV in infected host cells. More recently, another cis-acting 
sequence, the central polypurine tract (cPPT) from the pol open reading frame (ORF), was added 
back into the vector. This sequence has been demonstrated to improve nuclear import of the 
proviral DNA and subsequently accelerates transduction (Follenzi et al., 2000; Zennou et al., 
2000; Demaison et al., 2002).  
Like gammaretroviral vectors, the lentiviral vectors have also been modified to 
incorporate an internal promoter, such as the SFFV promoter for efficient expression in 
haematopoietic cells. Improvement of transgene expression has also been achieved by the 
addition of elements that act post-transcriptionally. The incorporation of the post-transcriptional 
regulatory element (PRE) of the woodchuck hepatitis virus (WPRE) has substantially increased 
the levels of expression from HIV-1 derived vectors (Huang and Liang et al., 1993; Donello et 
al., 1996; Zufferey et al., 1999; Demaison et al., 2002). Schematic representations of the HIV-1 
wild type genome and a typical SIN-lentiviral vector are shown in Figure 1.6. 
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Figure 1.6: Schematic representation of the HIV-1 provirus (A) and a modified SIN-lentiviral vector 
used in this study (B). Besides the gag,  pol  and  env genes, the HIV-1 proviral DNA contains the six 
additional genes vif, vpr, vpu, tat, rev and nef, and the RRE element. In the HIV-based SIN-lentiviral vector, 
the viral gag, pol and env have been replaced by promoter and transgene sequence and are flanked by the viral 
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LTRs. Packaging of viral RNA genome is ensured by the presence of a packaging signal from the 5’ 
untranslated region of the gag ORF. In addition, two cis-acting sequences RRE and cPPT are present in the 
vector. The 3’ LTR contains a large deletion in the U3 region (depicted as ∆U3) to prevent transcription from 
the LTR. A WPRE element downstream from the transgene is used to improve transcription efficiency. The 
SFFV promoter is used in this example as an internal promoter to drive the expression of enhanced GFP 
(eGFP) (modified from Kootstra and Verma, 2003; Gaspar et al., 2004). 
 
  For the production of lentiviral vector particles, the natural HIV-1 Env glycoprotein has 
been replaced by the vesicular stomatitis virus glycoprotein (VSV-G), which allows high 
transduction of haematopoietic cells (Kootstra and Verma, 2003). The VSV-G protein has a 
broad host range and is expressed from a individual construct during vector production (Naldini 
et al., 1997; Zufferey et al., 1997). Figure 1.7 summarises the lentiviral vector production with a 
SIN-vector. 
A. 
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Figure 1.7: Representation of lentiviral vector production: (A) A HIV-based SIN-lentiviral vector (see 
legend for Figure 1.6). The lentiviral packaging system consists of two constructs encoding Gag/Pol and VSV-
G. (B) Lentiviral vectors are produced by transient transfection of the vector constructs together with the 
packaging constructs into producer cells. Vector RNA is packaged by Gag/Pol precursor proteins at the 
cellular membrane. Subsequently, the vector particles bud through the cellular membrane, obtaining the viral 
envelope that contains the VSV-G glycoprotein (modified from Kootstra and Verma, 2003). 
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1.3.2  CGD as a Gene Therapy Model 
 
An alternative treatment for CGD is the genetic transfer of a functional copy of the 
defective gene to haematopoietic progenitor cells. Some of the features that make X-CGD an 
attractive candidate for a gene therapy strategy are (Roos et al., 1992; Woodman et al., 1995, Bu-
Ghanim et al., 1995): 
 
•  X-CGD is a monogenic disease that is well characterised at the molecular level. 
•  Constitutive expression of gp91
phox is likely to be effective for reconstitution of 
the NADPH oxidase. 
•  Transduction and engraftment of haematopoietic stem/progenitor cells should 
provide a long-term source of functional monocytic cells. 
•  The level of transduction required for a therapeutic benefit is low, both in terms of 
protein expression within the cell and the percentage of functional cells. A small 
population (about 5%) of corrected neutrophils with normal NADPH oxidase 
activity should be sufficient to correct or at least abrogate the clinical phenotype. 
•  There are well-established laboratory tests and mouse models available for testing 
the efficiency of gene transfer vectors in vivo.  
 
1.3.2.1   In Vitro and In Vivo CGD Gene Therapy Experiments 
 
In the past 20 years, in vitro systems allowing reconstitution of the respiratory burst 
oxidase activity in human CGD leukocytes using gene transfer technology have been well 
established. Various gene transfer vectors and different cell lines have been utilised. Epstein-
Barr virus (EBV)-transformed B-cell lines from CGD patients that express small amounts of the 
NADPH oxidase protein have been used as a model by a number of groups. Respiratory burst 
activity has been corrected in all 4 genetic subgroups using retroviral and/or plasmid-based 
vectors containing appropriate cDNA (Maly et al., 1993; Porter et al., 1993; Chanock et al., 
1996; Iwata et al., 1998). More recently, a human myeloid X-CGD cell line, generated by gene 
targeting, has been used in several studies. For example, gp91
phox expression and superoxide 
formation has been quantitatively evaluated in retrovirus-reconstituted cells (Becker et al., 1998; 
Kume et al., 1994). Similarly successful results were also achieved with retrovirally transduced 
myeloid progenitors from PB or BM obtained from CGD patients. Functional expression of 
proviral transcripts was documented in vitro using diverse methods to monitor reconstitution of 
NADPH oxidase activity (Porter et al., 1996; Weil et al., 1997). A recent study demonstrated that 
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phagocyte superoxide levels was corrected to levels (68.9%) similar to those of normal cells after 
transduction of human CD34
+ marrow cells with a murine stem cell virus-based retroviral vector 
expressing gp91
phox (Grez et al., 2000). In addition, the development of HIV-based vectors has 
significantly increased the transduction efficiency in vitro. One study reported transduction of up 
to 63% of cells from a human X-CGD cell line using a HIV-1-based lentiviral vector containing 
gp91
phox (Saulnier et al., 2000). Recently, the use of third-generation SIN gp91
phox lentiviral 
vectors allowed correction of superoxide production in transduced CD34
+ PB cells from X-CGD 
patients to 53% of normal levels, which was lower than that obtained with retroviral vectors. 
However, the lentivirus-transduced stem cells produced higher numbers of gene corrected 
neutrophils than the retroviral vector-transduced cells when transplanted into immunodeficient 
mice (Roesler et al., 2002). 
The feasibility of a gene therapy approach for X-CGD was revealed in the gp91
phox–/– (X-
CGD) knock out mouse model. The gp91
phox-deficient mice were generated by the disruption of 
the X-linked murine CYBB locus. The mice have a similar phenotype to human CGD in that 
they lack phagocyte superoxide production and are susceptible to infections with Staphylococcus 
aureus and Aspergillus fumigatus (Morgenstern et al., 1997). BM cells from the X-CGD mice 
were transduced with retrovirus vectors containing the gp91
phox cDNA and transplanted into 
lethally irradiated syngeneic X-CGD recipients. NADPH oxidase activity was detected in 50–
80% of circulating neutrophils by the NBT test 12–14 weeks post-transplantation and persisted 
for at least 18 months; gene-corrected neutrophils were also maintained in secondary recipients 
(Ding et al., 1996; Dinauer et al., 1999, 2001). A study by Sadat et al. (2003) demonstrated that 
high levels of NADPH oxidase activity could be achieved in transplanted X-CGD mice using a 
bicistronic vector containing gp91
phox and the ∆LNGFR marker. Additionally, partial 
reconstitution of NADPH oxidase activity after retroviral gene transfer was shown to improve 
host protection against bacterial and fungal infections in X-CGD mice, when a sufficient number 
of cells was corrected (Bjorgvinsdottir et al., 1997; Dinauer et al., 2001). 
 
1.3.2.2   Phase I Clinical Trials of CGD Gene Therapy 
 
A limited number of human clinical trials of gene therapy in CGD patients have been 
performed in the USA and Germany. Malech et al. (1997, 2000) conducted two clinical trials of 
ex vivo gene therapy to treat five patients with autosomal recessive p47
phox-deficient and five 
patients with X-linked gp91
phox-deficient CGD. Autologous CD34
+ stem cells from cytokine-
mobilised PB were used as the targets for retroviral-mediated gene transfer of the normal p47
phox 
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and gp91
phox cDNAs. The mobilised PB CD34
+ cells were collected by aphaeresis and 
transduced over a 3-day period ex vivo. The transduction rates were 20% for p47
phox-transduced 
cells and 70% for gp91
phox-transduced cells. Afterwards, the transduced cells were transfused 
back into the patients. In eight of ten patients, peak levels of 0.004 to 0.13% oxidase-corrected 
PB neutrophils and monocytes were observed at 3–6 weeks, with the effect lasting several 
months per cycle of gene therapy. However, the number of circulating gene-corrected 
neutrophils declined over time (Malech et al., 1997, 2000). More recently, research groups from 
Frankfurt am Main, Germany have conducted clinical phase I treatment of 2 adult X-CGD 
patients by gene transfer. G-CSF mobilised CD34
+ PB cells were collected and transduced with 
gammaretroviral vectors containing normal gp91
phox cDNA. Five days later, the transduced cells 
were re-infused into the patients, which had received a non-myeloablative dose of busulfan prior 
to re-infusion. To date, over 16 months after gene therapy, the treatment has been well tolerated 
and no adverse effects have been observed in either patient. A significant reconstitution of 
NADPH oxidase activity was observed in granulocytes from both patients with the NBT and 
DHR tests. In addition, the corrected cells were able to eliminate bacterial and fungal infections 
in vitro and in vivo (Manuel Grez, personal communication). 
 
1.3.3  Drawbacks of Gene Therapy for Inherited Diseases of the Haematopoietic System 
 
The idea of HSC gene therapy is as exciting as that of stem cell transplantation itself. The 
development of techniques for transferring and expressing genes in HSCs has indicated that new 
genes can be expressed in repopulating stem cells of multiple species. Optimisation of the vector 
design, i.e. utilisation of pseudotyped vectors and of lentiviral vectors, has opened up whole new 
areas of possible clinical applications. In addition, the use of diverse cytokine combinations and 
fibronectin fragments has greatly improved the transduction efficiency of HSCs (Vollweiler et 
al., 2003). However, gene therapy has not fulfilled the expectations promised by the press in the 
early 1980s. There are still some limitations that inhibit the ability to reach and to maintain 
therapeutically relevant levels of genetically modified cells and their progeny after gene delivery. 
The major challenges at present are (Hossle et al., 2002):  
 
•  Low frequency and quiescent nature of target cells. As described in chapter 1.1, 
there are only limited numbers of true HSCs (about 1 in 10
6 BM cells), which are 
in the G0 phase of the cell cycle with densely packed DNA and an intact nuclear 
membrane. 
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•  Poor engraftment of transduced cells after cell activation with cytokines. 
Activated cells have been shown to possess lower engraftment capacity than 
unmanipulated cells by competitive assay (Qin et al., 1999). 
•  Lack of selective growth advantage post-engraftment and unpredictable 
expression of the transgene in transduced cells (see chapter 1.4). 
•  Unexpected insertional mutagenesis and multiple random integrations. 
 
1.4  Selection of Genetically Modified HSCs 
 
In principle selective expansion of stem cells could be reached by inhibition of cell 
differentiation, activation of proliferation signals and anti-apoptotic signals, or maintenance of 
stem cell properties. As mentioned earlier, the lack of a selective growth advantage of 
genetically modified cells is a major limitation of gene therapy of HSCs. A natural selective 
advantage of gene-transduced cells occurs in only a very few diseases, for example in the case of 
X-linked SCID. However, in most other haematopoietic genetic diseases there is an unfortunate 
competition between transduced and non-transduced cells which leads to low engraftment of 
therapeutic gene modified cells (Choi et al., 2000). Therefore, introduction of an artificial 
selection advantage will be needed to increase the number of genetically modified cells ex vivo 
and/or in vivo.  
Various strategies have been developed to selectively expand gene-modified cells in vitro 
and in vivo. A number of selective markers have been used for in vitro selection, such as the 
neomycin resistance gene (neo), murine heat shock antigen CD24, low affinity nerve growth 
factor receptor (∆LNGFR) and fluorescent proteins (e.g. green fluorescence protein). Transduced 
cells can be positively selected through the use of drugs such as G 418, a neomycin analogue, or 
on the basis of FACS sorting (Dick et al., 1985; Migita et al., 1995; Berger et al., 2003; Kalberer 
et al., 2000). However, these approaches are seriously limited. Normally the frequency of 
transduced cells is very low and elimination of all nontransduced cells would probably result in a 
graft unable to support a normal haematopoiesis. So far, several strategies have been reported for 
in vivo selective expansion of gene-modified HSCs, and these are outlined in Table 1.5. As 
indicated in Table 1.5, the strategies can be classified into two categories. One involves the 
transfer of a drug-resistance gene and elimination of non-transduced cells with a relevant 
cytotoxic compound, normally an anti-tumour agent. The other confers a direct growth 
advantage on the target HSCs. The latter approach can be divided into two subclasses based on 
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whether the growth advantage is derived from an overexpressed intrinsic protein e. g HOXB4 
gene or a chimeric cytokine receptor controlled by an artificial ligand (Kume et al., 2002).  
 
Category Strategy  Example 
Passive selection  Drug resistance  ABC transporters (e.g. MDR-1) 
    DNA repair (e.g. MGMT) 
    Folate metabolism (e.g. DHFR variants) 
Direct growth 
advantage 
Fusion protein plus drug  Steroid-based (e.g. Oestrogen receptor) 
FKBP-based (e.g. AP20187) 
 Intrinsic  factor  HOXB4 
 
Table 1.5: Strategies for in vivo expansion of genetically modified cells. MDR, multidrug resistance 
gene; DHFR, dihydrofolate reductase gene; MGMT, O
6-methylguanine-DNA methyl-transferase gene; 
FKBP, FK506-binding protein 12; HOXB4, HoxB4 transcription factor; ABC, ATP-binding cassette 
(modified from Kume, 2002; Milsom and Fairbairn, 2004) 
 
1.4.1  The Homeobox B4 Transcription Factor as a Candidate for Selective Expansion of 
Gene-Modified HSCs 
 
Various complex combinatory effects of external and internal signals regulate the 
proliferation and differentiation of haematopoietic cells. The regulatory machinery includes 
haematopoietic growth factors (cytokines), cell cycle regulators and transcription factors. The 
function of transcription factors is to bind to specific DNA sequence motifs upstream of the 
target gene and regulate its transcription, resulting in RNA transcripts. The homeobox (HOX) 
transcription factors are recognised as important players in murine and human haematopoiesis.  
There are two main groups of HOX genes in mammals, class I and class II. There are 39 
class I HOX genes known, organised in four clusters, A–D, each cluster containing 9–11 genes 
on four different chromosomes (Scott, 1992; Boncinelli et al., 1989; Grier et al., 2005). Figure 
1.8 shows the organisation of the HOX clusters. All haematopoietic progenitors express HOX 
genes in a pattern characteristic for the lineage and stage of differentiation of the cell. For 
example, at least 22 of the 39 HOX genes are expressed in human CD34
+ cells (Sauvageau et al., 
1994; Lawrence and Largman, 1992). The function of HOX genes in haematopoiesis has been 
extensively investigated using overexpression strategies. It has been reported that retroviral 
overexpression of HOXA5, HOXA9 and HOXA10 leads to perturbation of myeloid and/or 
lymphoid haematopoiesis, both in murine and human haematopoietic cells (Crooks et al., 1999; 
Lawrence et al., 1997; Thorsteinsdottir et al., 2002; Schiedlmeier et al., 2003). 
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Figure 1.8: Schematic representation of the chromosomal organisation of mammalian HOX genes. 
Groups 1–13 are called paralogue groups and share high sequence homology in the homeodomain. Black 
boxes indicate the lack of a gene (modified from Grier et al., 2005).  
 
The two HOX genes from the HOXB group, i.e. HOXB3 and HOXB4, are strongly 
expressed in BM cells enriched for pluripotent progenitors (Giampaolo et al., 1994). Even 
though expression patterns for these two genes during haematopoiesis are similar, results from 
retroviral-engineered overexpression are clearly contrasting. In murine BM cells, overexpression 
of HOXB3 causes a myeloproliferative disorder that can give rise to myeloid leukaemia and 
disruption of lymphoid differentiation, increased granulopoiesis and a reduced number of pro-B 
clonogenic progenitors (Sauvageau et al., 1997). However, most reports demonstrate that 
overexpression of HOXB4 does not result in a malignant phenotype but instead strongly 
enhances the regenerative capability of the stem cell pool. When overexpressed by retroviral 
gene transfer, HOXB4 showed an enhanced ability to regenerate the most primitive stem cell 
compartment in serial transplantation studies. This resulted in a 50–80 fold increase in the 
number of transplantable pluripotent HSCs in both primary and secondary recipients (Sauvageau 
et al., 1995; Thorsteinsdottir et al., 1999; Antonchuk et al., 2001). Additionally, HOXB4-
mediated ex vivo expansion of adult murine HSCs resulted in 1000-fold higher levels relative to 
controls and a 40-fold net increase in HSCs. This demonstrated that the unique effects of 
HOXB4 on HSC regeneration are greater than any other known regulatory factor or cytokine 
combination. A recent study has also shown that HOXB4 can induce rapid ex vivo expansion of 
transduced HSCs (Antonchuk et al., 2002) and the use of a soluble recombinant HOXB4 protein 
led to strong ex vivo expansion of HSCs (Krosl et al., 2003). A study of mice deficient in the 
HOXB4 gene demonstrated a clear connection between this gene and the stem cell compartment 
since HOXB4 deficiency led to reduced regeneration of LTR-HSCs (Björnsson et al., 2001). 
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These observed actions have potential important clinical implications and could be utilised to 
correct the low number of HSCs after BM cell transplantation. However, Schiedlmeier et al. 
(2003) reported that, in addition to expansion of the CB stem cell pool, strong ectopic expression 
of HOXB4 hampered myeloerythroid differentiation and caused a reduction in B-lineage output 
in transplanted NOD/SCID mice. In this study, modified FMEV-based retroviral gene transfer 
vector was used for transduction of human CB cells, resulting in 7-fold higher HOXB4 levels 
than originally described by Sauvageau et al. (1995). However, a study by another group using a 
MSCV-based retroviral vector showed that enforced HOXB4 expression increased the number of 
primitive human repopulating cells by 3–4 fold without perturbing the lymphomyeloid 
reconstitution in vivo (Buske et al., 2002). Therefore, the suitability of HOXB4 for enhancing the 
stem cell pool in therapeutic applications appears to depend upon the level of expression. 
The molecular mechanisms governing HOXB4 expression are unknown, but essential 
DNA binding sites have been identified in the HOXB4 promoter region. The upstream 
stimulating factors (USF)-1 and -2 bind to this sequence and induce proliferation in response to 
cytokines that stimulate self-renewal rather than differentiation (Giannola et al., 2000). A more 
recent study using the FDCP-mix cell line demonstrated that ectopic overexpression of HOXB4 
can elicit an in vitro differentiation delay in murine BM cells, a process which might be essential 
for HSC expansion, but may not be easily detectable in vivo (Milsom et al., 2005). 
 
1.4.2  Drug Resistance Genes as Selective Cassettes for Gene-Modified HSCs 
 
The idea for this strategy comes from marrow protection in cancer patients undergoing 
treatment with anti-cancer drugs. The principle of the method is shown in Figure 1.9. Cells 
expressing a drug resistance gene would tolerate the selective pressure of the relevant cytotoxic 
drug, whereas non-transduced cells of sensitive tissues would be eliminated. The relative number 
of transduced cells would thereby increase. A number of vectors have been developed to transfer 
various drug-resistance factors into HSCs with a view to protecting the BM compartments 
against collateral toxicity (Rafferty et al., 1996; Milsom and Fairbairn, 2004). The most 
extensively studied drug resistance gene is the multidrug resistance gene 1 (MDR-1), which 
confers resistance to a variety of chemotherapeutic drugs, such as anthracyclines. Clinical trials 
of MDR-1 gene therapy have been carried out and are characterised by low transduction 
frequencies in repopulating cells and short-term engraftment of MDR-1-positive cells. However, 
protection of the gene-transduced cells from chemotherapy-induced myeloablation could be 
achieved in some patients (Hanania et al., 1996; Hesdorffer et al., 1998; Cowan et al., 1999; 
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Moscow et al; 1999). Other drug resistance genes, including mutants of dihydrofolate reductase 
(DHFR) and O
6-methylguanine-DNA methyltransferase (MGMT), are also utilised in preclinical 
trials for selection of gene-modified HSCs (Allay et al., 1998; Sawai et al., 2001).  
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Figure 1.9: Principle of passive expansion. Non-transduced cells are eliminated by cytotoxic drugs, whereas 
cells carrying a drug-resistance gene survive and repopulate. 
 
Although attractive in theory, there are significant drawbacks to this approach. No true 
expansion of the desired transduced cells is achieved, only elimination of non-transduced cells. 
An elimination of >95% of non-transduced cells would result in aplastic anaemia. Additionally, 
the host would be exposed to recurrent cycles of chemotherapy with the accompanying side 
effects on non-haematopoietic cells. 
 
1.4.3  Direct Growth Advantage with Chimeric Receptors from Cytokine or Growth 
Factor Receptors 
 
A less toxic approach to expand genetically modified cells is to confer a direct growth 
advantage to transduced cells (Figure 1.10). For this purpose, conditional systems that regulate 
the fate of genetically modified cells based on protein dimerization have been developed. Protein 
dimerization is an important physiological process in mammalian cells and controls many 
behaviours, such as proliferation, differentiation and apoptosis (Scott, 2000). The conditional 
system consists of two main members: a fusion protein and a drug (or hormone). The fusion 
protein contains a growth factor receptor signalling domain which is linked to one or more drug-
binding sites (or hormone receptor). By administering a small synthetic molecule (chemical 
inducer of dimerization, CID), therapeutically relevant expansion of the target cells can be 
attained. The principle and mechanism of this positive selection is outlined in Figure 1.10. The 
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treatment with the dimerizer could be performed repeatedly over time with an optimal titred dose 
and its effect must be reversible (Ito et al., 1997; Matsuda et al., 1999; Milsom 2004). 
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Figure 1.10: Schematic representation of dimerizer-induced selective expansion of transduced cells. 
Corrected cells, transduced with the therapeutic gene, are co-transduced with a fusion protein containing 
the signal transduction domain (SIG) from a truncated growth factor receptor (GF-R) and a CID binding 
domain. The specific binding of the CID to its domain causes dimerization of the SIG, giving rise to 
transduced cell proliferation. This can be detected by e.g. expression of the gp91
phox protein and its 
product O2
– (modified from Hossele et al., 2002). 
 
The most intensively researched fusion protein used in haematopoietic cell lines and 
murine BM cells is derived from the truncated G-CSF and oestrogen binding sites. Binding of 
oestrogen (or tamoxifen in the case of the tamoxifen-responsive mutant of the oestrogen 
receptor) leads to activation of the G-CSF receptor (Xu et al., 1999; Matsuda et al., 1999). 
Oestrogen-dependent growth has been observed in transduced IL-3-dependent BaF/3 cells and 
primary murine BM progenitors (Ito et al., 1997). Selective expansion has also been 
demonstrated in primary and secondary BM recipients in mouse transplantation studies (Kume et 
al., 2003). Additionally, following in vivo administration of oestrogen in non-human primates, 
selection for gene-modified cells was achieved in one of two animals (Hanazono et al., 2002). 
Recently, tamoxifen-inducible, in vitro expansion of haematopoietic cells following transduction 
with a chimeric version of the human thrombopoietin receptor (hmpl) has been reported 
(Nagashima et al., 2003). 
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Another extensively characterised system is based on the immunolipophilin FKBP12, 
which binds the immunosuppressive agent FK506. The fusion protein is cross-linked by a CID, 
which leads to activation of the signalling transduction domain. Early work, using an FK506-
binding domain (FKBP) fused to the signalling domain of the erythropoietin receptor, showed a 
significant growth-factor dependent selective effect in haematopoietic cell lines (Blau et al., 
1997). Furthermore, a mutant version of FKBP (F36V) was developed which binds derivatives 
of FK506 (e.g. AP20187) that can not bind to endogenous FKBP12 (see web page 
www.ariad.com). Use of a protein containing F36V fused with the signalling domain of hmpl led 
to a marked selective expansion of gene-modified haematopoietic progenitor cells in vitro, and 
the effect was superior to that of a fusion protein containing the G-CSF receptor and flat-3 (Jin et 
al., 1998; Zheng et al., 2001). Clear evidence of selection could also be found in in vivo murine 
studies using the hmpl dimerizer system (Jin et al., 2000). In this study, the murine 
haematopoietic cells were expanded by introduction of a fusion protein consisting of FKBP and 
the hmpl cytoplasmic domain. In serial samples of BM taken before and after drug treatment of 
animals, an increased number of gene-modified GM-CFCs was observed post-selection; 
however, selection was not based on true stem cells. Experiments in large animals using this 
system have also shown clear evidence for selection of gene-modified (GFP
+) cells, although 
expression was transient and mostly restricted to the erythroid and platelet compartments where 
hmpl signalling plays an important role (Neff et al., 2002). 
 
1.5  Epidermal Growth Factor Receptor and Prolactin Receptor 
 
As described above, data from in vitro and in vivo experiments have so far not indicated a 
true expansion of HSCs through the use of dimerizer systems with a signalling domain from the 
G-CSF, thrombopoietin (mpl) or other receptors. Therefore, we looked for other signalling 
domains which may induce selective expansion of early HSCs with the dimerizer system. Two 
growth factor receptors, the epidermal growth factor receptor (EGFR) and the prolactin receptor 
(PrlR) were used in our studies,. These growth factor receptors belong to the family of cell 
surface receptors, which integrate a multitude of extracellular signals such as environmental 
stresses, growth factors, neuropeptides or hormones, and thereby regulate a large diversity of 
signalling pathways and cell responses. The structure, signalling pathway, and physiological, 
pathophysiological functions of both receptors are explained in following text.  
 
1.5.1  Epidermal Growth Factor Receptor 
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The EGFR is a well-known signal transducer that has been well conserved during 
evolution. It induces a wide range of cellular processes, including cell fate determination, 
proliferation, cell migration and apoptosis (Carpenter et al., 2000). The activity of the EGFR is 
subject to modulation by multiple positive and negative regulators and is transduced into the 
nucleus by several conserved signalling cassettes. 
 
1.5.1.1   Structure and Signalling Pathway of EGFR 
 
The EGFR belongs to a subgroup of cell surface receptors, the receptor tyrosine kinases 
(RTKs), which possess an intrinsic tyrosine kinase activity. The RTK subgroup consists of four 
members: EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. The EGFR was the first 
cell surface signalling protein and proto-oncogene to be characterised (Ullrich et al., 1984). All 
members of the EGFR family are composed of an extracellular ligand-binding domain, a single 
membrane-spanning domain and a cytoplasmic domain containing a conserved protein tyrosine 
kinase core, flanked by regulatory sequences (Schlessinger, 2002) (Figure 1.10). The 
extracellular domain has two cysteine-rich domains, CRI and CRII, which are responsible for 
ligand binding. Three conserved sequence domains have been recognised within the cytoplasmic 
region. The juxtamembrane region is required for feedback reduction by the protein kinase. It is 
followed by the tyrosine kinase domain, a Src homology domain 1 (SH1). This is the most 
conserved region among the EGFR proteins and it mediates auto-phosphorylation of the 
carboxy-terminal tail on six tyrosine residues. EGFR can be activated by a large group of EGF-
related growth factors, such as EGF and transforming growth factor α (TGF-α). Binding of EGF 
to EGFR leads to the dimerization of the receptor to form a complex containing two ligand 
molecules and two receptor molecules. This activates several conserved signalling cassettes that 
are required to transmit the signal from the receptor to the nucleus or to the cytoplasm. The first 
important pathway to be activated is the Ras-mitogen-activated protein kinase or MAP kinase 
pathway. When this pathway is activated, the SOS guanine nucleotide exchange factor is 
recruited to the plasma membrane via adaptors such as Grb2 and Drk. SOS stimulates the 
exchange of GTP to GDP on the small G-protein Ras. Subsequently, activated Ras stimulates the 
MAP kinase pathway to promote cell proliferation. Phospholipase Cγ (PLCγ) and 
phosphatidylinositol 3-kinase (PI3-kinase) can also transduce the EGFR activity responsible for 
cell motility (Bogdan and Klämbt, 2001). Figure 1.11 presents the structure and the major 
signalling pathways of EGFR. 
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Figure 1.11: Schematic representation of EGFR structure and signalling transduction pathways. At the 
plasma membrane, the non-stimulated EGFR is present as a monomer of 1186 amino acids (left). Upon 
binding of extracellular ligand, EGFR undergoes dimerization resulting in trans-autophosphorylation of its 
cytoplasmic domain. EGFR activity is transduced to the cell via cascades such as the Ras-Raf-MAP pathway, 
PLCγ and PI3-kinase (see text). The positions of 6 tyrosine residues are shown. CR, cysteine-rich domain; TM, 
transmembrane region; JM, juxtamembrane region (modified from Bogdan and Klämbt, 2001). 
 
1.5.1.2   Physiological and Pathophysiological Roles of EGFR 
 
The basic functions of the pleiotropic signal transducer EGFR execute multiple roles 
during cell fate determination, differentiation, proliferation and apoptosis. This is evident from 
the analysis of genetically modified mice. Mice lacking EGFR usually die during the first 
postnatal weeks as a result of respiratory problems. They also show gastrointestinal phenotypes, 
thin skin and hair-follicle defects (Miettingen et al., 1995; Sibilia and Wagner, 1995).  
However, various studies have made clear that EGFR overexpression or mutations 
contribute to the development of many human cancers. The ErbB1 protein is a prototype of the 
EGFR family and its identification provided one of the first links between an activated oncogene 
and the development of cancer. The expression status of ErbB1 is also changed in a large number 
of tumours and it has been used as a prognostic marker for many years (Olayioye et al., 2000). 
As many as 77% of colorectal cancer cases demonstrate a significant overexpression of EGFR 
(Vallbohmer and Lenz., 2005). In human breast cancer, gene amplification of another member of 
the EGFR family (HER2) is correlated with a shorter overall survival and relapse-free survival 
(Slamon et al., 1987). Many studies have demonstrated a role of EGFR mutants in tumour 
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development. Several deletions in the extra- and intracellular domains have been found in 
glioblastomas (Ekstrand et al., 1992), non-small-cell lung carcinomas (Garcia de Palazzo et al., 
1993), breast cancer (Wikstrand et al., 1995) and ovarian carcinomas (Moscatello et al., 1995).  
In general, the EGFR is thought to be either not expressed or expressed at low levels in 
haematopoietic cells. A recent study has shown that it is expressed at a low level in the murine 
cytokine-dependent haematopoietic cell line FDC-P1 but not in the murine IL-3 dependent cell 
line FL5. EGF induces a mild effect on DNA synthesis and ERK activation in EGFR-positive 
FDC-P1 cells but not in EGFR-negative FL5.12 cells (Shelton et al., 2005). A direct correlation 
between EGFR and haematopoietic cells cancers has not been observed. 
  
1.5.2  Prolactin and its Receptor 
 
The natural ligand of PrlR, prolactin (Prl), is a paradoxical hormone. It is secreted by the 
anterior pituitary gland and was originally identified by its ability to stimulate the development 
of the mammary gland and lactation (Freeman et al., 2000). Prl has a similar amino acid 
sequence to the two other peptide hormones, growth hormone (GH) and placental lactogen (PL) 
(Goffin et al., 1996). More recently, based on both molecular and functional evidence from 
studies of the immune system, the Prl/GH/PL hormones have been linked to a further extended 
family of proteins, referred to as haematopoietic cytokines (Horseman and Yu-Lee, 1994). The 
functions of PRL are effected through binding to its receptor. The PrlR is a single membrane-
bound protein belonging to the class I cytokine receptor subfamily (Bazan et al., 1990). Just like 
their respective ligands, the PrlR and growth hormone receptor share several structural and 
functional features despite their low (30%) sequence homology (Goffin et al., 1998). The PrlR 
structure is explained below. 
 
1.5.2.1   Structure and Signalling Pathway of PrlR 
 
PrlR is a membrane-bound protein and contains an extracellular domain, a 
transmembrane domain and an intracellular domain. Because PrlR can be transcribed from 
different alternative promoters and from diverse splicing of non-coding and coding exons, 
various isoforms have been described from different tissues (Ali et al., 1991; Davis and Linzer, 
1989). Although the length and composition of the cytoplasmic domains of PrlR are different, 
the extracellular domains are identical (Lesueur et al., 1991) (Figure 1.11). Three major PrlR 
isoforms, termed short (291 aa), intermediate (393 aa) and long (591 aa), have been detected in 
rats. For mice, one long and three short forms have been reported (Clarke and Linzer, 1993; 
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Bole-Feysot et al., 1998). The extracellular domain of PrlR can be divided into an NH2-terminal 
D1 containing the conserved feature of two pairs of disulphide bonds (Cys-) and a membrane-
proximal D2 subdomain with a “WS motif”. Each PRL molecule has two binding sites and 
activation of PrlR involves ligand-induced sequential receptor dimerization (Bole-Feysot et al., 
1998). The role of the 24 amino acid transmembrane domain in activation is not clear. The 
intracellular domain is a key player in the signal transduction pathway and differs in length and 
composition among the various isoforms. However, there are two relatively conserved regions, 
the proline-rich motif region Box 1 and the less conserved Box 2. 
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Figure 1.12: Structure of the rat PrlR and isoforms. The short and long isoforms result from alternative 
splicing, while the intermediate form represents a deletion mutant of the long isoform. Tyrosine residues are 
indicated by –Y, cysteine residues by Cys- and the tryptophan-serine-X-tryptophan-serine motif by 
“WSXWS”. aa, amino acids (modified from Clevenger et al., 1998; Bole-Feysot et al., 1998). 
 
The function of the Prl/PrlR complex is mediated by the receptor-associated signalling 
proteins. In contrast to the EGFR, the PrlR per se lacks intrinsic enzymatic activity. Ligand-
induced dimerization of the PrlR complex serves to activate the associated signalling cascades, 
which include (Freeman et al., 2000; Clevenger et al., 1998; Bole-Feysot et al., 1998): 
 
  JAK/STAT pathway: STAT1, STAT3, STAT5a and STAT5b, members of the signal transducer 
and activator of transcription family, are the central transducer molecules of the signal 
transduction pathways initiated by PrlR activation (Goffin et al., 1998). Binding of PRL to its 
receptor activates phosphorylation of the STAT proteins by the receptor-associated JAK kinase, 
triggering their dimerization. Finally, the STAT dimers translocate into the nucleus and activate a 
STAT DNA-binding motif in the promoter of a target gene. 
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  Mitogen-activated protein kinase (MAPK) cascade: Phosphorylation of JAK2 kinase enables the 
association of the signalling adaptor protein SHC with PrlR, which in turn activates the 
Shc/Grb2/Vav/Sos/Ras/Rac/Raf/MEK/MAPK signalling cascades. This triggers activation of a 
wide range of transcription factors. 
   Src kinase: PRL also induces the activation of members of the Src kinase family, such as Fyn, 
which is involved in the tyrosine phosphorylation of PI3-kinase. 
 
A schematic representation of major signalling transduction pathways induced by the Prl/PrlR 
complex is shown in Figure 1.13. 
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Figure 1.13: Signal transduction pathways initiated by PrlR activation. Ligand-induced activation of the 
PrlR complex has been found to activate the JAK/STAT (black), Shc-MAPK (red) and Fyn (blue) pathways.  
 
1.5.2.2   Functions of Prl/PrlR in Haematopoiesis 
 
Prl, historically known as the pituitary hormone of lactation, has now been found in more 
than 300 disconnected actions, which could be correlated to the quasi-ubiquitous distribution of 
its receptor. It has been demonstrated that this hormone has numerous and various functions 
attributed to six broad categories: (i) reproduction and lactation, (ii) growth and development, 
(iii) endocrinology and metabolism, (iv) brain and behaviour, (v) immunomodulation and (vi) 
electrolyte balance (Bole-Feysot et al., 1998).  
The effect of PRL on the immune system is similar to that of cytokines and was first 
described in avian and murine species. In the presence of mitogen, PRL can act as a co-mitogen 
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for T- and B-cells of human or murine origin, and also for NK cells and macrophages (Nagy and 
Berczi., 1991; Skwarlo-Sonta, 1990; Matera et al., 1992). In human studies, a transient, but 
significant reduction in the overall response of isolated PB lymphocytes to mitogens was 
observed following a decrease in PRL levels (Devins et al., 1992; Bailey and Burchett, 1997). 
However, data from Prl/PrlR double knock out mice revealed no obvious defect in the 
haematopoietic system, and the haematopoietic organs, such as PB, spleen, thymus and lymph 
nodes, revealed normal T- and B-cell numbers. This evidence indicates that PRL alone is not 
required for the development of a normal number of immune system cells (Horseman et al., 
1997; Ormandy et al., 1997). 
Despite the fact that it does not play a key role in the haematopoietic system, evidence 
indicates that Prl and its receptors exist in many types of BM-derived cells, such as T-cells, B-
cells, NK cells, monocytes and granulocytes (Sabharwal et al., 1992). In vivo experiments have 
indicated that the physiological level of PRL can correct the fatal anaemia in hypophysectomised 
rats induced by administration of PRL antibodies, and restore normal myeloid and erythroid 
parameters (Nagy and Berczi, 1991). In normal mice, administration of recombinant human PRL 
(r-hPrl) can increase splenic haematopoiesis with a small, but significant increase in BM 
progenitors (Woody et al., 1999) and promote T-cell function (Murphy et al., 1993). Syngeneic 
BM transplantation in mice has shown that Prl can accelerate myeloid, erythroid and platelet 
recovery in the BM, spleen and PB, as well as thymic recovery. PRL can also enhance myeloid 
and erythroid recovery following myelosuppression induced by reverse transcriptase inhibitors, 
such as AZT (Woody et al., 1999). In vitro data from BM stromal cells, which have been shown 
to both produce PRL and express PrlR, has demonstrated the promoting function of PRL in 
haematopoiesis (McAveney et al., 1996).  
Activation of the PrlR in the haematopoietic system also leads to biological effects, such 
as cell proliferation, survival and inhibition of apoptosis via the signal transduction pathways 
described above (see chapter 1.5.2.1). Evidence for PrlR expression and a direct action of Prl on 
haematopoietic stem and/or progenitor cells is less clear. One group has demonstrated that the 
CD34
+ population expresses PrlRs and addition of PRL to these cells in colony assays enhanced 
the growth of granulocytic and erythrocytic progenitors (Bellone et al., 1995). In contrast, 
another group using r-hPrl in mouse BM cells did not find any evidence of Prl effects on 
progenitor numbers (Woody et al., 1999). Further experiments are necessary to investigate the 
contribution of Prl/PrlR to haematopoietic stem/progenitor cell function. 
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2.  Goals of The Present Study 
 
Low transduction efficiency ex vivo and the disappearance of gene-modified 
transplanted HSCs in vivo are still critical issues that need to be addressed before gene 
therapy approaches can be used to correct genetic defects. The aim of this project was to 
develop a positive selection system to expand gp91
phox gene-modified murine HSCs in vitro, 
ex vivo and in vivo. This selection should be inducible to allow controllable expansion of the 
cells. 
 
At first, a positive selection system based on the homeobox transcription factor 
HOXB4, an essential factor for stem cell expansion, was created. A bicistronic 
gammaretroviral vector, coding for HOXB4 and the therapeutic gene gp91
phox, was designed 
and its influence on cell proliferation and selective expansion of transduced HSCs was 
analysed. The ability of these cells to contribute to normal haematopoiesis in vivo was then 
tested. Most importantly, the amount of gp91
phox-transgene expression in the peripheral blood 
of transplanted mice, indicating successful gene correction, was investigated 
 
The second strategy aimed to produce inducible expansion of gp91
phox-transduced 
HSCs. For this purpose, a dimerizer system based on fusion proteins containing two FBKP12 
drug-binding domains and the intracellular signalling domain of the EGF or PrlR was 
designed. The following tasks were performed: 
a)  Construction of a lentiviral vector containing the FKBP12 and signalling domains of the 
EGF or PRL receptor and examination of the resulting inducible/reversible cell 
proliferation and transgene expression in transduced BaF/3 cells. 
b) Generation of a bicistronic gammaretroviral vector containing the tested dimerizer 
system and therapeutic gp91
phox gene, and assessment of the effect on cell proliferation 
and gp91
phox transgene expression in transduced BaF/3 cells. 
c) Analysis of the influence on selection capacity of Sca1
+ murine haematopoietic 
stem/progenitor cells ex vivo. Furthermore, transgene expression, normal multilineage 
differentiation and polycolonality of the ex vivo-expanded HSCs were determined after 
selection.  
d)  Assessment of cell engraftment and gene transfer efficiency in peripheral blood, spleen 
and bone marrow cells in mouse transplantation models 8 weeks post transplantation. 
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3. Materials and Methods 
 
3.1 Materials for Molecular Biological Experiments 
 
3.1.1   Equipments and Necessary Materials 
 
ACL
TM-analysis system  Instrumentation Laboratories, Lexington, 
MA, USA 
analysis balance  Sartorius, Göttingen, Germany 
autoclave  Integra Biosciences, Baar, Switzerland 
autoradiographie-film (Hyperfilm
TM MP)  Amersham Pharmacia, Little   Chalfont, UK 
incubator  Heraeus, Hanau, Germany 
electrophoresis chamber   
 - for agarose gel (Horizon 11-14)  Life Technologies, Karlsruhe, Germany 
 - for SDS-PAGE (Mini Protean 3)  Bio-Rad, Munich, Germany 
 - for EMSA  Bio-Rad, Munich, Germany 
FACS-Scan  Becton Dickinson, Heidelberg, Germany 
FACS-Calibur  Becton Dickinson, Heidelberg, Germany 
fluorescence microscope  Nikon, Düsseldorf, Germany 
tissue culture flask  Greiner, Frickenhausen, Germany 
hot plate  Techne, Princeton, NJ, USA 
magnetic particle concentrator  Dynal, Hamburg, Germany 
needle  Becton Dickinson, Heidelberg, Germany 
cell strainer (100 µm, 40 µm)  Becton Dickinson, Heidelberg, Germany 
cryocontainer  Nalgene, Rochester, NY, USA 
cryotube  Nalgene, Rochester, NY, USA 
light microscope  Zeiss, Göttingen; Leica, Wetzlar, Germany 
PCR-block (GeneAmp 2400)   Perkin-Elmer, Weiterstadt, Germany 
pH-meter  Knick, Berlin, Germany 
pipettes  Becton Dickinson, Heidelberg, Germany 
pipette helper  Hirschmann Laborgeräte, Eberstadt, Germany
reaction tube  Eppendorf, Hamburg; Sarstedt, Nümbrecht, 
Germany 
injection  Becton Dickinson, Heidelberg, Germany 
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stericup-filter  Millipore, Eschborn, Germany 
sterilbank  Heraeus, Hanau, Germany 
sterilfilter (0,22 µm; 0,45 µm)  Millipore, Eschborn, Germany 
table centrifuge  Eppendorf, Hamburg, Germany 
vortexer  Janke & Kunkel, Staufen, Germany 
water bath  Gesellschaft für Labortechnik, Burgwedel, 
Germany 
whatman-Paper  Schleicher & Schuell, Dassel, Germany 
cell culture flasks  Greiner, Frickenhausen; Becton Dickinson, 
Heidelberg, Germany 
cell culture dishes  Greiner, Frickenhausen; Becton Dickinson, 
Heidelberg, Germany 
cell scraper  Corning, Wiesbaden, Germany 
irradiation instrument  Department of Radiology, University 
Frankfurt, Germany 
 
3.1.2  Chemicals and Reagents for Cell Culture 
 
ammonium chloride  StemCell Technologies, Vancouver, Canada 
AP20187  ARIAD Pharmaceuticals, Inc. Cambridge, 
UK 
calcium chloride  Sigma, Taufkirchen, Germany 
chloroquine  Sigma, Taufkirchen, Germany 
dinatriumhydrogenphosphate  Merck, Darmstadt, Germany 
DMEM  Dulbecco's Modified Eagle Medium (High 
Glucose); Life Technologies (#21969-035), 
Karlsruhe, Germany 
DMSO  Dimethylsulfoxid; Sigma, Taufkirchen, 
Germany 
DNase I (RNase-free)  Roche (#776785), Mannheim, Germany 
dNTPs  New England Biolabs, Frankfurt, Germany 
EasySep-system  Stemcell Technologies, Vancouver, Canada 
EDTA  Sigma, Taufkirchen, Germany 
enfluran 2-Chloro-1.1.2-trifluoro-
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ethyldifluoromethylether (Ethrane); Abbott, 
Wiesbaden, Germany 
FBS  Fetal Bovine Serum, Seromed (#S0115), 
Berlin, Germany & StemCell Technologies 
(#06400), Vancouver, Canada 
formaldehyde  Roth, Karlsruhe, Germany 
gelatine (powder)  Merck, Darmstadt, Germany 
glutamine  L-Glutamine; BioWhittaker, Verviers, 
Belgium 
HBSS  Hanks' Balanced Salt Solution; Sigma 
(#H6648), Taufkirchen, Germany 
HEPES  Sigma, Taufkirchen, Germany 
HSA  Human Serum Albumin (20% solution); 
DRK-Blutspendedienst Niedersachsen, 
Springe, Germany 
IMDM/2% FBS  Iscove's Modified Dulbecco's Medium with 
2% FBS; StemCell Technologies, Vancouver, 
Canada 
MethoCult GF M3434  StemCell Technologies, Vancouver, Canada 
sodium acid  Roth, Karlsruhe, Germany 
sodium chloride  Roth, Karlsruhe, Germany 
PBS  Dulbecco's Phosphate Buffered Saline (ohne 
Ca
2+ und Mg
2+); BioWhittaker, Verviers, 
Belgium 
penicillin-Streptomycin  BioWhittaker, Verviers, Belgium 
polybrene  Sigma, Taufkirchen, Germany 
poly-L-lysine solution  Sigma, Diagnaostics INC., St. Lous, USA 
protaminsulfate  Sigma (#2162), Taufkirchen, Germany 
retronectin  Takara, Shiga, Japan 
RPMI 1640  RPMI 1640 (without Glutamine); Life 
Technologies (#31870-025), Karlsruhe, 
Germany 
StemSep-Systeme  StemCell Technologies, Vancouver, Canada 
tris  Roth, Karlsruhe, Germany 
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trypan blue  0,4% solution; Sigma, Taufkirchen, Germany 
trypsine -EDTA  Trypsine-EDTA in HBSS; Life Technologies 
(#25300-054), Karlsruhe, Germany 
sterile water for tissue culture  Sigma (#W3500), Taufkirchen, Germany 
  
3.1.3   Enzymes 
 
alkaline phosphatase (CIP)  New England Biolabs, Frankfurt, Germany 
ampli-Taq-DNA-polymerase  Biosystems, Weiterstadt, Germany 
Klenow-Fragment DNA-polymerase I  New England Biolabs, Frankfurt, Germany 
Pfu Turbo DNA-polymerase  Stategene, Amsterdam, Netherlands 
RNase A  Sigma, Taufkirchen, Germany 
restriction endonucleases  New England Biolabs, Frankfurt, Germany 
T4 DNA-ligase  New England Biolabs, Frankfurt, Germany 
 
3.1.4   Cytokines 
 
rmIL-3 (recombinant murine interleukin 3)  PeproTech, Frankfurt, Germany 
rmIL-6 (recombinant murine interleukin 6)  PeproTech, Frankfurt, Germany 
rmSCF (recombinant murine stem cell factor)  PeproTech, Frankfurt, Germany 
WEHI-medium (conditioned RPMI-medium 
with mIL-3) 
GSH, Laboratory Dr.Grez, Frankfurt, 
Germany 
 
3.1.5   Antibodies 
 
3.1.5.1   Antibodies for Western Blot and Intracellular Staining 
 
anti-FKBP  ABR Affinity Bioreagents Inc., CO, USA 
monoclonal anti-α-Tubulin  Sigma, Taufkirchen, Germany 
488 goat anti-rabbit IgG1  Molecular Probes, Eugene, Oregon, USA 
546 goat anti-mouse IgG1  Molecular Probes, Eugene,Oregon, USA 
anti-Plcγ  Sigma, Taufkirchen, Germany 
anti-phospho-STAT5A/B(Y694)  Cell Signalling Technology, MA, USA 
anti-STAT5  BD Transduction Laboratories, Lexington, 
KY, USA 
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anti-PI3-Kinase BD  Transduction Laboratories, Lexington, 
KY, USA 
polyclonal Rabbit anti-Stat5a  Zymed Laboratories Inc, San Francisco, CA, 
USA 
anti-maus IgG-peroxidase  BD Transduction Laboratories, Lexington, 
KY, USA 
anti-rabbit IgG-peroxidase  BD Transduction Laboratories, Lexington, 
KY, USA 
 
3.1.5.2   Antibodies for FACS-analyse 
 
7D5 antibody (anti-gp91
phox)  GSH, Loboratory Grez, Frankfurt, Germany 
rat anti-mouse IgG1(RAM IgG1)-PE  Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA 
anti-mouse CD3-Biotin  BD Pharmingen, Heidelberg, Germany 
anti-mouse B220-Biotin  BD Pharmingen, Heidelberg, Germany 
anti-mouse Gr1-Biotin  BD Pharmingen, Heidelberg, Germany 
streptavidin-APC  BD Pharmingen, Heidelberg, Germany 
anti-LNGFR(C40-1457)-PE  BD Pharmingen, Heidelberg, Germany 
rat anti-mouse IgG1-APC  BD Pharmingen, Heidelberg, Germany 
anti-CD45.1-PE  BD Pharmingen, Heidelberg, Germany 
anti-mouse Sca1-PE  BD Pharmingen, Heidelberg, Germany 
anti-mouse c-kit-PE  BD Pharmingen, Heidelberg, Germany 
anti-mouse IgG1-PE (Isotype)  BD Pharmingen, Heidelberg, Germany 
anti-mouse IgG1(pure)  BD Pharmingen, Heidelberg, Germany 
anti-mouse IgG2a-biotin  BD Pharmingen, Heidelberg, Germany 
 
3.1.6   Reagents and Enzymes for Molecular Biological Experiments 
 
acryl amide for SDS-PAGE  Rotipherese
® Gel 30 (30% Acrylamid, 0,8% 
Bisacrylamid); Roth, Karlsruhe, Germany 
agarose  Roth (#T846.3), Karlsruhe, Germany 
alkaline phosphatase  New England Biolabs, Frankfurt, Germany 
ampicillin  Roche, Mannheim, Germany 
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APS  Ammonium peroxydisulfate; Merck, 
Darmstadt, Germany 
bromphenol blue  Sigma, Taufkirchen, Germany 
bradford-reagent  Bio-Rad Laboratories, Inc., CA, USA 
chloroform  Roth, Karlsruhe, Germany 
DNA isolation kit  DNeasy
TM Tissue Kit; Qiagen, Hilden, 
Germany 
dried milk powder  Roth, Karlsruhe, Germany 
ECL-solution SuperSignal
 ® West Pico Chemiluminescent 
Substrate; Pierce, Rockford, IL, USA 
acetic acid  Roth, Karlsruhe, Germany 
alcohol (ethanol, 100%)  Roth, Karlsruhe, Germany 
ethidium bromide  Roth, Karlsruhe, Germany 
glycerol  Roth, Karlsruhe, Germany 
glycine  Roth, Karlsruhe, Germany 
glycogen  Roche (#901393), Mannheim, Germany 
IPTG Isopropyl-β-D-1-thiogalactopyranoside; 
Sigma, Taufkirchen, Germany 
isopropanol    Roth, Karlsruhe, Germany 
potassium acetate  Sigma, Taufkirchen, Germany 
LB Agar  Life Technologies (#22700-025), Karlsruhe, 
Germany 
LB Broth Base  Life Technologies (#12780-029), Karlsruhe 
manganese chloride  Sigma, Taufkirchen, Germany 
marker  
        - DNA  Smart Ladder; Eurogentec, Seraing, Belgium 
  
        - Protein  BenchMark
TM Prestained Protein Ladder; 
Invitrogen Life Technologies, Karlsruhe, 
Germany 
  Bio-Rad Laboratories, Inc., CA, USA 
methanol  Roth, Karlsruhe, Germany 
sodium acetate  Sigma, Taufkirchen, Germany 
sodium  hydroxide  Merck, Darmstadt, Germany 
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PCI Phenol/Chloroform/Isoamylalcohol  (25:24:1); 
Roth, Karlsruhe, Germany 
PCR-Reagents  
       - AmpliTaq  Perkin Elmer, Weiterstadt, Germany 
       - AmpliTaq Gold  Perkin Elmer, Weiterstadt, Germany 
       - GeneAmp
® PCR-buffer  Perkin Elmer, Weiterstadt, Germany 
       - Magnesium chloride  Perkin Elmer, Weiterstadt, Germany 
       - PfuTurbo DNA polymerase  Stratagene, Amsterdam, The Netherlands 
plasmid-maxipreparation kits  JetStar, Hannover, Germany 
protease inhibitor cocktail tablets, 
Complete (mini) 
Boehringer Mannheim, Germany 
PVDF-membrane Roti
 ®-PVDF  Roth, Karlsruhe, Germany 
 QIAquick- gel extraktion kits  Qiagen, Hilden, Germany 
RotiLoad1 loading buffer  Roth, Karlsruhe, Germany 
rubidium chloride  Sigma, Taufkirchen, Germany 
SDS, sodium didecyl sulfate  Roth, Karlsruhe, Germany 
To-Pro-3 iodide  Eugene, Oregon, USA 
TEMED N,N,N',N'-Tetramethylethylendiamin;  Roth, 
Karlsruhe, Germany 
triton X-100  Sigma, Taufkirchen, Germany 
 
3.1.7   Oligonucleotides 
 
3.1.7.1   Primer for PCR  
 
gp91(human): 
5'-Primer (gpfor01): TTGTACGTGGGCAGACCGCAGAGA 
3'-Primer (gprev02): CCAAAGGGCCCATCAACCGCTATC 
Length of PCR fragments: 510 bp 
β-Actin (mouse): 
5'-Primer (ACT-DFI5): CTA AGG CCA ACC GTG AAA AG 
3'-Primer (ACT-DFI3): TGA TAG ATG GGC ACA GTG TG 
Length of PCR fragments: 166 bp 
F2PrlR: 
5'-Primer: TCG AGA CTA GAG GAG TGC AGG TGG 
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3'-Primer:  CTT GCC CTT CTC TAG CAG ATG AG 
Length of PCR fragments: 428 bp 
 
3.1.7.2   Oligonucleotides for Cloning 
 
Amplification of intracellular PrlR:  
PrlRforSpe:    5’- GGA CTA GTA AGG GTT ATA GCA TGA CC-3’ 
PrlRrevKpn : 5’ – GGG GTA CCT CAG  TGA  AAG GAG TGC – 3’ 
Length of PCR fragment: 1036 bp 
 
Amplification of  intracellular EGFR: 
EGFRSpe-for: 5’- GAA ACT AGT CGA AGG CGC CAC ATC G – 3’ 
EGFRKpn-rev: 5’ – GGG GTA CCG CTC ATG CTC CAA TAA ATT CAC – 3’ 
Length of PCR fragment: 1700 bp 
 
Amplification of HOXB4 gene: 
HOXBamHIrev: 5’ – CGG GAT CCC TAG AGC GCG CGG  GGG CCT CCA – 3’ 
HOXHindIIIfor: 5’ – CCC AAG CTT GGC CAG AAA TTA ATG GC – 3’ 
Length of PCR fragment: 789bp 
 
3.1.7.3   Oligonucleotides for Sequencing 
 
Sequencing of the F2PrlR construct: 
SFFV for1: 5’ – GCT TCT GCT TCC CGA GCT C – 3’ 
F2PrlRfor: 5’- GCT CTA GAG CCA CCA TGG GCG TCC AAG – 3’ 
 
Sequencing of the F2 construct: 
SFFV for1: 5’ – GCT TCT GCT TCC CGA GCT C – 3’ 
gsF2for: 5’ – CCC AAG CTT GCC ACC ATG GGC GTC CAA GTC – 3’ 
gsF2rev: 5’ – ACT CCT CTA GTC TCG AGC TTC – 3’ 
 
Sequencing of the NF2PrlR construct: 
PrlRrev1: 5’ – GCC CTT CTC TAG CAG ATG – 3’ 
PrlRfor1: 5’ – GCT GGA TTA CCT GGA TCC – 3’ 
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Sequencing of the NF2EGFR construct: 
EGFRfor1: 5’ – GGC ATC TTT AAG GGC TCC – 3’ 
EGFRrev1: 5’ – CCA CTG GGT GTA AGA GGC – 3’ 
 
Sequencing of the gsHOXB4 construct: 
HOXfor1: 5’- GTT CCT CCC CAC TCC CCG ACC-3’ 
HOXrev1: 5’-TGC CCC CCG CAC GCA CGC GGG -3’ 
 
3.1.7.4   Primers for Integration Test (LM-PCR) 
 
Blunt-end Adapter: 
SL_linker_for: 5’-GTAATACGACTCACTATAGGGCACTATAGGGCACGCGTGGT-3’ 
SL_linker_rev: 5’-ACCACGCGTGCCCTATAGT-3’ (with 5’ phosphate) 
 
Primer against Adapter: 
SL-AP1: 5’-GTAATACGACTCACTATAGGGC-3’ 
SL-AP2: 5’-ACTATAGGGCACGCGTGGT-3’ 
 
Primer against SFFV-LTR: 
SL-R1-bio: 5’-TGGCCCAACGTTAGCTATTTTCATGTA-3’ (with 5’ biotin) 
SL-R1: 5’-TGGCCCAACGTTAGCTATTTTCATGTA-3’  
SL-R2-: 5’-CCTTGATCTGAACTTCTCTATTCTTGGTTTG-3’  
 
Sequencing primers for inserts of TOPO-Vectors: 
M13_for (-40): 5’-GTTTTCCCAGTCACGAC-3’ 
M13_for (-20): 5’-GTAAAACGACGGCCAG-3’ 
M13_rev: 5’-CAGGAAACAGCTATGAC -3’ 
 
3.1.8   Vectors  
 
pBluescript KS      Stratagene, CA, USA 
pCR￿ 2.1-TOPO    Invitrogen
TM,
 Life Technologies, Karlsruhe, Germany 
pCMV4Fv2E     Ariad,  UK 
pSF91-GFP2AHOXB4    Christopher Baum, MHH, Hannover, Germany 
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pSF71gp        GSH, Laboratory Grez, Frankfurt, Germany 
pSxgs-NF2hmpl      Stefan Stein, GSH; Frankfurt 
pSxgs-NF2d3YF      Stefan Stein, GSH; Frankfurt 
pS-NF2hmpl     Stefan  Stein,  GSH;  Frankfurt 
pSxgs-L∆S     Stefan  Stein,  GSH;  Frankfurt 
 
3.1.9 Bacterial  E.Coli Strains 
 
one Shot
TM (TOP 10F’):     Invitrogen,  Karlsruhe,  Germany 
Genotype:F’{lac/
q  TN 10(Tet
R)}mcrA  □(mrr-hsd/RMS-mcrBC)  □80lacZ□M15  □lacX74 
deoR recA1 araD139 □(ara-leu) 7697 ga/U ga/K rpsL endA1 nupG 
 
Stbl2
TM:       Life  Technologies,  Karlsruhe,  Germany 
Genotype: F mcrA ∆(mcrBC-hsd/RMS-mrr) recA1 endA1 gyrA96 thi supE44 relA1  λ` 
∆(lac-proAB) 
 
DH5a:        Stratagene,  CA,  USA 
Genotype. F ¢80dlacZ∆M15 ∆(lacZYA-argF) U169 deoR recA1 endA1 hsdR17(rk
-
 , mk
+) 
PhoA supE44 λ
- thi-1 gyrA96 relA1 
 
3.1.10 Medium for Bacterial Culture 
 
3.1.10.1  5 x LB-liquid medium 
 
To produce 5x LB-liquid medium, 100 g LB Broth Base per litre dH2O was weighted 
and autoclaved. Before usage 400 ml dH2O was mixed with 100 ml 5x LB medium together 
with equivalent antibiotics of choice. 
 
3.1.10.2 LB-Agar 
 
For the production of LB-Agar, 32 g LB-agar per litre dH2O was weighted and 
autoclaved. After cooling of the agar in a 50°C water bath, the corresponding antibiotic was 
added to the agar. The mixture was applied into 10 cm petri-dishes (about 15 ml/dish). After 
gelation of the agar, the 1 x agar-dishes can be stored at 4° C for further 4 weeks. 
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3.1.11   Cell lines 
 
293 T  human embryonic kidney, DSMZ No. ACC 305 
Phoenix-E  modified  293T , Phoenix
TM  Retroviral system, Orbigen, Canada 
SC1  mouse embryonic fibroblast, ATCC No. CRL-1404  
BaF/3  mouse pro B cells, DSMZ No. ACC 300 
 
3.2   Materials for animal experiments 
 
3.2.1 Mice 
 
The C57BL/6NCr1 (Ly5.2) mice (age between 6-8 weeks, all female) were purchased 
from Charles River Laboratories GmbH in Munich, Germany and served as the recipient mice 
for all the animal experiments.  
The donor mice C57BL/6 (Ly5.1) were obtained from the Jackson Laboratory, USA, 
and were further bred under IVC condition in the animal house of Georg-Speyer-Haus, 
Frankfurt.  
 
3.2.2  Materials for Preparation of Mice 
 
enfluran 2-Chloro-1.1.2-trifluoro-ethyldifluoromethylether; Abbott, 
Wiesbaden 
heparin Ratiopharm,  Germany 
EDTA Roth,  Germany 
preparation set  Roth, Germany 
water bath (45°C)  Lauda, Germany 
micro isolator cages  EBECO, Germany 
injection syringe with needle  
(1 ml and 0.5 ml) 
BD, Germany 
animal food  SNIFF, Specialisation GmbH, Soest, Germany 
 
 
3.3  Molecular Biological Methods 
 
3.3.1 Working  with  E.coli and Preparation of Plasmid DNA and Genomic DNA 
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3.3.1.1   Transformation of Competent Bacterial Strains 
 
Transfomation is the method to infiltrate DNA into bacteria. CaCl2-competent E. coli 
(50 µl) were thawed on ice, 1-25 ng plasmid DNA in 0.5-2 µl volume were added and the 
suspension was mixed gently with pipeting up and down and incubated on ice for 30 minutes. 
Cells were heat-shocked in a water bath at 42° C for 45-60 seconds, then immediately cooled 
on ice for 2 minutes. Finally 250 µl SOC medium (supplied from Invitrogen) was added. For 
expressing the resistance gene and subsequent selective outgrowth, bacteria were incubated 
for 1 hour at 37° C in the shaker. Then 100 µl of the preparation were plated on a LB-agar 
plate, which contains the antibiotic necessary for selection of transformed cells. Those plates 
were incubated overnight at 37° C in the incubator. Normally the plasmids, which were used 
in this study, have a coded sequence for the ampicillin resistance gene. Thereby positive 
selection of bacteria that inoculated the plasmid DNA is possible. After 24 hours single 
colony inoculums were cultured overnight in 3 ml of LB-Ampicillin (100mg/ml) on a shaking 
incubator (175 rpm) at 37° C.  
 
3.3.1.2   Preparation of plasmid DNA (Mini prep) 
 
This method is suitable for the preparation of small amounts of plasmid DNA (5µg-
10µg). 2 ml overnight bacterial cultures were pelleted by centrifugation at 13.000 rpm for 5 
minutes and resuspended in 300 µl buffer 1 (10 mM HCL, pH 8; 10 mM EDTA) containing 
of 100mg/ml RNAase. After incubation for 5 minutes in RT, 300 µl buffer 2 (200 mM NaOH; 
1% [w/v] SDS) were added. The cells were lysed throughout careful invention of the cell 
suspension. 300 µl buffer 3 (3 M KAc, pH 4.8) were added into the tube, in order to neutralize 
the samples. The samples were incubated 5 minutes on ice. Further the mixture was 
centrifuged at 13.000 rpm, 4°C for 15 minutes, in order to remove the precipitated proteins, 
membrane components and the chromosomal DNA. The supernatant containing the low 
molecular plasmid DNA was transferred into a new Eppendorf tube and precipitated by 
addition of 0.6 ml isopropanol. The samples were centrifuged at 13.000 rpm, 4°C for 20 
minutes. The obtained plasmid DNA pellets were washed 2 times with 70% ethanol and dried 
at RT. At last the DNA was resuspended in 30 µl TE (10 mM Tris, pH8.0; 10 mM EDTA) or 
dH2O. 
 
3.3.1.3   Plasmid Maxi-Preparation via JETstar Genomed-columns (Combination 
of an Anion Exchange Resin) 
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This method is suitable for DNA plasmid preparation yields of 50 µg - 500µg. 3 ml 
overnight bacterial culture was added to 300 ml LB-Ampicillin and incubated overnight by 
shaking at 175 rpm, 37°C. Bacteria were pelleted by centrifugation at 5000 rpm, 4°C for 10 
minutes (JA20-rotor, Beckman centrifuge) and resuspended by adding of 10 ml buffer 1(50 
mM Tris; 10 mM EDTA, pH 8.0; 0.1 mg/ml RNase), further lysed by a 5 minute incubation at 
RT in 10 ml buffer 2 (200 mM NaOH; 1 % (w/v) SDS). Consequently adding 10 ml buffer 3 
(3.1 M potassium acetate, pH 5.0) and incubating 10 minutes on ice neutralized the sample. 
The precipitated proteins, membrane components and genomic DNA were removed via 
centrifugation at 15.000 rpm, 4°C for 10 minutes (JA10, Beckman centrifuge). The 
supernatant was applied to an already with buffer 4 (600 mM NaCl ; 100 mM sodium acetate, 
pH 5.0; 0.15 % Triton X-100)with buffer 4) equilibrated column and run by gravity flow. The 
column was washed with buffer 5 (800 mM NaCl 100 mM; sodium acetate, pH 5.0)  to 
remove the non-DNA fractions and the plasmid DNA was eluated using a high salt solution 
(1250 mM NaCl, 100 mM Tris-HCl, pH 8.5) and then de-salted by precipitation with 
isopropanol. Then plasmid DNA pellets were washed in 70% ethanol and then resuspended in 
dH2O or TE. The concentration of plasmid DNA was measured by a spectrometer with the 
wavelength of 260 nm and stored in –20° C. 
 
3.3.1.4    Preparation of Genomic DNA from Cultured Eukaryotic Cells with 
DNeasy Kit (Qiagen) 
 
Genomic DNA from various cell types was prepared by using the blood and cell 
culture DNeasy kit from Qiagen. The isolation of total DNA is based on the silicagel 
membrane technology. All the buffers are designed for optimal binding of DNA to the 
membrane after cell lysis. Finally the DNA is eluted after repeated washing steps from the 
membrane via change of the pH-value. 
Maximal 5x10
6  cells were centrifuged at 1500 rpm, 4 °C for 5 minutes and 
resuspended in 200 µl 1x PBS after washing one time with ice cold 1x PBS. Thereafter 20 µl 
RNase (20 mg/ml) was added to the cell suspension. The suspension was incubated for 2 
minutes at RT. Then 20 µl proteinase K and 200 µl Buffer AL were added. The mixture was 
vortexed and incubated at 70°C for 10 minutes. After that 200 µl 100 % ethanol was added to 
the sample, which was mixed by vortexing and transferred to the column, which was placed 
in a 2 ml collection tube. The sample was centrifuged at 9000 rpm for 1 minute, further the 
membrane bound DNA was washed with 500 µl Buffer AW1 at 9000 rpm for 1 minute and 
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AW2 at 13.000 rpm for 3 minutes separately. Then the flow-through was discarded and the 
DNA was then eluted from the membrane with 200 µl elution solution via an additional 
centrifugation step (9000 rpm; 1 minute). The yield of DNA could be increased when the 
elution step had been repeated. The concentration of the DNA was determined with a 
spectrometer in the wavelength of 260 nm. The DNA was stored at 4°C. 
 
3.3.2  Enzymatic Modification of Nucleotide Acids 
 
3.3.2.1   Restriction of Plasmid DNA 
 
The restriction endonucleases used for restriction of plasmid DNA belong to the type 
II endonucleases, which can recognize short DNA sequences and cleave double stranded 
DNA at specific sites. Thereby either blunt ends or sticky ends can be obtained. 
Restriction endonuclease cleavage is accomplished simply by incubating the enzymes 
with DNA in the appropriate reaction conditions. 0.5 µg – 1 µg plasmid-DNA was used for 
one restriction reaction. The DNA was incubated together with 5-fold excess of enzyme (5 U 
enzyme/µg DNA), with the appropriate restriction buffer for 1-2 hours at 37° C. For 
purification of DNA fragments from a restriction reaction the DNA was isolated by phenol-
chloroform extraction. Running on a 1% agarose gel separated the digested DNA fragments.  
 
3.3.2.2   Dephosphorylation of Linear Plasmid-DNA by Alkaline Phosphatase CIP 
(calf intestinal phosphatase) 
 
This method can be used to decrease the self-ligation of the cut plamid DNA. The 
CIP-treated fragments lack the 5’ phosphoryl-termini, which are required by ligases for 
proper ligation. The reaction was done directly after enzymatic restriction of the plasmid 
DNA by addition of the related CIP-buffer and 1 µl (0.5 U/µg vector) CIP and incubation at 
37° C for 1 hour. The following phenol-chloroform extraction or gel extraction was 
performed to purify the DNA fragments. 
 
3.3.2.3   Fill-in of 5’-Overhangs to Form Blunt Ends by Klenow-Reaction 
 
The 5’overhang of DNA ends can be filled up by Klenow-fragment, a large subunit of 
the DNA polymerase I of E. coli. The enzyme is active in all the NEB buffers and was 
incubated with the restricted DNA (1 U/µg DNA) and dNTPs for 15 minutes at 25° C. The 
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enzyme activity was stopped by adding EDTA to a final concentration of 10 mM and heating 
at 75° C for 20 minutes. 
 
3.3.2.4   Phenol-Chloroform Extraction for Purification of DNA Fragment  
 
To purify the DNA fragments without using the gel extraction method the phenol-
chloroform extraction was used. The DNA sample was filled up to a volume of 200 µl with 
dH2O (or 1x TE) and the same volume of a mixture of phenol/chloroform/isoamylalkohol 
(25/24/1) was added. The reaction was centrifuged (3 minutes; 13.000 rpm; RT) to separate 
the water phase. The upper water phase containing the DNA was transferred into a new tube 
loaded previously with 200µl chloroform. After well mixture, the reaction was centrifuged 
again (3 minutes; 13.000 rpm; RT). The upper water phase was transferred to a new tube. 
Then 1 µl glycogen, 1/10 volume 3 M NaAc (pH=7) and 2 volumes of 100% ethanol were 
added, in order to precipitate the DNA. The sample was stored at –80° C for 30 minutes. After 
further centrifugation of the sample for 30 minutes at 13.000 rpm, 4° C, the DNA was 
precipitated. The DNA pellet was washed 2 times with 70% ethanol, dried at RT and 
resuspended in an appreciate volume of 1x TE. 
 
3.3.2.5   Ligation of DNA Fragments 
 
Cut DNA and vector fragments can be combined with T4 DNA ligase. T4 DNA ligase 
catalyses the formation of a phosphor-diester bonds between juxtaposed 5’ phosphate and 3’ 
hydroxyl termini in duplex DNA. 15 µl reaction was done with 25-50 ng vector, 3-6 fold 
molar excess of insert, 1.5 µl 10x ligase buffer and 1 U T4 DNA ligase overnight at 16°C and 
7,5 µl of the reaction was used for the transformation with chemically competent E.Coli 
carried out ligation. To control for the self-ligation an additionally vector-only ligation 
reaction was included. 
 
3.3.2.6   Transformation of TOPO-Ligation Product in TOP 10F’ E.coli 
 
1-2 µl TOPO-ligation product was added into 50 µl on the ice melted “One shot Top 
10F’ Cells with carefully mixing. The mixture was incubated for 30 minutes on ice followed 
by a 30 seconds heat shock in a 42°C water bath. After two minutes incubation on ice, 250 µl 
SOC medium were added to the sample, which was then further incubated for 45 minutes at 
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37°C and rotation. 10-50 µl of the sample was plated on the LB-Ampcillin plates, which were 
spread with 40 µl IPTG-Gal (40 mg/ml) solution prior to use. The plates were incubated in a 
37°C incubator overnight. The white colonies containing the ligated DNA-fragment were 
picked for the colony-PCR analysis. 
 
3.4  Polymerase Chain Reaction (PCR) 
 
3.4.1   PCR of Plasmid DNA for Amplification of DNA Sequences 
 
The purpose of a PCR is to make a huge number of copies of a special gene, e.g. in 
this study to amplify the sequences of the intracellular domain of the PrlR, EGFR and 
HOXB4 for cloning of the various constructs. The reagents and standard procedure of the 
PCR reaction are described in the following.  Dependent on the various primers, the annealing 
temperature is changed between 57° C - 62° C. Also the length of the DNA, which should be 
amplified, plays an important role. Normally, the large fragments need longer fractions of 
time for each single reaction step. 
The PCR reaction is divided into 3 steps. The second part, the amplification, is 
repeated for 25 - 40 times (cycles). This is carried out on an automated cycler machine 
(Perkin Elmer), which can heat up and cool down the tubes with the reaction mixtures in a 
very short time. In the first step, the denaturation, the DNA double strand melt and open to 
single strand DNA at 94°C. Thereby the bonds of the strand primer to the single strand DNA 
is possible, this step is called annealing. Furthermore the polymerase can attach and start 
copying the template.  
After the PCR reaction, the products were applied on an agarose gel and the length of 
the amplified DNA sequences were controlled. The correct products were purified either with 
the DNA isolation kit (Qiagen) or with the phenol-chloroform extraction (3.3.2.4). Further the 
PCR product was cut out with the corresponding restriction enzymes prior to cloning.  
 
 
Required reagents: 
DNA polymerase  2,5 U/µl  Pfu Turbo- polymerase with the supplied reaction buffer (10x) 
Primers  0.4 µM  sense-/antisense primers (10 µM) 
dNTP  0.2 mM  dATP, dCTP, dGTP, dTTP (5mM each) 
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Standard PCR protocol: 
PCR reaction  PCR program 
10-100 ng plasmid-DNA  5 minutes at 94° C 
5 µl buffer (10x buffer with 20 mM MgSO2)  
2 µl sense primer (10 µM)  1 minute at 94° C 
2 µl antisense primer (10 µM)  1 minute at 55° C            25-35 cycles 
2 µl dNTPs (5 mM)  2 minutes at 72° C 
1 µl Pfu Turbo-polymerase (2.5 U/µl)   
  15 minutes at 72° C 
  
Add H2O to 50 µl   
 
 
3.4.2   PCR on Genomic DNA for Determination of Integration of Viral Vector 
 
The principle is similar as explained in chapter 3.4.1. To determine gp91
phox and 
F2PrlR fusion gene sequences the following protocol was used: 
 
PCR reaction  PCR program 
100-200 ng genomicDNA  10 minutes at 95° C 
5 µl buffer (10x buffer with 20 mM MgSO2)   
2 µl sense primer (10 µM)  1 minutes at 95° C  
2 µl antisense primer (10 µM)  1 minute at 55° C               30-35 cycles 
2 µl dNTPs (5 mM)  1 minute at 72° C 
1 µl Tag DNA polymerase (2.5 U/µl)   
  15 minutes at 72° C 
  
Add H2O to 50 µl   
 
 
 
3.4.3  Ligation Mediated PCR (LM-PCR) 
 
Ligation mediated PCR is a modified PCR method to proof of the provirus integration 
in host-genomic DNA. It is also suitable for the test of clonality of tranduced cells. 
 
Required primers: See chapter 3.1.7.4 
Required buffers and reagents: 
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10x restriction buffer 1  NEB, Cambridge, UK 
10x native Pfu buffer  Stratagene, CA, USA 
Dynalbeads M-280 Streptavidin (10 µg/µl)  Dynal, Hamburg, Germany 
2x BW buffer  10 mM Tris pH7.5; 1 mM EDTA; 2 M NaCl 
5x annealing linker  0.5 M Tris pH 7.4; 0.35 M MgCl2
Extensor Hi-fidelity PCR master mix  AB gene, Hamburg, Germany 
 
Preparation of ligation mix with polylinker: 40 µl H2O, 20 µl primer linker 1 (200 
pmol/µl) and 20 µl primer linker 2 (200 pmol/µl) were incubated for 5 minutes at 70°C. Then 
20 µl 5x annealing buffer were added. After that, the samples were incubated again for 5 
minutes at 70°C and further incubation overnight at RT. The aliquots were stored at -20°C. 
250 ng genomic DNA prepared from ex vivo cultured mBM cells under cytokine or 
selective condition was mixed together with 3 µl 10x restriction buffer, 0.5 µl RNase (Roche), 
0.5 µl Tsp5091 restrictase and H2O to an end volume of 30 µl. Samples were incubated for 2 
hours at 65°C in water bath. After that, the mixture was cleaned with MiniElute Cleanup 
Reaction Kit (Qiagen) and acquired to 10 µl elution. 10 µl elute inclusive different DNA 
fragments was mixed with 2 µl 10x native Pfu buffer, 0.8 µl 5 mM dNTPs, 1 µl primer 
A1RV-bio (0.25 pmol/µl), 1 µl native pfu DNA polymerase and 5.2 µl H2O to an end volume 
of 20 µl. The biotin-labeled primer was incorporated into the fragment throughout 1 circle 
PCR program as listed in Table 3.4.1 
 
Table 3.4.1: 1 step PCR program for binding of biotin-labelled primer 
95°C 5  minutes 
65°C 30  minutes 
72°C 15  minutes 
4°C  ∞ 
 
Samples were cleaned again with the MinElute Cleanup Reaction Kit and acquired to 
a volume of 40 µl. Twenty µl Dynalbeads were washed 2 times with 100 µl dH2O and 
resuspended in 40 µl 2x BW buffer, then together mixed with 40 µl elutes. After 1 hour 
incubation at RT and rotation (800 rpm), the mixture was washed 2 times with 100 µl water 
and resuspended in 10 µl Ligation Mix, then incubated at 800 rpm, 16°C for a process of 2 
minutes on, 5 minutes off at rotation overnight. Half of the ligation mix (5 µl) was mixed with 
2 µl NEB buffer 2, 0,2 µl restriction enzyme HindIII and 12,8 µl H2O, then incubated for 1 
hour at 37°C. Thereafter, the samples were washed 2 times with 100 µl H2O in the magnetic 
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particle concentrator (Dynal) and resuspended in 5 µl H2O. The first integration PCR (Int 1-
PCR) was performed in an end volume of 25 µl according to Table 3.4.2. 
 
Table 3.4.2:  Reaction materials and program of Int 1-PCR 
PCR reaction  PCR program 
1µl DNA from HindIII cut ligation mix  2 minutes at 94° C 
12.5 µl extensor Hi-fidelity PCR master mix  15 seconds at 94° C 
1 µl SL AP1 primer (25 pmol/µl)  30 seconds at 60° C        30 cycles 
1 µl A2RV primer (25 pmol/µl)  2 minutes at 68° C 
9.5 µl H2O  10 minutes at 68° C 
  4°C        ∞ 
 
The products from the Int 1-PCR were diluted 1:50 and 1 µl was used as the template 
DNA for the second nested PCR (Int 2-PCR) as shown in Table 3.4.3. 
Table 3.4.3: Reaction materials and program of Int 2-PCR (nested PCR) 
PCR reaction  PCR program 
1µl DNA (1:50 diluted from Int1-PCR)  2 minutes at 94° C 
12,5 µl extensor Hi-fidelity PCR master mix  15 seconds at 94° C 
1 µl A3 RV primer (25 pmol/µl)  30 seconds at 60° C        30 cycles 
1 µl SL AP2 primer (25 pmol/µl)  2 minutes at 68° C 
9.5 µl H2O  10 minutes at 68° C 
  4°C        ∞ 
 
The PCR products were analysed on 2.5% agarose gels. The DNA fragments, obtained 
from the selective expanded cells, were ligated into TOPO-pCR-2.1 vector (3.3.2.5) and 
transformed into TOP 10F’ E Coli. (3.3.2.6). The white colonies were picked for the “colony-
PCR” according to Table 3.4.4. 
Table 3.4.4:  Colony-PCR: reaction material and PCR program 
PCR reaction  PCR program 
1 white colony  10 minutes at 94° C 
5 µl buffer (10x buffer with 20 mM MgSO2)  
1 µl M13 rev (10 µM)  1 minute at 94° C  
1 µl M 13 for (-40) (10 µM)  1 minute at 53° C              30-35 cycles 
2 µl dNTPs (5 mM)  2 minutes at 72° C 
0.3 µl Taq DNA polymerase (5 U/µl)   
  5 minutes at 72° C 
  
Add  50 µl H2O  
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The PCR-products were analysed on 2% agarose gels. The products resulting in a 
single band were purified with NucleoSpin®Extract II Kit (Machery-Nagel) before 
sequencing using M13 (-20) forward and M13 reverse primer. 
 
3.5  Working with Proteins 
 
3.5.1 Preparation of Whole Cell Lysates 
 
The used protein extraction buffer is modified from a protocol of Dinauer et al.(Yu et 
al., 1999). Briefly, cells were harvested, centrifuged at 1500 rpm, 4°C and 5 minutes, then 
washed 3 times in ice cold 1x PBS, resuspended for10-20 x 10
6 cells/ml either in triton buffer 
(50 mM Tris-HCl, pH 7.4; 1% Triton; 150 mM NaCl; 2 mM EDTA) for determination by 
Western blotting with anti-FKBP or in Ripa buffer (120 mM NaCl; 50 mM Tris, pH 8.0; 1% 
Triton; 0.5% Deoxycholat; 0.1% SDS) for EMSA. The mixture was transferred into a 
previously cooled 1,5 ml tube. The lysates were kept on ice for 15 minutes before 
centrifugation at 13000 - 15000 rpm, 4°C for 5 minutes. The protease inhibitors (BOE 
protease inhibitor, Rothe) were added into the buffer before usage. 
The supernatants were aliquoted into 1.5 ml centrifuge tubes and stored at –80°C until 
usage. For determination of protein phosphorylation, the phophotase inhibitors were added 
into the lysis buffer before preparation of the protein extracts.  
 
3.5.2 Bradford Protein Assay 
 
Duplicates of each protein sample were measured in 96-well micro titre plates. Per 
well 149 µl H2O, 30 µl working reagent (Bradford solution, supplied from BioRad) and 1 µl 
sample or protein standard (BSA, 6 different protein concentrations from 0.125 mg/ml to 8 
mg/ml) were combined, incubated for 5 minutes at RT and then absorbance was measured at 
595 nm wave length on a plate reader (SoftMaxpro). The protein concentration of each 
sample was calculated using the parameters obtained from linear regression of the protein 
standard values. 
 
3.5.3 Western Blotting 
 
Western blotting is based on the one-dimensional gel electrophoresis of proteins and 
can be provide information about the molecular size of a certain protein and the purity of a 
protein extraction, as well as the number and molecular size of subunits. The whole procedure 
of western blotting comprises gel electrophoresis, transfer of the proteins to a polyvinylidene 
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difluoride (PVDF) membrane, incubation of the membrane with specific antibodies and 
finally the development and detection of specific signals. 
 
3.5.3.1 Discontinuous SDS-PAGE 
 
The gel concentration of the SDS-PAGE gel should conform to the molecular size of 
the protein of interest as shown below 
 
Molecular weight  Gel concentration 
< 30 KD  15% 
30-50 KD  12% 
50-100 KD  10% 
> 100 KD  8% 
 
Required reagents for preparation of SDS gels: 
Table 3.1: Solutions for preparing resolving gels (for 5 ml mini-gels): 
  acryl amide mix 
30% 
1.5 M tris  
(pH 8,8) 
10% SDS  Ammonium persulfate 
10% 
TEMED H2O 
8% gel  1.3 ml  1.3 ml  0.05 ml  0.05 ml  0.003 ml  2.3 ml 
10% gel  1.7 ml  1.3 ml  0.05 ml  0.05 ml  0.002 ml  1.9 ml 
12% gel  2.0 ml  1.3 ml  0.05 ml  0.05 ml  0.002 ml  1.6 ml 
 
Table 3.2: Solutions for preparing 5% stacking gels (for 2 ml): 
Acryl amide mix, 
30% 
1,0 M tris (pH 6,8)  10% SDS  Ammonium persulfate 10%  TEMED  H2O 
0.33ml  0.25 ml  0.02 ml  0.02 ml  0.002 ml  1.4 ml
 
The separating gel was cast at first according to Table 3.1 and overlaid with water-
saturated isobutanol until polymerisation. Then isobutanol was exchanged by stacking gel 
according to Table 3.2 on top of the separating gel. After complete polymerisation, the gel 
was put into the electrophoresis tank and mounted with running buffer (25 mM Tris-Base; 
192 mM Glycine; 0.1% [w/v] SDS; pH 8.3). Meanwhile, the protein samples were mixed with 
an equal volume 4x sample buffer (laemli buffer), boiled for 5 minutes at 95° C and loaded 
into the lanes. Gels were run at first about 30 minutes at 80 volts throughout the stacking gel 
and furthermore at 120 volts for 3-4 hours. 
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3.5.3.2 Western Blotting 
 
After separation by SDS-PAGE (3.5.3.1), proteins were blotted via electrophoresis 
onto a PVDF membrane (Roti-PVDF transfer membrane, Roth) using a semi-dry technique 
(Towbin et al., 1979). The membrane was cut to gel size and soaked with methanol, then 
placed on top of 3 sheets of 1 sponge and 2 filter paper soaked with 1x blotting buffer (25 
mM Tris-Base; 192 mM Glycin; 20 [v/v] Methanol) (bottom, on the anode). The SDS-PAGE 
gel was removed from the glass plates and placed on top of the membrane. Another 2 sheets 
of filter paper and 1 sheet sponge soaked with blotting buffer were put on top of the gel, 
followed by the cathode. Protein transfer was conducted for 2 hours at 120 volts. 
 
3.5.3.3 Immunostaining of Blotted Proteins 
 
Blotted membranes were blocked at RT for 45 minutes either with 1x TBST (1% 
Tween-20 in TBS) plus 5% low fat dried milk (for STAT5 phosphorylation) or 1x PBST (1% 
Tween-20 in PBS) plus 5% milk powder (for FKBP protein). Blots were then washed two 
times for 5 minutes in TBST (or PBST) and incubated with the primary antibody overnight at 
4°C. FKBP was stained with anti-FKBP diluted 1:1000 in 2% milk powder, STAT5 were 
detected with anti-STAT5 diluted 1:5000 in 4% milk powder. Phospho-STAT5 was stained 
with anti-phospho-STAT5 diluted 1:1000 in 2% milk powder. After washing the membrane 
three times for 10 minutes with TBST or PBST, respectively, the blots were incubated with 
the corresponding secondary antibody diluted 1:10000 at RT for 1 hour (either HRP-
conjugated goat anti-rabbit antibody for FKBP, anti-Phospho-STAT5 or HRP-conjugated goat 
anti-mouse for anti-STAT5). At last the blots were washed again three times for 10 minutes 
with 1x TBST or 1x PBST and bound antibodies were visualized using the ECL-solution 
(Pierce). To control for equal protein loading of the different lanes, the blots were stripped 
with 0.1 M glycine (pH 2.9) by RT for 30 minutes and stained furthermore with anti-PLC-
gamma or anti-PI3 kinase according to manufacturer’s instructions. 
 
3.5.4   Electrophoretic Mobility Shift Assay (EMSA) 
 
In the nucleus, gene expression is controlled by DNA-binding transcription factors 
which bind to characteristic DNA motifs to initiate or repress transcription. The 
electrophoretic mobility shift assay (EMSA) is a powerful tool for evaluating DNA-protein 
interactions. It is based on the principle that when subjected to electrophoresis in native poly 
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acrylamide gels, free DNA has a different electrophoretic mobility than a DNA-protein 
complex. The process of the experiment contains steps below: 
•  Annealing of oligonucleotides: Equal amount of complementary single-stranded 
synthetic oligonucleotides (2 x 10
-10 moles of each) was prepared to a final volume of 
10 µl by adding TE (pH 8.0). The mixture was heated for 5 minutes at 70°C and then 
allowed to cool to room temperature (overnight at RT). The annealed oligos with final 
concentration of 2 x 10
-11 moles/µl were stored at 4°C for a short time or at –20°C for 
a long time. 
•  Labelling the probe (30 µl): 100-200 ng of annealed oligos, 3 µl 10x T4 polynucleotid 
kinase buffer, 7.5 µl ￿
32P-ATP (50 µCi (3000µCi/mmol), Amersham, Pharmacia, 
Freiburg, Germany) and 4 µl T4 polynucleotid kinase were mixed on ice by adding 
sterile H2O to a end volume of 30 µl. The mixture was incubated for 1 hour at 37°C. 
After that, 1 µl 0.5 M EDTA (pH 8.0) was added to stop the reaction. Thereafter, 20 µl 
H2O was added to an end volume of 50 µl. 
•  Preparation of binding reaction mixture without antibody: 100000 cpm/µl 
radiolabelled probe was mixed with fresh prepared incubation buffer (10 mM HEPES 
pH 7.9; 50 mM KCl; 1 mM DTT; 1 mM EDTA pH 8.0; 10% glycerol; 0.1 µg/µl poly 
(dl-C); 0.5 µg/µl BSA) to an end volume of 10 µl. The probe sample was then mixed 
well with 10 µl from 8 µg whole cell extract, 1µl 10x incubation buffer and sterile 
H2O. 
•  Preparation of binding reaction mixture with antibody: 10 µl probe mixture was mixed 
with 10 µl reaction from 8 µg whole cell extract, 1 µl specific antibody (STAT5a and 
STAT5b respectively) and 1µl 10x incubation buffer and sterile H2O. 
•  Separation of the samples with 5% polyacrylamide gel: The samples were incubated 
for 30 minutes at 30°C, then 5 µl 6x DNA loading buffer was added. After 
centrifugation, the samples were loaded into gel and further running in electrophoresis 
buffer (250 mM Tris; 192mM glycine; 50 mM EDTA pH 8.0) out for 2 hrs at 100 
volts. 
•  After running, gel was rinsed at first with 120 ml fixing solution, then washed with 
500 ml sterile H2O. After that, the gel was attached to a piece of Whatman paper and 
dried on a vacuum gel dryer with heat for 2 hours 
•  The dry gel with paper was exposed to films. 
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3.6   Cell  Culture 
 
3.6.1   Cell Culture Conditions and Passaging of Cells 
 
Retroviral producer cell line Phoenix E is based on 293T cell line, a human embryonic 
kidney cell line transformed with adenovirus E1a which carries a temperature sensitive T 
antigen co-selected with neomycin. This cell line is highly transfectable using the calcium 
phosphate mediated transfection method. The producer line was created by placing constructs 
capable of producing gag-pol and env proteins for ecotopic virus particle production in 293T 
cells. SC1 cell line for titre determination is a cell line derived from mouse embryonic 
fibroblast cells. 
BaF/3 cell line, used for cell proliferation assays and functional assays for the 
constructs, is a mouse pro-B cell line, established from peripheral blood derived from BALb/c 
mice. These cells grow under stimulation with murine IL-3 (10 ng/ml). 
If not noted otherwise, cells like SC1 or Phoenix E were cultured in DMEM 
supplemented with L-glutamine (4 mM), antibiotics (50 U/ml penicillin and 50 mg/ml 
streptomycin) and 10% FCS. BaF/3 cells were cultured in RPMI 1640 with the same amount 
of L-glutamine, antibiotics and FCS and further with 10 ng/ml murine IL-3 or with 10% 
conditioned medium (WEHI medium) containing mIL-3. Cells were cultured at 37°C, 5% 
CO2 and 95% relative humidity in an incubator. Before usage FCS was heat-inactivated for 30 
minutes at 56°C. 
 
3.6.2  Assessing Cell Viability by Trypan Blue Exclusion 
 
The number of viable and dead cells was determined by trypan blue exclusion. The 
cell suspension was diluted with trypan blue solution (0.2 % (w/v) trypan blue in 0.9% NaCl 
solution) and cells were counted in a Neubauer haematocytometer. The concentration of 
viable cells was then calculated using the equation: 
 
Number of viable cells/ml:  N x F x 10 
4
  N = average of unstained cells per corner square 
(1 mm
2 containing 16 sub-squares) 
  F = dilution factor 
 
3.6.3  Freezing and Thawing Cells 
 
Cells were harvested and suspended in freezing medium (90% FCS; 10% DMSO) in 
1-10 x 10
6 cells/ml. Such suspension was preserved in cryo-vials. To allow gradual freezing at 
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a rate of 1°C per hour, the vials were placed in an isopropanol-filled cryocontainer and frozen 
at –80° C for 24 hours. For long-term storage, samples were then transferred to the liquid 
nitrogen (-196° C). To recover the frozen cells, the cell suspension was thawed quickly in a 
water bath at 37° C. To avoid toxic effects of DMSO to viability, the cell suspension was 
transferred into a falcon tube containing 15-25 ml warm 1x PBS with 20% FCS as soon as 
thawed and consequently the cells were spun down (6-8 minutes at 1200 rpm and 4° C) and 
resuspended in fresh medium. For the thawing of mouse bone marrow cells, 40 U/ml DNase 
were added into the thawing medium. 
 
3.6.4  Primary Mouse Bone Marrow Cells 
 
Fresh prepared murine bone marrow (mBM) cells (see 3.7.2) were cultured in RPMI 
1640 (complete components described in capter 3.6.1) with 10 ng/ml mIL-3, 50 ng/ml mIL-6 
and 50 ng/ml mSCF. The cell density after isolation or enrichment was kept minimum at 1x 
10
6 cells/ml in a 24-well plate. 
 
3.6.5    Retroviral Virus Particle Production via Calcium Phosphate Mediated 
Transfection 
 
The calcium phosphate mediated transfection method is based on the ability of the 
producer cells to take up the DNA calcium phosphate precipitate via endocytosis. Phoenix E 
cells carry the MLV gag, pol and env gene, which are necessary for the packaging of the 
retroviral vectors. Another packaging construct M57 (M. v. Laer, Frankfurt/GSH), which also 
contains the MLV gag-pol sequences, was co-transfected into the producer cells, in order to 
increase the transfection efficiency (Figure 3.1). 
 
SV40 pA
gag
pSV40
pol
beta
Ψ
sd
SFFV
gp91
sa
SFFV
FKBP PrlR
M57, packaging construct
Retroviral vector (Sxgs-F2PrlR)
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Figure. 3.1: Retroviral construct for virus production: As an example, construct of Sxgs-F2PrlR and 
helper plasmid with gag-pol elements are shown.  Except of the retroviral cassettes,  all the  retroviral 
plasmids have a bacterial repopulation origin and an ampicillin resistance gene. 
 
Phoenix E producer cells were seeded 1 day before transfection at a density of 3.5-4 x 
10
6 in 10 cm diameter dishes and allowed to grow to 60% confluence (sub confluent). Two 
hours before transfection, the cells were provided with fresh medium. 10 µg expression 
construct DNA, 3 µg M57 helper plasmid, 50 µl CaCl2 (2,5 M) were pipetted together with 
0.1x TE H2O to the end volume of 500 µl. Then 500 µl 2x HBS (50 mM HEPES pH 7.05; 280 
mM NaCl; 1.5 mM Na2HPO4; pH 7,12)  were added drop wise into the solution under 
continuously blubbering. The precipitate was put aside for 5 minutes before drop wise giving 
it onto the Phoenix E cells. In order to increase the transfection efficiency, 2 minutes before 
transfection, 1 µl chloroquine (100 mM) was added into the DMEM medium. 6-8 hours after 
transfection, the medium was exchanged by 5 ml fresh RPMI medium, in order to concentrate 
viral particles. 24 h after medium exchange, viral supernatant was harvested by filtration 
through a 0.22 µm filter, which was soaked with sterile water before usage. The supernatant, 
containing viral particles, was aliquoted and stored at – 80° C. In the case of a good viability 
of the producer cells, the supernatant was harvested a second time under the same conditions. 
The titre of retroviral particles used in this study was determined by transduction of 
SC1 cells.  Briefly, one day before titre determination, 5x 10
4 SC1 cells were seeded in 24-
well plate, on the day of titre determination, 1 ml fresh DMEM was changed and virus 
supernatants were added into the well duplicates with the dilutions 1:10 (100 µl virus 
supernatant) and 1:100 (10 µl virus supernatant). To increase the infection efficiency, 10 µl 
polybrene (from stock solution 400 mg/ml) was added into the wells. 3 days after infection of 
SC1 cells, FACS staining with equivalent antibodies was performed. The percentage of 
positive cells was between 5-15 %. The following equation was used for calculation of titre:  
 
Titre (TU/ml)  = N x A x F 
  N: cell number at day of infection 
  A: percent of positive cells 
  F: dilution factor 
 
3.6.6 Lentiviral Virus Particle Production via Calcium Phosphate Mediated 
Transfection of 293t Cells 
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The lentiviral virus particles were produced by 293T cells cotransfection with 
plasmids carry out the gag, pol (pCMV∆R8.91) and env (pMD.G) gene (Romain Zufferey, 
Genf; Zufferey et al., 1997) as shown in Figure 3.2. 
 
CMV pA
gag pol
rev
tat pCMV∆R 8.91 
CMV pA
VSV-G
pMD.G
 
 
Figure. 3.2: Structure of lentiviral helper plamids: Except the lentiviral cassettes, both helper plasmids 
have a bacterial repopulation origin, a SV40-repopulation origin and an ampicillin resistance gene. 
 
293T cells were seeded as described in chapter 3.6.5. 10 µg expression construct 
DNA, 6.3 µg pCMV8.91 and 3,7 µg pMD.G helper plasmid were cotransfected in sub- 
confluent 293T cells in the same way as explained above. The obtained lentiviral supernatants 
were aliquoted and stored at – 80° C.  
 
3.6.7  Transduction of BaF/3 Cells and Primary mBM cells with Retroviral Particles 
 
For the transduction of BaF/3 and primary mBM cells, the definitely MOI 
(multiplicity of infection) was used to control the number of virus particles which transduced 
the cells like below. 
MOI = Virus titre (TU/ml) x volume of the used virus supernatent (ml)  
Number of the cells 
BaF/3 cells were transduced according to the standard spin protocol. 1x 10
5 cells were 
seeded in 24-well plates and a definitely amount of virus supernatant with MOI = 5 was added 
into RPMI medium supplemented with mIL-3 (10 ng/ml) and 4µg/ml of protaminsulfate. 
Then the cells were centrifuged at 32° C and 2500 rpm for 90 minutes and incubated in the 
incubator for 6-8 hours. At last fresh complete RPMI medium containing all necessary 
cytokines was added. 3 days after transduction, the transduction efficiency was measured by 
FACS-staining analysis (see chapter 3.8). 
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The mBM cells (Sca1
+ or total mBM cells) were transduced as described by 
Christopher Baum (protocol kindly provided by Prof. Dr. Christopher Baum). Fresh isolated 
and enriched Sca1 positive mBM cells were pre-stimulated with cytokines for 48 hours before 
the first transduction cycle. One 24-well plate (non-tissue coated) was coated with 400 µl 
retronectin per well (from a 50 µg/ml stock solution, Takara, Japan) and further incubated for 
2 hours at RT. Then retronectin solution was discarded and 1 ml H2O containing 2% HSA 
was added in order to block the plate for 30 minutes at RT. Thereafter, HSA solution was 
discarded and the wells were washed with 1 ml HBSS/2.5% (v/v), 1M Hepes and 1 ml 1x 
PBS. The 1x PBS remained in the wells until the viral supernatant was added. The viral 
supernatant was thawed quickly in a 37°C water bath and added into the previous retronectin 
coated wells with an MOI of 5 (the total volume of the viral supernatant never exceeded 1,5 
ml). The virus-loaded plate was centrifuged at 2000 rpm for 30 minutes at 4° C. After that, the 
supernatant was carefully discarded and the new virus supernatant was added. This 
centrifugation process was repeated 2 times. The pre-stimulated mouse Sca1
+ BM cells were 
diluted to a concentration of 4 x 10
5 cells/ml and 500 µl of the cell suspension were then 
added into the prepared wells after removing of the viral supernatant. During the following 
overnight incubation at 37°C in the incubator, the virus infected the cells. Within the next two 
days infection was repeated twice like described below: one time infected cells were 
resuspended well and transferred into a new virus-coated well. The used well was washed 2 
times with 1x PBS to collect remaining cells. Those were added in 300 µl fresh cytokine 
medium to the already transferred cell suspension. 24 - 36 hours after transduction, the cells 
were collected for FACS-analysis of transduction efficiency, CFU-assay (see chapter 3.6.7) 
and potentially transplantation (see chapter 3.7.4). 
 
3.6.8  Methylcellulose Based CFU-assay (StemCell Technologies Inc) 
 
This method was used to determine the potential of haematopoietic progenitor cells in 
total bone marrow or peripheral blood to form colonies in semi-solid medium. 
Methylcellulose based medium allows cells, derived from the same progenitor cell, to build 
colonies. The process of CFU-assay is showed below in Figure 3.3. 
 
 77   Materials and Methods 
9 days
methylcellulose
(2.7 ml+300 µl
cell suspension)
plating (1 ml mixture/dish)
count colony number
1000 cells/dish
Colony forming units (CFU) assay
 
 
Figure 3.3: Methylcellulose based CFU-assay.  1000 cells/dish Sca1
+ mBM cells were diluted with 
IMDM medium in the volume of 300 µl, and then added into previously aliquoted 2.7 ml methylcellulose 
in a poly tube. After well vortexing the samples were allowed to dissipate 5-10 minutes until the air bubbles 
disappeared. Then 1.0 ml mixtures were dispensed into each of two 35 mm culture dishes using a 3 ml 
syringe and a 16 gauge blunt-end needle. The dishes were gently rotated to spread the methylcellulose 
evenly. Then the dishes were placed in a 100 mm petri dish with a third 35 mm dish containing 3 to 4 ml of 
sterile water. This plate was incubated for 9-10 days at 37° C and 5% CO2 in the incubator. When counting 
the colonies, the cell populations over 50 cells per colony were calculated as one colony.  
 
3.6.9 Selective Expansion of Transduced BaF/3 Cells and mBM Cells  with Small 
Molecular Dimerizer AP20187 
 
To achieve selective expansion of transduced cells, we employed in this study the 
FKBP/AP20187 system from the company Ariad (Cambrige, Uk). This homodimerization kit 
is based on the modified human protein FKBP12 (FKBP, for FK506 binding protein) and its 
small binding molecule AP20187. This molecule has the benefit to bind with subnanomolar 
affinity to FKBP and is suitable for in vitro and in vivo experiments. The structure and the 
mechanism of AP20187 are shown in Figure 3.4. 
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Figure 3.4: Structure and mechanism of the FKBP/AP20187 system. A: The signal transduction domain 
can be activated after drug binding domain (FKBP) binding with dimerizer AP20187. B: Chemical 
structure of small dimerizer AP20187. 
 
3 days after transduction with retroviral or lentiviral vectors, AP20187 induced 
proliferation was investigated. 6 x 10
5 transduced BaF/3 cells were washed three times with 1 
x PBS, then divided in 3 wells in a 24-well plate in a total end volume of 1 ml under three 
different conditions: RPMI; RPMI + mIL-3 (10 ng/ml); RPMI + AP20187 (10 nM). The cell 
number was counted (see chapter 3.6.2) in the interval of 2-3 days and the cumulative cell 
number was calculated. The transduced mBM cells were washed three times with 1x PBS and 
then cultured under following conditions: RPMI + cytokines (see chapter 3.6.4), RPMI + 
mSCF (50 ng/ml) + AP20187 (10 nM). The cell number was determined weekly. To proof for 
reversibility of the effect of AP20187 on the transduced cells, 3 weeks after selection, the 
AP20187 was removed from the culture by extensive washing with 1xPBS. The cells were 
further cultured with RPMI (for BaF/3 cells) or RPMI + mSCF (50 ng/ml for mBM cells) for 
3 weeks and the cumulative cell number was calculated as described in chapter 3.6.2. 
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3.7 Animal  Experiments 
 
3.7.1    Breeding of Animals 
 
All mice used in the experiments were bred in the animal centre of the Georg-Speyer-
Haus (Frankfurt, Germany). The health status of the animal centre was monitored based on 
the guidelines of the Federation of European Laboratory Animal Science Associations 
(FELASA). Minimal of 3 days before transplantation, the C57BL/6 inbred female mice were 
purchased from Charles River Laboratories. They were bred in standard sterile cages 
(maximal 5 mice /cage) and feed with standard rodent diets and water. The donor mice Ly 5.1 
were purchased from Jackson Laboratory/USA, and further maintained in the animal centre. 
For the bone marrow cell preparation, mice of an age between 6-8 weeks were chosen. All 
experiments were performed out according to the German Animal Protection Law 
(Tierschutz: Genehmigungs-aktenzeichen: 211-2531-31/2002). 
 
3.7.2  Preparation of Murine Bone Marrow Cells  
 
The mice chosen for the bone marrow cell preparation were killed after narcosis with 
enfluran. The bone marrow from femurs and tibias of each mouse was isolated by flushing 
with 25 ml preparation buffer (1x PBS + 5 % FCS+1 % pen-strep) using a 23-gauge needle (3 
mice in a 50 ml tube). Then the bone marrow cells were suspended well and centrifuged at 
1200 rpm and 4° C for 5 minutes. The cell pellet was resuspended in 1 ml preparation buffer. 
To lyse the erythrocytes, 9 volumes of lysis buffer (0.8% NH4Cl; 10 µM EDTA) were added 
to the cell suspension and mixed well by vortexing. After that mixture was incubated for 10 
minutes at RT. 30 ml preparation buffer was added to the tube after lysis and centrifuged for 6 
minutes at 1200 rpm and 4° C. This washing step was repeated 1 time and cell pellet was 
resuspended in 5 ml preparation buffer. Thereafter the cell suspension was filtered through a 
nylon mesh (BD, 100 µm filter) into a fresh 50 ml tube, in order to remove the big pieces of 
bone or fat tissues. The cell number was determined and the bone marrow cells were ready to 
go for the further purpose or for freezing.  
 
3.7.3  Enrichment of Sca1 Positive Cells from Total mBM Cells with EasySep
TM  kit 
(StemCell Technology) 
 
Sca1
+ mouse haematopoietic progenitor cells can be enriched from total mBM cells 
via immunomagnetic cell selection procedure, which requires a PE-conjugated monoclonal 
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Sca1
+ antibody. Fresh prepared mBM cells were counted with Tuekish’ solution and 
suspended at a concentration of 1 x 10
8 cells/ml in buffer containing 1x PBS, 1 mM EDTA 
and 2% FCS. Murine FcR blocker (applied from EasySep kit) was added at a concentration of 
10 µl/ml to the cells and the sample was well mixed. Then Sca1- PE labelling reagent was 
added at a concentration of 15 µl/ml. After well mixing the cells were incubated at 4° C for 15 
minutes. The sample was washed once with 10-fold excess buffer and resuspended in half of 
the original volume, further transferred in a 12 x 75 mm polystyrene tube to properly fit into 
the EasySep
TM Magnet. Thereafter 100 µl/ml PE-selection cocktail was added to the sample 
and the sample was incubated at 4° C for 15 minutes. At last, EasySep
TM  Magnet 
nanoparticles were added at 50 µl/ml to the sample and the mixture was further incubated at 
room temperature for 10 minutes. The total sample volume was brought up to 2.5 ml by 
adding buffer. Finally the tube was placed into the magnet and set aside for 5 minutes. Then 
the supernatant fraction was poured off and the magnetically labelled cells remained inside 
the tube. The tube containing the negative sample was removed from the magnet and 2,5 ml 
buffer was added. The sample was mixed by gently pipetting up and down 2-3 times and 
placed into the magnet again. This process was repeated 3-6 times and at the end the selected 
cells were suspended in the suitable culture medium for further experiments.  
 
3.7.4  Bone Marrow Transplantation of Genetically Modified Cells 
 
At the day of transplantation, the recipient mice (C57BL/6, Ly5.2) were sublethally 
irradiated with 8.0 Gy from a 
137Cs γ-ray source at the University Hospital Frankfurt/Main, 
Germany. The cells for transplantation with the appropriate cell number were washed 3 times 
with 1x PBS, and then kept on ice before transplantation. 2-4 hours after irradiation, 
transplantation was performed through the injection of the cells into the tail vein of the 
recipient mice. The analysis of the mice was carried out 8-10 weeks after transplantation.  
 
3.8 Flow  Cytometry 
 
To characterize the phenotype of the different cell types, the cell surface expression of 
a number of membrane proteins was assessed by flow cytometry. For determination of surface 
expression, 1-2 x 10
5 cells per staining reaction were washed twice for 5 minutes with 3 ml of 
ice-cold FACS buffer (1x PBS; 1% FBS; 0.1% Sodium acid)  and immunostained for 20 
minutes at 4° C with a selection of biotin, fluorescein-isothiocyanate (FITC)- and 
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phycoerythrin (PE)-conjugated antibodies or non-conjugated antibodies as listed in Table 3.3. 
Cells stained with non-conjugated primary antibodies had to be incubated with a secondary 
antibody like rat anti mouse IgG1-PE, IgG1-APC or streptavindin-APC (SA-APC) for 15 
minutes in 4° C. Between two incubation steps the cells were washed once with 1x PBS. At 
least, stained cells were fixed with 200 µl fixing buffer (1x PBS; 1% Formaldehyde) after 
washing process. For the samples from mouse primary bone marrow cells or peripheral blood, 
the Fc-block was added into each sample (2 µl from 1:10 diluted solution) before staining in 
order to block the non-specific binding positions.   
 
Table 3.3: Antibodies for FACS analysis. 
Cell surface expressed protein  Primary antibody  Secondary antibody 
gp91  human 7D5  RAM IgG1-PE; RAM IgG1-APC 
CD 45.1  mouse α-CD45.1-PE  - 
LNGFR  human α-LNGFR-PE  - 
CD 3  mouse α-CD3-biotin  Streptavidin-APC 
Gr-1  mouse α-Gr1-biotin  Streptavidin-APC 
B220  mouse α-B220-biotin  Streptavidin-APC 
Sca1  mouse α-Sca1-PE  - 
c-kit  mouse α-ckit-PE  - 
Fc-block  mouse α-CD16/CD32  - 
 
 
3.9   Intracellular Immunostaining 
 
The localization of proteins in cells can be proved by indirect immunofluorescence 
with proper antibodies. This method relies on the following steps: fixation of cells; exposition 
of the cells to the primary antibody of interest; removing of the unbound antibody; incubation 
of the cells with a fluorescence-tagged secondary antibody. 
The sterilized coverslips (24 mm) used for the staining of SC1 cells were coated with 
1 % polylysine for 5 minutes at room temperature. After 2 times washing with water, the 
coverslips were dried properly at least for 2 hours at room temperature. 2 x 10
5 SC1 cells 
were plated on a coverslip placed in a 6-well. After 24 hours the cells were transfected with 
pure plasmid DNA and incubated for 2 days. At the day of staining, the cells were washed 2 
times with 1 x PBS for 5 minutes and fixed in fixing buffer (1x PBS + 3% formaldehyde) for 
15 minutes. After two further washing steps (each step 5 minutes), the cells were 
permeabilized with permeability buffer (1x PBS + 0,1% triton) for 4 minutes and then 
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furthermore washed 2 times with 1x PBS for 5 minutes. After 5 minutes blocking of the cells 
in blocking buffer (the cells were incubated for 40 minutes at room temperature with the first 
antibody (e.g. anti-FKBP) diluted 1:1000 in blocking buffer. After 2 washing steps with 
blocking buffer (1x PBS + 3% BSA) 5 minutes each step. Cells were incubated with the 
secondary antibody (1:5000 - 1:10000 diluted) in blocking buffer for 40 minutes at room 
temperature. Finally, the cells were washed again 2 times with blocking buffer for 5 minutes. 
The coverslips with cells were transferred on a glass-slide and mounted in mounting medium 
(Vectashield, Vector Lab., CA, USA) with DAPI. The slide was now ready for viewing on the 
fluorescence microscope. As a negative control cells stained only with a secondary antibody 
were used. 
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4. Results 
 
Gene transfer in haematopoietic stem cells (HSCs) holds the promise of providing a 
long-standing cure for many inherited and acquired blood cell disorders. However, the low 
efficiency of gene transfer into human HSCs with retroviral vectors is one of the major 
obstacles associated with HSC gene therapy. Therefore, methods aimed at achieving selective 
expansion of genetically modified HSCs are required (see chapter 1.3). Additionally, the 
development of gene and cell therapies would benefit substantially from methods allowing 
specific control over the growth of genetically modified cells after transduction and 
transplantation. In this study, 2 separate positive selection systems were developed for the 
expansion of genetically modified murine HSCs to attain therapeutic levels of cells expressing 
the transgene. One system relies on the constitutive overexpression of HOXB4. The other 
strategy makes use of an inducible selection system. Chemically induced dimerization of a 
cytokine receptor activates function of the selection marker genes epidermal growth factor 
(EGF) receptor and prolactin-receptor. Cell proliferation, transgene expression and 
differentiation potential were measured in vitro and / or in vivo for both strategies. 
 
 
4.1  HOXB4 Induces Selective Expansion of gp91
phox Gene-Modified Murine 
HSCs 
 
The homeodomain-containing transcription factors of the HOX gene family, regulators 
of pattern formation and tissue identity during embryogenesis, have also been identified as 
regulators of haematopoietic cell proliferation and differentiation (Pekins et al., 1993; 
Sauvageau et al., 1995; Thorsteinsdottir et al., 1997). The most interesting member of the 
homeobox gene family in the haematopoietic system is HOXB4. Ectopic expression of this 
gene with retroviral vectors has led to a 1000-fold expansion of HSCs in transplantation 
studies  in vivo (Sauvageau et al., 1995;  Antochuck et al., 2001) and, importantly, no 
haematological abnormalities were found in a large group of mice transplanted with HOXB4-
transduced HSCs. In contrast, overexpression of HOXB3, for example, can induce myeloid 
leukaemia and perturbed lymphopoiesis (Thorsteinsdottir et al., 1999). This prompted us to 
investigate whether expression of HOXB4 can also increase the proportion of HSCs 
expressing the therapeutic gene gp91
phox, when both genes are co-expressed in HSCs. 
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4.1.1  Cloning and Titre of Bicistronic Construct Sxgs-HOXB4 
 
The bicistronic retroviral construct Sxgs-HOXB4 was cloned as indicated in Figure 
4.1.1. The initial construct containing the full-length HOXB4 sequence was provided by 
Christopher Baum (Hannover Medical School). In this construct, the enhanced green 
fluorescence protein (eGFP) sequence was fused with HOXB4 via 2A sequences and served 
as the marker gene for expression. The retroviral vector Sxgs-dLN from Dr. Stefan Stein in 
our laboratory was used as the cloning vector. 
 
EGFP HA HOXB4
forword primer (NotI)
reverse primer (BamHI)
SFFV SFFV
Sxgs-dLN     
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
SF91-
GFP2AHOXB4
Sxgs-HOXB4
(7779 bp)
Ψ
sd
SFFV
gp91
sa
SFFV SF71gp
A
B
C
D
Ψ
sd
SFFV
gp91
sa
SFFV
HOXB4 HA
 
 
Figure 4.1.1: Cloning of the bicistronic construct Sxgs-HOXB4. All constructs were derived from a 
MLV (murine leukaemia virus)-based retroviral vector under the control of the SFFV promoter. A: 
Amplification of the full-length HOXB4 gene sequence with PCR primers designed with NotI and BamHI 
restriction sites. B: Backbone of the retroviral cloning vector Sxgs-L∆S. The therapeutic gene gp91
phox is 
located between the viral splice sites and the gene for ∆LNGFR (truncated low affinity receptor for human 
nerve growth factor). This vector was cut with NotI and BamHI and ligated with the PCR product from step 
A. C: Final construct Sxgs-HOXB4. The full-length HOXB4 sequence and HA tag from A was cloned into 
Sxgs-L∆S, forming the new construct containing gp91
phox and HOXB4. D: Control construct SF71gp with 
the human gp91
phox sequence. SFFV: spleen focus forming virus LTR; EGFR: epidermal growth factor 
receptor; HA: influenza haemagglutinin tag; sd: splice donor; sa: splice acceptor; ψ: packaging signal.  
 
SF71gp, which only contains the gp91
phox gene (Figure 4.1.1 D), served as a control 
construct for the following in vitro and in vivo experiments. Ecotropic retroviral particles 
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were generated in Phoenix-E producer cells as described in chapter 3.6.4, and titres of the 
viral supernatants were determined in the murine fibroblast cell line SC1. Figure 4.1.2 shows 
gp91
phox gene expression in SC1 cells transduced with supernatants diluted 1:100. The titres 
ranged from 4 × 10
5 to 16 × 10
5 for different vector preparations (Table 4.1.1). 
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Figure 4.1.2: Titre determination of SF71gp and Sxgs-HOXB4 retroviral particles.  1 day before 
transduction, 5 × 10
4 SC1 cells in 1ml DMEM were plated per well of a 24-well plate. Twenty to 24 hours 
after plating, the viral particles were added to the SC1 cells at dilutions of 1:10 (100 µl) and 1:100 (10 µl). 
Three days after transduction, the gp91
phox-positive cells were detected by FACS analysis with the anti-
gp91
phox antibody 7D5. The percentage of 7D5-positive cells, which ranged between 2 and 20%, was used 
to calculate of the titres in transduction units (TU)/ml. SF71gp-transduced SC1 cells were 4% positive 
(middle) and Sxgs-HOXB4-transduced cells were 5% positive (right). The viral particles used here were 
diluted 1:100. ntd: non-transduced cells. 
 
Table 4.1.1: Range of titres of SF71gp and Sxgs-HOXB4 retroviral vectors 
Constructs SF71gp  Sxgs-HOXB4 
Titre on SC1 cells TU/ml  4–13 × 10
5 5–16 × 10
5
 
 
4.1.2  In Vitro Functional Analysis of Sxgs-HOXB4 Transduced Primary BM Cells 
 
To test the ability of HOXB4 to exert expansion of HSCs, functional analyses were 
carried out with Sxgs-HOXB4-transduced cells. Total murine bone marrow (mBM) cells were 
freshly prepared from C57BL/6 mice. After 2–3 days prestimulation with the cytokine 
combination mIL-3 (10 ng/ml), mIL-6 (50 ng/ml) and murine stem cell factor (50 ng/ml) 
(SCF/IL-3/IL-6), the mBM cells were transduced for 3 days with either Sxgs-HOXB4 or 
SF71gp. The transduction efficiency is shown in Figure 4.1.4. Following transduction, cells 
were cultured in a cytokine combination of SCF/IL-3/IL-6 for 3 weeks. The proliferation 
potential and transgene expression are illustrated in Figures 4.1.3 and 4.1.4.  
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Figure 4.1.3: Cell proliferation of Sxgs-HOXB4-transduced primary mBM cells. Total mBM cells 
were transduced as explained in the text. After transduction, the cells were cultured for an additional 3 
weeks in a standard cytokine combination. Pink line: proliferation curve of cells transduced with Sxgs-
HOXB4. Blue line: proliferation curve of non-transduced cells. Grey line: proliferation curve of SF71gp-
transduced cells. 
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Figure 4.1.4: Transgene expression of Sxgs-HOXB4- and SF71gp-transduced primary BM cells. The 
percentage of 7D5-positive cells was calculated from FACS analysis with the 7D5 anti-gp91
phox antibody 
on days 6, 13 and 20. 
 
As shown above, 3 weeks after transduction, the number of Sxgs-HOXB4-transduced 
cells had increased by about 8-fold compared to day 6. In contrast, the number of non-
transduced or SF71gp-transduced cells increased by about 3.5 fold during the first culture 
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week, after which the cells stopped proliferating. The significant proliferation of Sxgs-
HOXB4-transduced cells was mirrored by the gp91
phox transgene expression (Figure 4.1.4), 
which was 7-fold higher after 2 weeks expansion. Cells transduced with the control construct 
showed only a minor increase (1 fold) in 7D5-positive cells (Figure 4.1.4). 
 
The standard in vitro method for identifying murine haematopoietic progenitor cells is 
the methylcellulose based CFU-assay, which allows the formation of colonies from one single 
progenitor cell in semi-solid medium. Primary mBM cells transduced with the Sxgs-HOXB4 
and control constructs were plated in methylcellulose containing the appropriate cytokines 1 
day and 1 week after transduction. After 10 days incubation, clusters of 50 or more cells were 
counted as 1 colony. In addition, the morphology of the colonies was investigated under the 
microscope (Figure 4.1.5). 
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Figure 4.1.5: Colony forming unit (CFU) assay in methylcellulose. A: Colony number. Transduced cells 
were plated in methylcellulose (StemCell) at a concentration of 5000/35cm dish 1 and 6 days after 
transduction. After 10 days incubation at 37°C, the total colony number was determined. B: Colony 
morphology was observed under the microscope. Right: colony from Sxgs-HOXB4-transduced cells. Left: 
colony from cells transduced with the control construct. 
As illustrated in Figure 4.1.5, the total colony number of Sxgs-HOXB4-transduced 
cells had increased to 62 colonies/1000 cells 1 week after transduction, almost 2-fold higher 
than the colony number counted on day 6. In contrast the colony number of mock-transduced 
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cells remained at a low level. Colonies from expanded Sxgs-HOXB4-transduced cells 
included early progenitor cell colonies, such as CFU-GEMM, BFU and CFU-GM, whereas 
those from cells transduced with the control construct were dominated by CFU-GM colonies. 
 
4.1.3  In Vivo Experiments 
 
As demonstrated above, expression of the Sxgs-HOXB4 construct in murine primary 
BM cells led to the selection of modified cells, especially of haematopoietic progenitor cells. 
Previously, it was reported that expression of HOXB4 caused 50–1000 fold expansions of 
murine haematopoietic cells in vivo, whereas no strong proliferation advantage could be 
observed ex vivo (Antochuck et al., 2002). To investigate whether our construct has a similar 
effect  in vivo, we performed transplantation experiments in mice. In this setting, the 
constructs SF71gp and SF91-GFP2AHOXB4 served as the negative and positive controls. 
Fresh total mBM cells from the C57BL/6 Ly5.2 mice (see chapter 3) were prepared 
and enriched with an anti-Sca1 antibody as described in the EasySep kit (StemCell 
Technology; see chapter 3.7.3). After enrichment, the percentage of Sca1
+ cells was about 
87%. These cells were cultured with a cytokine combination of SCF/IL-3/IL-6 for BM cells 
for 3 days. Pre-stimulated cells were then incubated with retroviral particles containing Sxgs-
HOXB4, SF71gp and SF91-GFP2AHOXB4 vectors. The titres of the viral particles, 
multiplicity of infection (MOI) and transduction efficiencies are listed in Table 4.1.2. 
 
Table 4.1.2: Titres of viral particles, MOI and transduction efficiencies for in vivo experiments 
  Titre (TU/ml)  MOI (total)  7D5+/GFP+ cells 
Sxgs-HOXB4  8 × 10
5 18 11% 
SF71gp  12 × 10
5 18 11% 
SF91-GFP2AHOXB4  5 × 10
5 18 36% 
 
One day after transduction, the transduced cells from all groups were injected i.v. into 
8.0 Gy-irradiated C57BL/6 recipient mice. All the mice survived until analysis 8–10 weeks 
after transplantation, when the percentages of transgene-expressing cells (7D5-positive or 
GFP-positive cells) in the BM cells were determined. The results from all the recipients and 
average values from the 3 groups are shown in Table 4.1.3 and Figure 4.1.6. In addition, 2 
irradiated but non-transplanted mice were used as a control for the irradiation dose. These 
mice died 12 and 14 days after irradiation.  
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Table 4.1.3: Engraftment of the transplanted cells in recipients 
Mouse  
number 
Construct  % 7D5+ or GFP
+ 
cells in total BM 
cells 
Mouse  
number
Construct  % 7D5+ cells in 
tatal BM cells 
No.1  ntd 0  No.11  Sxgs-HOXB4  0.2 
No.2  ntd 0  No.12  Sxgs-HOXB4  0.3 
No.3  SF71gp 4,5  No.13  Sxgs-HOXB4  2.4 
No.4  SF71gp 5,6  No.14  Sxgs-HOXB4  0.3 
No.5  SF71gp 3,3  No.15  Sxgs-HOXB4  2.6 
No.6  SF71gp 13,3  No.16  Sxgs-HOXB4  1.8 
No.7  SF91-GFP2AHOXB4 78 No.17  Sxgs-HOXB4  0.5 
No.8  SF91-GFP2AHOXB4 79 No.18  Sxgs-HOXB4  0.9 
No.9  SF91-GFP2AHOXB4 79 No.19  ntpl - 
No.10  SF91-GFP2AHOXB4 83 No.20  ntpl - 
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Figure 4.1.6: Average engraftment for each experimental group of recipient mice. Average values and 
standard deviations of the percentage of 7D5-positive or GFP-positive cells were calculated from the data 
in Table 4.1.3. 
 
As shown above, the transgene expression levels of the transplanted mice differ 
significantly. Cells transduced with the positive control construct SF91-GFP2AHOXB4 
repopulated recipient mice with about 80% GFP transgene expression. However, the 
expression of the gp91
phox transgene in recipient mice, which were transplanted with cells 
transduced with our construct Sxgs-HOXB4, was very low, only about 1%. This value is even 
lower than the number of gp91
phox-positive cells in recipients of cells transduced with the 
negative construct lacking HOXB4 sequences (about 5%). Therefore, high transgene 
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expressing cells cannot be observed in recipient mice transplanted with Sxgs-HOXB4-
transduced Sca1+ cells. 
In summary, overexpression of the retroviral vector Sxgs-HOXB4 in primary BM cells 
in vitro can lead to a 3–4-fold higher cell proliferation with high numbers of gp91
phox 
expressing cells compared to cells transduced with the control construct. The expanded cell 
population contained a high number of progenitor cells, as determined by CFU-assay. 
Nonetheless, high transgene expressing cells were not determined in the BM cells of recipient 
mice transplanted with Sxgs-HOXB4-transduced cells, although 11% of the transduced Sca1+ 
BM cells were gp91
phox positive. 
It has been reported that high ectopic expression of HOXB4 impairs lymphoid and 
myeloid differentiation in transplanted mice (Schiedlmeier et al., 2003). The function of 
HOXB4 is dependent on the expression level, which we cannot quantitatively control. My 
aim, therefore, became the development of a retroviral vector that is suitable for the 
controllable selective expansion of gene-modified cells.  
 
4.  2  Testing of Truncated Forms of Epidermal Growth Factor Receptor 
(EGFR) and Prolactin Receptor (PrlR) as Selection Molecules 
 
The receptors for EGF and prolactin are membrane-bound proteins. Following ligand-
induced dimerization, the intracellular region serves as the signal transduction domain, which 
is important for cell proliferation, survival and other physiologic functions (see Introduction, 
chapters 1.1 and 1.4). If dimerization can be controlled with chemical inducers of 
dimerization (CID), then the proliferation advantage of EGFR and PrlR can also be used for 
the selective expansion of gene-modified HSCs. In the following approach, activation of 
receptor signalling was coupled with inducible dimerization of the fusion constructs S-
NF2/PrlR and S-NF2/EGFR, allowing it to be controlled by the addition of activators, such as 
the drug AP20187 (Ariad, www.ariad.com). 
 
4.2.1  Lentiviral Vectors Containing Selectable domains Derived from the EGF and 
Prolactin Receptors  
 
The human EGFR cDNA and the mouse PrlR cDNA are shown in Figures 4.2.1 and 
4.2.2. The intracellular domains of both receptors were amplified using PCR with appropriate 
primer pairs, as described in chapter 3.1.7, and cut with the restriction enzymes SpeI and 
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KpnI. The lentiviral cloning vector contained the marker gene LNGFR in frame with 2 copies 
of FKBP (see description in chapter 3.6.8) and the intracellular domain of human 
thrombopoietin receptor (hmpl). The cloning strategy is shown in Figure 4.2.1. The resulting 
constructs, S-NF2EGFR and S-NF2PrlR, were used for further functional analysis. 
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Figure 4.2.1: Cloning of S-NF2EGFR. The sequence encompassing the intracellular domain of the human 
EGFR was amplified by PCR to introduce SpeI and KpnI restriction sites. This product was cloned into 
SpeI- and KpnI-digested vector DNA. Positive clones were detected by restriction digest and appropriate 
cloning was proven by DNA sequencing.  
TM = transmembrane domain; sd = splice donor; ga = gag; RRE = rev response element; sa = splice 
acceptor; cPPT = central polypurine tract; SFFV = promoter/enhancer from spleen focus forming virus; Ψ: 
packaging signal. 
 
The lentiviral vector SEW, which contains the eGFP sequence as a marker gene in 
place of the selection cassette, served as a control construct for these experiments. 
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Figure 4.2.2: Cloning of S-NF2PrlR. The intracellular domain of murine PrlR was amplified by PCR and 
subcloned into the TOPO vector pCR2.1 (Invitrogen). This was then cleaved with SpeI and KpnI and the 
DNA-fragment containing the PrlR was cloned into SpeI- and KpnI-digested S-NF2hmpl vector DNA 
resulting in the new construct S-NF2PrlR. Abbreviations are as in Figure 4.2.1. 
 
4.2.2  Lentiviral Vector Production and Titre Determination on 293T Cells 
 
The lentiviral particles were produced as described in chapter 3.6.6 and their titre was 
determined on 293T cells (Figure 4.2.3). LNGFR-positive cells were measured using FACS 
analysis with an appropriate antibody (Figure 4.2.3 A) or direct determination of green 
fluorescence-positive cells (Figure 4.2.3 B). Table 4.2.1 gives a summary of all titres 
determined for S-NF2EGFR, S-NF2PrlR and SEW from different experiments. 
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Figure 4.2.3:Titre determination on 293T cells. The virus particles were diluted 1:10 and 1:100, and 
added to plated 293T cells. Three days after transduction, the cells transduced with the S-NF2PrlR and S-
NF2EGFR constructs were prepared for FACS analysis with anti-LNGFR-PE antibody. For the SEW-
transduced cells, eGFP-positive cells were measured without staining. A: In this experiment (dilution 
1:100), the titres of S-NF2PrlR and S-NF2EGFR were 5.4 × 10
5 and 9.3 × 10
5 TU/ml, respectively. B: The 
titre from control SEW-transduced cells (dilution again 1:100) was over 7.1 × 10
6 TU/ml. 
 
Table 4.2.1: Range of virus titres from lentiviral constructs 
Construct Titre  (TU/ml) 
S-NF2EGFR  2–7 × 10
5
S-NF2PrlR  5–12 × 10
5
SEW  7–13 × 10
6
 
 
4.2.3  Selective Proliferation Advantage Supplied by S-NF2EGFR and S-NF2PrlR in 
Transduced BaF/3 Cells 
 
To test whether the fusion proteins allow control of proliferation via dimerization, we 
used lentiviral particles containing the fusion constructs to transduce BaF/3 cells. BaF/3 is a 
mouse pro-B cell line, which continuously requires mouse interleukin 3 (mIL-3) for growth. 
In this study, 5% conditioned WEHI medium was used as a source for mIL-3. AP20187 was 
used at a concentration of 10 nM. The MOI applied and transduction efficiency is indicated in 
Table 4.2.2. 
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Table 4.2.2: The MOI and percentage of 7D5-positive cells in lentiviral vector-transduced BaF/3 
cells. 
Construct MOI  Transduction  efficiency 
S-NF2EGFR 5 21% 
S-NF2PrlR 5  19% 
SEW 20  21% 
 
The proliferation rates of transduced cell were compared during 2 weeks of culture 
with and without AP20187. As shown in Figure 4.2.4, cells transduced with S-NF2EGFR and 
stimulated with AP20187 had a high proliferation rate over the 17 days, similar to that of 
control cultures in conditioned WEHI medium. The S-NF2PrlR-transduced cells stimulated 
with AP20187 did not expand significantly in the first 10 days, but started to expand on day 
10. The control SEW-transduced cells underwent cell death 1 week after the WEHI 
conditioned medium had been replaced with AP20187. A high percentage of both S-
NF2EGFR- and S-NF2PrlR-selected cells expressed the LNGFR marker gene (Figure 4.2.5). 
In contrast, non-selected cells (cultured with WEHI medium, without AP20187) did not show 
an increase in LNGFR-positive cells. Similarly, SEW-transduced cells maintained only low 
levels of transgene expression (eGFP+ cells) after 2 weeks in culture.  
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Fig 4.2.4: Transduced BaF/3 cell proliferation under stimulation with AP20187. BaF/3 cells were 
transduced with SEW (blue), S-NF2PrlR (pink) and S-NF2EGFR (green). Three days after transduction, 
transduced cells were washed extensively with PBS and cultured further with either conditioned WEHI 
medium (containing mIL-3) (dotted lines) or 10 nM AP20187 (without mIL-3) (solid lines). The cell 
number was counted every 2 days by trypan blue dye exclusion. 
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Fig 4.2.5: Transgene expression in selected and non-selected transduced BaF/3 cells. The percentage of 
transgene-expressing cells (LNGFR+ cells or eGFP+ cells) was determined by FACS analysis with 
antibodies against human LNGFR for S-NF2PrlR- and S-NF2EGFR-transduced cells or direct fluorescence 
for SEW-transduced cells at the indicated time points.  
 
As demonstrated in Figure 4.2.5, 2 weeks after selection, the S-NF2EGFR- and S-
NF2PrlR-transduced cells showed about 99% (dotted green columns) and 96% (dotted pink 
columns) LNGFR-positive cells, respectively. In contrast, the S-NF2EGFR-transduced cells 
cultured in WEHI medium (green columns) did not show any major increase in LNGFR 
transgene expression. S-NF2PrlR-transduced cells showed a slight decrease in LNGFR-
positive cells in conditioned WEHI medium (pink columns). 
 
4.2.4 Reversibility of Dimerizer-Induced Selective Expansion of BaF/3 Cells 
Expressing EGFR and PrlR Fusion Genes 
 
EGFR and PrlR have putative roles in tumour development, and are often found to be 
overexpressed in tumour samples, for example PrLR in breast cancer cells (Clevenger et al., 
2003). Therefore, reversibility of AP20187-dependent proliferation cells is an important 
feature of this strategy. To test the reversibility of S-NF2EGFR- and S-NF2PrlR-mediated 
proliferation, we removed the chemical dimerizer AP20187 from the culture medium of the 
selected and expanded BaF/3 cells. Proliferation rates of these cells are demonstrated in 
Figure 4.2.6. 
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Figure 4.2.6: Removal of AP20187 from the selected BaF/3 cell cultures. This experiment was carried 
out using the proliferation test as described in Figure 4.2.4. On day 8 after the start of selection (indicated 
by the arrow in the figure), the cells were washed 3 times with PBS. One sample of the cells was cultured 
further with AP20187 (continuous line), while the other was cultured without (dotted line). The y-axis 
shows the calculated cumulative cell number. 
 
As demonstrated in Figure 4.2.6, selected S-NF2EGFR-transduced BaF/3 cells 
continued to proliferate independently even after removal of the dimerizer AP20187 from the 
medium, whereas proliferation of S-NF2PrLR-transduced cells was entirely dependent on the 
presence of AP20187. 
 
4.2.5  Protein Detection of Fusion Constructs by Western Blotting  
 
Expression of the fusion proteins was proved by western blotting with an anti-human 
FKBP antibody (see description in chapter 3.5.3). The expected sizes of the NF2EGFR and 
NF2PrlR fusion proteins are about 110 kDa and 92 kDa, respectively.  
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Figure. 4.2.7: Protein detection in cell extracts from transduced BaF/3 cells by western blotting. 
Whole cell extracts were prepared from SEW-, S-NF2PrlR- and S-NF2EGFR-transduced BaF/3 cells with 
Triton-X lysis buffer. The proteins were separated by SDS-PAGE, blotted onto a PVDF membrane and 
incubated with a polyclonal antibody against human FKBP (anti-FKBP12, ABR Affinity Bioreagents). In 
SEW transduced cells, no FKBP protein was observed (lane 1). Fusion protein expression was detected in 
S-NF2PrlR- (lane 2) and S-NF2EGFR-transduced cells (lane 3) as a double band. Arrows indicate the 
expected bands. 
 
As illustrated in Figure 4.2.7, the fusion proteins NF2PrlR and NF2EGFR were 
detected at the expected sizes of 92 kDa and 110 kDa, respectively. In addition, a higher band 
signal was observed with both constructs, probably due to glycosylation of the LNGFR part 
of the fusion protein (Junker et al., 2003). 
 
4.3 Development of a Bicistronic Retroviral Vector Consisting of the 
Therapeutic Gene gp91
phox and a PrlR-Based Selection Cassette 
 
As shown in chapter 4.2, overexpression of the S-NF2EGFR construct led to a 
proliferation of BaF/3 cells that could no longer be controlled. These results indicate that, 
despite the advantages of the desired strong proliferation and anti-apoptosis activity, the 
intracellular domain of EGFR is not suitable for the selective expansion of HSCs, because 
activation of the selection construct became independent of the dimerizer. In contrast, 
overexpression of the fusion gene S-NF2PrlR, caused a selective expansion of modified 
BaF/3 cells that could be switched off by removing the small dimerizer AP20187. Therefore, 
all vectors used in the following experiments contain a selection cassette derived from the 
intracellular domain of the PrlR. This cassette was cloned together with the cDNA for the 
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therapeutic gene gp91
phox. As described in chapter 1.3, lentiviral vectors have the striking 
advantage of also being able to target non-dividing cells. However, the safety of these vectors 
for human gene therapy approaches is not yet fully established. We therefore used 
gammaretroviral vectors based on MLV (murine leukaemia virus), which have become a safe 
and powerful tool for efficient in vitro, ex vivo and in vivo gene transfer into proliferating 
cells.  
 
4.3.1  Cloning of Retroviral Constructs Sxgs-NF2 and Sxgs-NF2PrlR 
 
The control vector Sxgs-NF2 was obtained by inserting a PCR-amplified 1×FKBP 
element into the large XhoI- and BamHI-restricted fragment of the retroviral vector Sxgs-
NF2hmpl, as shown in Figure 4.3.1. The functional vector Sxgs-NF2PrlR was derived from 
the lentiviral vector S-NF2PrlR and the retroviral vector Sxgs-NF2d3YF containing the 
sequences for 2xFKBP, the truncated LNGFR, and, downstream of the coding sequence for 
the therapeutic gene gp91
phox. The cloning steps are shown in Figure 4.3.2. 
 
XhoI BamHI
FKBP
XhoI
BamHI
CMV
pC4M-Fv2E
A
Sxgs-NF2hmpl    
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
B
FKBP hmpl
Sxgs-NF2 
(8381 bp)  
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
C
FKBP
 
 
Figure 4.3.1: Cloning of the control vector Sxgs-NF2. One copy FKBP sequence was amplified by PCR 
using pC4M-Fv2E as a template (Ariad). The PCR primers were equipped with XhoI and BamHI restriction 
sites. The amplified fragment was cloned into the retroviral vector Sxgs-NF2d3YF, which was also cut with 
XhoI and BamHI. A: Structure of template plasmid pC4M-Fv2E. B: Structure of bicistronic cloning vector 
Sxgs-NF2hmpl containing gp91
phox (upstream) and the fusion construct with LNGFR, two copies of FKBP 
and the human thrombopoietin receptor. Expression of the proteins is controlled by the SFFV promoter and 
the viral splice donor, splice acceptor system (sd/sa). C: Control vector Sxgs-NF2 with the therapeutic gene 
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gp91
phox and the fusion construct lacking a receptor domain. Numbers indicate length of the entire plasmid 
in base pairs. 
 
XhoI ClaI
A
Sxgs-NF2∆3YF
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
B
FKBP ∆3YF
Sxgs-NF2PrlR 
(9455 bp)  
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
C
FKBP
S-NF2PrlR
SFFV
beta
FKBP PrlR
XhoI PvuI
LNGFR
PrlR
 
 
Figure 4.3.2: Cloning of the functional vector Sxgs-NF2PrlR. The insert consisting of one copy FKBP 
and the intracellular domain of PrlR was cut from the lentiviral vector S-NF2PrlR with PvuI. The fragment 
was then blunt-ended using the Klenow reaction. Thereafter, the fragment was restricted with XhoI and 
cloned into the vector Sxgs-NF2d3YF between the XhoI and blunted ClaI restriction sites. A: Scheme of S-
NF2PrlR (see also Figure 4.2.2). B: Cloning vector Sxgs-NF2d3YF. C: Functional vector Sxgs-NF2PrlR 
with the therapeutic gene gp91
phox and the fusion construct NF2PrlR. 
 
4.3.2  Production and Titre Determination of Sxgs-NF2 and Sxgs-NF2PrlR Retroviral 
Supernatants  
 
Retroviral particles were produced in the ecotropic cell line Phoenix E (see chapter 
3.6.6). The titre of the virus particles was determined by detecting gp91
phox expression in 
transduced SC1 cells. Cells were stained with the 7D5 antibody and analysed by FACS. An 
example is shown in Figure 4.3.3. Similar results were also obtained by the detection of 
LNGFR-positive cells. 
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Figure 4.3.3: Titre determination of virus particles carrying the constructs Sxgs-NF2 and Sxgs-
NF2PrlR. One day before transduction, 5 × 10
4 SC1 cells per well were plated in 24-well plates. The virus 
particles were diluted 1:10 and 1:100 (10 and 100 µl), and added into the wells with 1 ml fresh medium. 
Three days after transduction, 1 × 10
5 transduced cells were used for FACS analysis after staining with 40 
µl 7D5 antibody and 4 µl anti-RAM IgG-PE as the secondary antibody. The percentage of 7D5-positive 
cells was used to calculate the virus titre. Left: non-transduced SC1 cells (ntd) were used as the negative 
control. Middle: Percentage of 7D5-positive cells in Sxgs-NF2-transduced cells. Right: Percentage of 7D5-
positive cells in Sxgs-NF2PrlR-transduced cells. The formula from chapter 3 was used to calculate titres in 
TU/ml. In the example shown, the titres were 4 × 10
5 TU/ml for the Sxgs-NF2 construct and 9.5 × 10
5 
TU/ml for the Sxgs-NF2PrlR construct. 
 
4.3.3  Functional Analysis of the Sxgs-NF2 and Sxgs-NF2PrlR Constructs in 
Transduced Murine BaF/3 Cells 
 
To test the Sxgs-NF2PrlR construct, we first transduced it into the mouse pro-B cell 
line BaF/3 using retroviral particles. Cell proliferation was measured by cumulative cell 
numbers during 15 days stimulation with AP20187 (Figure 4.3.4). In addition, transgene 
expression (gp91
phox-positive cells) was also analysed by FACS with 7D5 antibody (Figure 
4.3.5). 
As illustrated in Figure 4.3.4, the number of Sxgs-NF2PrlR-transduced BaF/3 cells 
increased by about 120-fold during culture with AP20187. The selected cell population 
contained a high percentage of 7D5-positive cells (about 84% after 5 days stimulation and 
94% after 14 days) (Figure 4.3.5). In contrast, the Sxgs-NF2-transduced cells underwent cell 
death within 4 days of stimulation with AP20187. Cells transduced with both constructs and 
cultured with mIL-3 expanded very strongly. However, the percentage of 7D5-positive cells 
in these expanded populations decreased during cultivation. 
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Figure 4.3.4: AP20187-induced cell proliferation of Sxgs-NF2PrlR-transduced BaF/3 cells. 2 × 10
5 
BaF/3 cells were transduced with Sxgs-NF2PrlR and Sxgs-NF2 viral particles at a MOI of 5. Three days 
after transduction, the cells were washed 3 times with PBS and then cultured under 2 different conditions: 
either with mIL-3 (10 ng/ml) or with AP20187 (10 nM). Cell concentrations were counted at an interval of 
5 days and are plotted as cumulative cell numbers. Dotted line: Cell proliferation under stimulation with 
mIL-3. Pink line: Sxgs-NF2PrlR-transduced cells cultured with AP20187. Blue line: Sxgs-NF2-transduced 
cells cultured with AP20187.  
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Figure 4.3.5: AP20187-induced selection of Sxgs-NF2PrlR-transduced BaF/3 cells. The transduced 
cells were treated as described in the legend for Figure 4.3.4. At various time points, cells were stained with 
7D5 antibody and analysed by FACS. Blue column: Sxgs-NF2-transduced cells cultured with mIL-3. Pink 
column: Cells transduced with Sxgs-NF2PrlR and cultured with mIL-3. Pink hatched column: Cells 
transduced with Sxgs-NF2PrlR and stimulated with AP20187. 
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4.3.4  Functional Analysis of the Sxgs-NF2 and Sxgs-NF2PrlR Constructs in 
Transduced Murine Primary BM Cells 
 
Experiments were carried out in mBM cells, in order to confirm the effect of Sxgs-
NF2PrlR in primary cells. Total mBM cells were prepared as described in chapter 3.7.2. The 
cells were pre-stimulated with a cytokine combination consisting of 10 ng/ml mIL-3, 50 
ng/ml mIL-6 and 50 ng/ml mSCF for 2 days. The cells were then transduced with Sxgs-NF2 
and Sxgs-NF2PrlR retroviral particles. Three days after transduction, 7D5-positive cells were 
quantified by FACS analysis. Thereafter, the cells were washed and further cultured in the 
presence either AP20187 (10 nM) + mSCF (50 ng/ml) or the cytokine combination mIL-3, 
mIL-6 and mSCF. Figures 4.3.6 and 4.3.7 show the resulting cell proliferation curves and 
transgene expression profiles respectively. 
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Figure 4.3.6: AP20187-induced cell proliferation of Sxgs-NF2PrlR- and Sxgs-NF2-transduced mBM 
cells. 2 × 10
5 total mBM cells were transduced with Sxgs-NF2PrlR and Sxgs-NF2 at a MOI of 10. Three 
days after transduction (on day 6), the cells were washed 3 times with PBS and then cultured with either 
AP20187 (10 nM) + mSCF (50 ng/ml) (solid lines) or the cytokine combination mIL-3 (10 ng/ml), mIL-6 
(50 ng/ml) and mSCF (50 ng/ml) (dotted lines). Cell numbers were cumulative calculated every week. 
Dotted line: Cell proliferating under stimulation with the cytokine combination. Pink line: Sxgs-NF2PrlR-
transduced cells. Blue line: Sxgs-NF2-transduced cells.  
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Figure 4.3.7: AP20187-induced selection of Sxgs-NF2PrlR- and Sxgs-NF2-transduced mBM cells. The 
transduced cells were treated as described in the legend for Figure 4.3.6. At different time points, cells were 
stained with 7D5 antibody and analysed by FACS. Blue columns: Sxgs-NF2-transduced cells cultured with 
the cytokine combination (solid) or with AP20187 + mSCF (hatched). Red columns: Cells transduced with 
Sxgs-NF2PrlR and cultured with the cytokine combination (solid) or with AP20187 + mSCF (hatched). 
 
As demonstrated in Figures 4.3.6 and 4.3.7, Sxgs-NF2PrlR-transduced cells 
proliferated more strongly under stimulation with AP20187 than with the cytokine 
combination. Additionally, the percentage of 7D5-positive cells increased from an initial 13% 
to 92% after 2 weeks stimulation with AP20187. However, the control Sxgs-NF2-transduced 
mBM cells also expanded under stimulation with AP20187, albeit not as strongly as those 
growing in the presence of the cytokine combination. This was also accompanied by an 
increase in 7D5-positive cells from 25 to 55% after 2 weeks stimulation with AP20187 + 
mSCF. In contrast to the cells under dimerizer-induced selection, cells transduced with either 
construct did not show any increased number of 7D5-positive cells when cultured with the 
cytokine combination. 
The characteristics of the expanded cell populations were determined in 
methylcellulose-based CFU progenitor assays (Figure 4.3.8). 
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Figure 4.3.8: CFU assay of transduced mBM cells on days 6 and 20. On day 6, 3 days after transduction 
(also the start of selection), 1000 transduced cells for each construct were plated in 10 cm dishes with 1 ml 
methylcellulose medium. After 10 days incubation, the total colony numbers were counted. On day 20 
(after 2 weeks selection), 3000 transduced cells for each construct and culture condition were plated. 
 
As illustrated in Figure 4.3.8, after 2 weeks selection with AP20187, cells transduced 
with the control construct Sxgs-NF2 showed 6-fold higher total colony numbers, while the 
cytokine cultured cells had an 2-fold increase of CFUs. The Sxgs-NF2PrlR-transduced cells 
have about 4-fold increase in colony numbers either after 2 weeks selection with AP20187 or 
cultured with the cytokine combination. 
 
4.4  Development of Bicistronic Retroviral Vectors Sxgs-F2 and Sxgs-
F2PrlR Containing an Intracellular Signalling Molecule 
 
For unknown reasons, the negative control construct Sxgs-NF2 also increased the 
proliferation of transduced primary BM cells under AP20187 stimulation. Since this effect 
was possibly due to the presence of dLNGFR, this sequence was removed from the Sxgs-NF2 
and Sxgs-NF2PrlR constructs, and the resulting novel bicistronic constructs were analysed. 
The upstream gene gp91
phox was used as the marker gene in all the following experiments.  
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4.4.1  Cloning of Constructs Sxgs-F2PrlR and Sxgs-F2 
 
The novel vector was cloned by replacing the LNGFR and one copy FKBP sequence 
of Sxgs-NF2PrlR with a PCR product coding for one copy FKBP and containing XbaI and 
XhoI restriction sites, as shown in Figure 4.4.1. Sxgs-F2 served as the control vector and was 
cloned as described in Figure 4.4.2. 
 
XbaI XhoI
A
Ψ
sd
SFFV gp91
sa
SFFV
LNGFR
B
FKBP PrlR
Sxgs-NF2PrlR
SFFV
beta
FKBP PrlR
XbaI
XhoI
LNGFR
Ψ
sd
SFFV
gp91
sa
SFFV
C
FKBP PrlR
Sxgs-NF2PrlR
Sxgs-F2PrlR
 
 
Figure 4.4.1: Cloning strategy for the novel construct Sxgs-F2PrlR. The 1×FKBP fragment was 
amplified with 2 PCR primers designed with XbaI and XhoI restriction sites at the ends (see small arrows in 
A) using Sxgs-NF2PrlR as a template. This PCR product was subcloned into the pCR2.1-TOPO vector, cut 
with the enzymes XbaI and XhoI, and ligated to the large XbaI– XhoI DNA fragment from Sxgs-NF2PrlR 
(B) resulting in the new vector Sxgs-F2PrlR that lacks the LNGFR marker gene (C). 
 
HindIII XhoI
A
Ψ
sd
SFFV
gp91
sa
SFFV
LNGFR
B
FKBP
Sxgs-NF2
SFFV
beta
FKBP
HindIII
XhoI
LNGFR
Ψ
sd
SFFV
gp91
sa
SFFV
C
FKBP
Sxgs-NF2PrlR
Sxgs-F2
FKBP
 
 
Figure 4.4.2: Cloning of the control construct Sxgs-F2. The 1×FKBP fragment was amplified with 2 
PCR primers designed with HindIII and XhoI restriction sites at the end (see arrows in A) using Sxgs-NF2 
as a template. The PCR product was subcloned into the pCR2.1-TOPO vector, cut with the enzymes 
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HindIII and XhoI, and ligated to the large HindIII–XhoI DNA fragment from Sxgs-NF2 (B) resulting in the 
new vector Sxgs-F2 which lacks the LNGFR marker gene (C). 
 
4.4.2  Virus Particle Production in Phoenix-E Cells and Titre Determination on SC1 
Cells 
 
Retroviral virus particles were produced in Phoenix-E cells as described in chapter 
3.6.6. Titre determination was carried out on SC1 cells with viral supernatant diluted 1:10 and 
1:100. Figure 4.4.3 shows a FACS analysis of the titre determination for Sxgs-F2PrlR- and 
control construct Sxgs-F2-transduced cells. 
 
100 101 102 103 104 100 101 102 103 104
A: ntd B: Sxgs-F2 C: Sxgs-F2PrlR
100 101 102 103 104
1 0
0
1 0
1
 
 
 
 
 
 
 
 
1
0 2
1 0 3
1 0
4
FL1-High
7D5 
11,5 10,2
1 0
0
1 0
1
 
 
 
 
 
 
 
 
1
0
2
1 0
3
1 0 4
1 0
0
1 0
1
 
 
 
 
 
 
 
 
1
0
2
1 0
3
1 0
4
 
 
Figure 4.4.3: FACS analysis for the titre determination of Sxgs-F2PrlR and Sxgs-F2 retroviral 
vectors on SC1 cells. One day before transduction, 5 × 10
4 SC1 cells per well were plated in 24-well 
plates. The virus particles were given to the wells at a dilution of 1:100 in 1 ml fresh medium. Three days 
after transduction, 1 × 10
5 transduced cells were used for FACS staining with 40 µl 7D5 antibody and 4 µl 
RAM IgG1-PE as the secondary antibody. The percentage of 7D5-positive cells was used to calculate the 
titre (see chapter 3.6.6). A: ntd SC1 as the negative control. B: Percentage of 7D5-positive cells in Sxgs-F2-
transduced cells. C: Percentage of 7D5-positive cells in Sxgs-F2PrlR-transduced cells.  
 
With this method, retroviral virus particles were produced at different time points in 
different fractions. Titre determination was carried out for all fractions separately and the 
range of values for both retroviral vectors is shown in Table 4.4.1. 
 
Table 4.4.1: Titre determination on SC1 cells for Sxgs-F2PrlR and Sxgs-F2 from different 
experiments. Viral supernatants were stored at –80°C before use. 
Constructs  Titre on SC1 cells (TU/ml) 
Sxgs-F2PrlR  1.0–2.3 × 10
6
Sxgs-F2  1.2–2.5 × 10
6
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4.4.3  Cytoplasmic Localisation of Novel Fusion Protein F2PrlR  
 
The truncated form of the prolactin receptor used as the selection molecule in the 
Sxgs-F2PrlR construct lacks a membrane anchor signal and should therefore be located in the 
cytoplasm of transduced cells. To verify cytoplasmic localisation, murine SC1 cells were 
transduced with Sxgs-F2PrlR retroviral vectors and localisation of the truncated receptor was 
examined by laser confocal microscopy through detection with a specific anti-human FKBP 
antibody. In addition, the cytoplasmic indicator protein α-tubulin was stained to visualise the 
cytoplasm. As shown in Figure 4.4.4, the endogenous FKBP protein localises mainly to the 
nucleus, while an additional strong fluorescence signal was also detectable in the cytoplasm 
of the Sxgs-F2PrlR-transduced cells. Furthermore, overlay of both fluorescence signals 
indicated colocalisation in the cytoplasm of Sxgs-F2PrlR-transduced cells, but not in wild 
type cells. We conclude from this experiment that the truncated prolactin receptor localises to 
the cytoplasm of transduced cells. 
 
4.4.4  Selective Expansion of Transduced BaF/3 Cells Caused by the Sxgs-F2PrlR 
Construct Containing gp91
phox  
 
Retroviral particles containing the novel construct Sxgs-F2PrlR were used to transduce 
BaF/3 cells to investigate the function of the FKBP-prolactin receptor fusion protein which 
lacks the LNGFR sequence. BaF/3 cells were transduced as described in chapter 3.6.7 with an 
MOI of 5 (1× 10
6 TU per 2 × 10
5 cells). Three days after transduction, the number of 
gp91
phox-positive cells, was determined by FACS analysis. Transduced cells were then 
washed 3 times with PBS and cultured for 14 days with either mIL-3 (10 ng/ml) or AP20187 
(10 nM). Growth kinetics and transgene expression (7D5+ cells) from 2 independent 
experiments (A and B) are shown in Figure 4.4.5 and 4.4.6 respectively. In total, 4 expansion 
experiments were performed with BaF/3 cells, displaying similar outcomes. 
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Figure 4.4.4: The F2PrlR fusion protein resides in the cytoplasm of Sxgs-F2PrlR-transduced murine 
SC1 cells. I: Murine SC1 cells were transduced with Sxgs-F2PrlR retroviral particles diluted 1:10. Three 
days after transduction, transduced and wild type SC1 cells were stained with a polyclonal anti-human 
FKBP12 antibody. A 488-goat anti-rabbit IgG1 antibody (green fluorescence) was used as secondary 
antibody. The cytoplasmic protein α-tubulin was specifically stained with a monoclonal antibody and 
visualised with a Alixa 546-goat anti-mouse IgG secondary antibody (red fluorescence; Molecular Probes). 
A: Transmission pictures without UV light. B: Images of the cytoplasmic protein α-tubulin. C: Images of 
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the FKBP protein. D: Overlay of α-tubulin and FKBP. II: Enlargement of wild type and Sxgs-F2PrlR-
transduced SC1 cells from image I (number D). Colocalisation of green and red fluorescence is depicted by 
the yellow staining in the cytoplasm of Sxgs-F2PrlR-transduced cells. 
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Figure 4.4.5: Proliferation advantage of Sxgs-F2PrlR-transduced BaF/3 cells stimulated with 
AP20187. Three days after transduction, the non-transduced (ntd) Sxgs-F2-transduced and Sxgs-F2PrlR-
transduced cells were washed and cultured with either mIL-3 (10 ng/ml) (broken lines) or AP20187 (10 
nM)(solid lines). The cumulative cell numbers were calculated over 2 weeks at an interval of 2–3 days by 
trypan blue staining. Pink line: Sxgs-F2PrlR-transduced cells. Light and dark blue line: Ntd and Sxgs-F2-
transduced cells, respectively. A and B indicate two separate experiments. 
 110   Results 
 
In the experiments shown, the total number of Sxgs-F2PrlR-transduced cells increased 
1500-fold (experiment A) and 27000-fold (experiment B) after 14–15 days stimulation with 
AP20187. The rate of proliferation was similar to that of cells cultured with the growth factor 
mIL-3, albeit with a short lag phase (roughly 2 days in both experiments) treated with 
AP20187. Non-transduced and control Sxgs-F2-transduced cells underwent cell death within 
1 week of culture with AP20187. 
Transgene expression, i.e. the percentage of 7D5-positive cells in the transduced cell 
population, was analysed by flow cytometry. As shown in Figure 4.4.6, after 2 weeks of 
selection, the percentage of Sxgs-F2PrlR-transduced cells expressing the marker gene 
gp91
phox increased from 3 to 70% (experiment A) and 38 to 82% (experiment B) (column 
F2PrlR/AP). No increase occurred in Sxgs-F2-transduced cells (column F2/AP). In the mIL3 
cultures (columns F2/mIL-3 and F2PrlR/mIL-3), the number of gp91
phox-positive cells 
decreased after 2 weeks. 
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Figure 4.4.6: AP20187-induced selection of F2PrlR- and gp91
phox-expressing BaF/3 cells. FACS 
analysis was carried out on day 0 (3 days after transduction), day 6 (1 week of stimulation with 
AP20187) and day 14 (2 weeks of stimulation with AP20187) with the anti-7D5 antibody. The 
different columns represent the different constructs and different culture conditions. Blue: Sxgs-F2-
transduced cells stimulated with mIL-3. Red: Sxgs-F2PrlR-transduced cells stimulated with mIL-3. 
Yellow: Sxgs-F2PrlR-transduced cells stimulated with AP20187. 
 
4.4.5  The Proliferation Effect Is Reversible After Removal of the Dimerizer  
 
As described previously in chapter 4.2, the reversibility of AP20187-induced 
proliferation of the transduced cells is a crucial prerequisite for the potential clinical use of the 
dimerizer construct Sxgs-F2PrlR. Thus, after 14 days of stimulation, AP20187 was removed 
from the BaF/3 culture and the cells were cultured for another 2 weeks in RPMI with 10% 
FCS only. As shown in figure 4.4.7, the proliferation of Sxgs-F2PrlR-transduced BaF/3 cells 
ceased within 3 weeks after removal of the stimulator, although they proliferated during the 
first two weeks. This is probably dependent on the half-life of the small molecule AP20187 
under cell culture conditions. The non-transduced control cells rapidly underwent cell death 
after removal of mIL-3 from the culture medium. In contrast, the Sxgs-F2PrlR-transduced 
cells that were further cultured with mIL-3 expanded extensively. 
 112   Results 
0
1000
2000
0 2 5 8 13 16 21
days in culture after removal of AP/mIL-3 
c
u
m
u
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
 
x
1
0
^
5
ntd/-mIL-3
F2PrlR/-AP
F2PrlR/+AP
-mIL-3/AP
 
Figure 4.4.7: The effect of AP20187 on Sxgs-F2PrlR-transduced BAF/3 cells is reversible. After being 
stimulated with AP20187 for 2 weeks, the Sxgs-F2PrlR-transduced BaF/3 were extensively washed and 
further cultured either with (pink dotted line) or without AP20187 (pink line) for a further 3 weeks. Cell 
number was determined by trypan blue dye exclusion. Blue line: ntd control cells after removal of mIL-3. 
 
4.4.6  Identification of Fusion Protein Expression via Western Blotting 
 
Expression of the fusion protein F2PrlR in selected and non-selected transduced BaF/3 
cells was determined using western blotting with a specific anti-FKBP antibody. As shown 
before, while proliferation of BaF/3 cells is dependent on mIL-3, Sxgs-F2PrlR-transduced 
BaF/3 cells can be selected with AP20187. As illustrated in Figure 4.4.8, a weak and a strong 
band corresponding to the expected molecular weight of the fusion protein (~ 69 kDa) were 
observed in samples from the non-selected and selected cells, respectively. The significant 
difference in signal intensity can be explained by the high number of transgene-expressing 
cells in selected (80%) versus non-selected cells (20%), indicating a selection advantage for 
Sxgs-F2PrlR-transduced BaF/3 cells. 
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Figure 4.4.8: Fusion protein expression in transduced and selected BaF/3 cells. Cell extracts were 
prepared from BaF/3 wild type cells (lane 1), Sxgs-F2PrlR-transduced cells without stimulation (20% 
transduced cells, lane 2) and Sxgs-F2PrlR-transduced cells stimulated with AP20187 for 14 days (80% 
transduced cells, lane 3). The proteins were separated in a 10% SDS-PAGE gel and blotted onto a PVSF 
membrane. An antibody against human FKBP was used to detect the fusion protein (~ 69 kDa). Lower blot: 
After stripping the membrane, similar amounts of PLC-γ protein (~ 148 kDa) were detected with a 
monoclonal anti-PLC-γ antibody, indicating equal loading. 
 
4.4.7  Examination of Downstream Signal Transduction Pathways Activated by the 
Sxgs-F2PrlR Construct 
 
The wild type prolactin receptor was identified as a specific high-affinity membrane-
bound protein (Posner et al., 1974). The unusual localisation of the prolactin receptor fusion 
construct in this study prompted us to ask how the signal transduction cascade induced by 
Sxgs-F2PrlR compares to that triggered by the wild type prolactin receptor. A well-known 
substrate activated by the prolactin receptor is the signal transducer and activator of 
transcription 5, STAT5 (Goffin et al., 1998). The 2 isoforms of this protein, STAT5a and 
STAT5b, are activated by tyrosine phosphorylation in response to a wide variety of cytokines 
after ligand-induced receptor dimerization. We therefore investigated whether AP20187-
induced cell proliferation is caused by activation of STAT5, similarly to that caused by 
prolactin receptor overexpression and stimulation with prolactin, for example in BaF/3 cells 
(Pallard et al., 1995). Cell extracts from restimulated Sxgs-F2- and Sxgs-F2PrlR-transduced 
BaF/3 cells treated with different stimulation conditions were examined for STAT5 activation 
by western blotting with antibodies against STAT5 and phosphorylated STAT5 (phospho-
STAT5) (Figure 4.4.9). 
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Figure 4.4.9: Induction of STAT5 phosphorylation by addition of AP20187 to BaF/3 cells expressing 
Sxgs-F2PrlR.  Sxgs-F2-transduced BaF/3 cells (cultured with mIL-3, 25% transgene expression, left 3 
lanes) and Sxgs-F2PrlR-transduced cells (cultured for 2 weeks with AP20187, 85% transgene expression, 
middle 3 lanes) were deprived of mIL-3 or AP20187 for 24 hours and starved of FCS for a further 4 hours. 
The cells were then restimulated with either mIL-3 or AP20187 for 10 min. Extracts were prepared and 
equal protein amounts (60 µg per sample) were separated in an 8% SDS-PAGE gel. Western blotting was 
performed with an antibody against phospho-STAT5. After stripping the membrane, an antibody against 
STAT5 was used to determine the amount of the STAT5 protein. The right lane (+) shows a positive 
control obtained from cell extracts of wild type prolactin receptor-transfected cells stimulated with 
prolactin used to confirm the quality of antibodies. 
 
After restimulation with AP20187, only the cell extract from Sxgs-F2PrlR-transduced 
cells showed a strong signal corresponding to the expected molecular weight (~ 110 kDa) 
when analysed with the anti-phospho-STAT5 antibody. When restimulated with conditioned 
medium containing mIL-3, both cell populations showed strong STAT5 phosphorylation. 
Sxgs-F2PrlR-transduced cells that were not restimulated also displayed a weak signal with the 
anti-phospho-STAT5 antibody. This indicates that STAT5 activation induced by AP20187 in 
Sxgs-F2PrlR-transduced BaF/3 cells was not completely switched off after 28 hours of 
starvation following a previous 14 days stimulation.  
Phosphorylated STAT5 migrates to the nucleus of cells, where it binds to the promoter 
region of several target genes and activates transcription (Rane et al., 2002). One of the 
targets of prolactin receptor-induced signalling is the ß-casein gene. Therefore, the binding 
activity of STAT5 to the ß-casein promoter after dimerization of the truncated cytosolic form 
of the prolactin receptor was investigated using the electrophoretic mobility shift assay 
(EMSA) (Figure 4.4.10). A radioactively labelled oligonucleotide derived from the STAT5 
binding site in the ß-casein promoter was incubated with cell extracts obtained from 
transduced BaF/3 and control cells.  
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Figure 4.4.10: Signalling from the fusion receptor induces binding of STAT5 to its target gene 
promoter sequence. Whole cell extracts (WCE) were prepared by resuspending cells in lysis buffer after 
treating as described in Figure 4.4.7. WCE (8 µg per condition) were incubated for 20 minutes at 30°C with 
radiolabelled (T4 polynucleotide and γ
32P-ATP) ß-casein oligonucleotide (5’ – agatttctaggaattcaaatc). The 
protein-DNA complex was separated in a 5 % polyacrylamide gel in 0.25× TBE buffer and the radioactive 
signal was visualised by film exposure. Lanes 1–7: Control Sxgs-F2-transduced cells stimulated with mIL-
3 or AP20187. Lanes 8–14: Sxgs-F2PrlR-transduced cells stimulated with mIL-3 or AP20187. Binding of 
the antibodies against STAT5a and STAT5b to the STAT5/DNA complex is revealed by the respective 
supershifts of the complex (lanes 6, 7 and 13, 14). 
 
If the DNA (from the ß-casein) binds the STAT5a or STAT5b antibody, these 
protein/DNA complexes migrated more slowly than free DNA molecular when subjected to 
non-denaturing polyacrylamide gel electropjoresis. Therefore, a supershift could be observed. 
As shown in Figure 4.4.10, binding of STAT5 to the DNA probe (from ß-casein) is made 
evident by the retarded migration of the radiolabelled probe in the gel. Moreover, supershifted 
bands were observed in WCE from AP20187-stimulated, F2PrlR-transduced cells, similar to 
those from the positive control cells which were stimulated with mIL-3. In contrast, control 
non-stimulated, Sxgs-F2-transduced cells showed no binding activity. The weak signal 
observed in SXgs-F2PrlR-transduced cells that had not been restimulated with AP20187 (lane 
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8) was presumably due to the fact that the effect of AP20187 was not completely switched off 
within 28 hours after removal of the dimerizer. 
 
In summary, overexpression of the Sxgs-F2PrlR construct in BaF/3 cells led to a 
significant selective expansion of the transduced cells after stimulation with the dimerizer 
AP20187. The AP20187-induced cell proliferation might be a consequence of the activation 
of the STAT5 signalling pathway, similar to STAT5-derived proliferation of prolactin-
stimulated BaF/3 cells transduced with the full-length prolactin receptor construct (Pallard et 
al., 1995). In addition, the effect of AP20187 was reversible after withdrawal of the dimerizer. 
 
4.4.8  Selective Proliferation Advantage of Sxgs-F2PrlR-Transduced Primary Sca1+ 
mBM Cells 
 
The Sxgs-F2PrlR construct demonstrates a significant selection effect in transduced 
BaF/3 cells under stimulation with AP20187. Moreover, this effect is reversible after 
withdrawal of the drug. Subsequently, we therefore went on to investigate the constructs in 
the context of primary mBM cells and in vivo mouse models. As already mentioned in the 
Introduction (chapter 1.1), adult mBM contains different cells types, ranging from early 
pluripotent HSCs to committed differentiated cells. The HSCs have the capacity to self-
renew, maintain their progeny and to differentiate into all haematopoietic cell lineages. A 
variety of different phenotypic markers can be used to separate HSCs from other cell types or 
at least to enrich cell populations for these HSCs. Sca1 and c-kit are commonly accepted as 
markers for mouse HSCs and progenitor cells (see Introduction chapter 1.1). In the following 
studies, Sca1-positive cells were employed for the ex vivo and in vivo experiments. Sca1+ 
cells were isolated from the BM cells of C57BL/6 Ly5.1 mice using commercially available 
kits (StemCell Technology) and showed high purity (96% Sca1+ cells after enrichment) 
(Figure 4.4.11). To allow effective retroviral transduction, the isolated BM cells were pre-
stimulated for 48–60 hours in the presence of a cytokine combination consisting of 50 ng/ml 
mSCF, 50 ng/ml mIL-6 and 10 ng/ml mIL-3 (described as cytokines in the following text). 
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Figure 4.4.11: Enrichment of Sca1+ cells from primary BM cells (C57BL/6 Ly5.1). Sca1+ BM cells 
were separated from whole BM as described in chapter 3.7.3. Cells were stained with PE-conjugated anti-
mouse Sca1 antibody and analysed by FACS. A: Isotype control. B: Percentage of Sca1+ cells before 
enrichment (11%). C: Percentage of Sca1+ cells after enrichment (96%). 
 
The prestimulated Sca1+ cells were then transduced with retroviral particles carrying 
Sxgs-F2PrlR or the control construct Sxgs-F2 as described in chapter 3.6.7. One day after 
transduction, the transduction efficiency was determined with anti-7D5 antibody by FACS 
analysis. The results are shown in Figure 4.4.13. A sample of the Sxgs-F2PrlR-transduced 
cells was transplanted into recipient C57BL/6 Ly5.2 mice (see Figure 4.4.18). Remaining 
transduced cells were washed 3 times with PBS and cultured for a further 2 weeks in the 
presence of cytokines (cytokine in Figure 4.4.12) or 10 nM AP20187 + 50 ng/ml mSCF 
(F2PrlR/AP+mSCF and ntd/AP+mSCF in Figure 4.4.12). At the end of the 2-week culture 
period, the characteristics of non-selected and selected Sxgs-F2PrlR-transduced cells were 
determined via FACS analysis and methylcellulose-based CFU assay (see Figures 4.4.12, 
4.4.13, 4.4.14). The expanded cells were used for a second transplantation series of C57BL/6 
Ly5.2 mice (Figure 4.4.18). 
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Figure 4.4.12: Selective proliferation advantage of Sxgs-F2PrlR-transduced Sca1+ primary mBM 
cells stimulated with AP20187. Sca1+ cells were isolated from C57BL/6 Ly5.1 mice, pre-stimulated for 2 
days and transduced with the Sxgs-F2PrlR and Sxgs-F2 retroviral constructs. On day 6 (1 day after 
transduction), the cells were placed under 2 different conditions: with standard cytokine combination 
(dotted lines) or under selection with 10 nM AP + 50 ng/ml mSCF (solid lines), and further cultured for 
13–14 days. Cumulative cell numbers were counted every week by trypan blue. Pink line: Proliferation of 
Sxgs-F2PrlR-transduced cells. Dark and light blue lines: Non-transduced and control Sxgs-F2-transduced 
cells, respectively. The results in B were obtained from 2 experiments. 
 
As illustrated in Figure 4.4.12, the number of Sxgs-F2PrlR-transduced cells increased 
under stimulation with AP20187 to about 50–60-fold above starting cell numbers. An 
enhanced proliferation occurred in the second week of selection. In contrast, non-transduced 
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and Sxgs-F2-transduced cells survived for the 2 weeks stimulation with AP20187 and mSCF; 
however, they showed no overall proliferation. In principle, all cells stimulated with the 
cytokine combination (Il-3, IL-6, mSCF) expanded in the first week, while during the second 
week they stopped proliferating completely.To determine whether a selection of the cells had 
occurred, the percentage of gp91
phox-positive cells in transduced ex vivo cells was analysed by 
FACS. The results from one experiment are given in Figure 4.4.13. 
As demonstrated in Figure 4.4.13, during the 2 weeks of AP29187-induced expansion, 
the percentage of 7D5-positive cells in the Sxgs-F2PrlR-transduced cell population increased 
from 20 to70%, while that of cells cultured in the presence of the cytokine combination 
decreased slightly during same time period. A similar decrease in 7D5-positive cells was 
observed in the control Sxgs-F2-transduced cells in the presence of both cytokines and the 
AP20187 + mSCF selection mix. 
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Figure 4.4.13: 7D5 transgene expression (7D5+ cells) of transduced Sca1+ primary mBM cells 
measured 1 day after transduction and after an additional 2 weeks in the presence of cytokines or 
AP20187 + mSCF. The transduced cells were treated as described in the legend for Figure 4.4.12. One day 
after transduction and after 2 weeks selection, 1 × 10
5 Sxgs-F2PrlR- (top) or Sxgs-F2-transduced cells 
(bottom) for each culture condition were used for FACS analysis. 
 
4.4.9  The Selected Sxgs-F2PrlR-Transduced Cells Maintain Multilineage 
Differentiation Ability 
 
The ability of the selected cells to keep multilineage differentiation is very important 
to reduce the risk of leukaemia. Flow cytometric analysis of the myeloid cell surface marker 
Gr1, the B-cell surface marker B220 and the T-cell surface marker CD3 in combination with 
staining of the transgene expression marker 7D5 was performed and the results are shown in 
Figure 4.4.14.  
As illustrated in Fig. 4 4.14, the non-selected cells stimulated with the cytokine 
combination showed a lower proportion of gp91
phox-positive cells than the selected cells, as in 
Figure 4.4.13. 7D5-positive cells were found in all lineages under stimulation with cytokines 
or with AP20187 + mSCF. This suggests that the AP20187-stimulated cells retained the 
ability to differentiate into multiple cell lineages. However, the percentages of Gr1, B220 and 
CD3 cells in the 7D5-positive cells selected with AP20187 were 2.7, 24.4 and 1.2%. These 
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values are significantly lower than those of the cells stimulated with the cytokine 
combination, which were 35.9, 70.5 and 17.8%, respectively. 
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Figure 4.4.14: Flow cytometric analysis of cell surface lineage markers in non-selected and 
selected Sxgs-F2PrlR-transduced, Sca1+ mBM cells. The transduced cells were cultured for 2 
weeks in the presence of cytokines (A) or selectively expanded for 2 weeks under stimulation with 
AP20187and mSCF (B). The non-selected and selected cells were then separately incubated with 
biotin-conjugated lineage marker antibodies and APC-conjugated streptavidin as the secondary 
reagent. 7D5-PE was co-incubated with each sample to determine transgene expression.  
 
4.4.10 Maintenance of Early Haematopoietic Marker Gene Expression in ex vivo-
Cultured Cells 
 
As outlined above, the Sxgs-F2PrlR-transduced Sca1+ primary BM cells had a 
selective proliferation advantage during 2 weeks stimulation with AP20187 and mSCF. To 
characterise the features of these expanded cells, the expression profiles of early 
haematopoietic markers (Sca1, c-kit) during in vitro culture was analysed by flow cytometry. 
Figure 4.4.15 shows the data from 3 separate experiments. 
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Figure 4.4.15: Analysis of progenitor cell phenotype in transduced Sca1+ primary mBM cells 1 day 
after transduction and 2 weeks after stimulation with AP20187. Three separate experiments (1-3) were 
performed. One day after transduction (day 6 in culture), 1 week (day 13 in experiments 1 and 3, day 14 in 
experiment 2) and 2 weeks (day 20 in experiments 1 and 3, day 21 in experiment 2) after selection, 1 × 10
5 
cells from each culture condition were used for FACS staining with anti-Sca1-PE or with anti-c-kit 
antibody (experiments 2 and 3). 
 
As indicated in Figure 4.4.15, the percentage of Sca1+ cells had dropped from the 
initial over 95% in the freshly isolated and purified BM cells to 28–45% at beginning of 
selection (3 independent experiments). As expected, the number of Sca1+ cells went down to 
10–30% during the following 2 weeks of culture in the presence of the cytokine mix. 
Nevertheless, the Sxgs-F2PrlR-transduced and AP20187-expanded mBM cells showed a 
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significant increase in the proportion of Sca1+ cells, up to 55–65% during the same culture 
period. A similar kinetic was also observed for the c-kit marker in experiments B and C.  
 
4.4.11  CFU Assay of ex vivo Selectively Expanded BM Cells 
 
As mentioned previously in 4.3.2, the method usually utilised to calculate the number 
of progenitor cells in haematopoietic systems in vitro is the methylcellulose-based CFU assay. 
CFU assays were, therefore, performed to calculate the number of haematopoietic progenitors 
in the expansion cultures. On day 6 (1 day after transduction), day 14 (after 1 week 
stimulation) and day 22 (or day 20, after 2 weeks stimulation), an aliquot of the cells was 
plated on methylcellulose semisolid medium and incubated for 10 days. The total colony 
number per 1000 plated cells from 2 independent experiments is shown in Figure 4.4.16. 
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Figure 4.4.16: Increased colony numbers in selected Sxgs-F2PrlR-transduced cells obtained by 
primary CFU assay in methylcellulose The transduced cells were plated in methylcellulose at a 
concentration of 5000 cell/ml methylcellulose on day 6 (1 day after transduction), day 14 (after 1 week 
selection) and day 22 (or day 20, after 2 weeks selection). After 10 days incubation, the total colony 
numbers were counted and calculated as the colony number/1000 plated cells. Grey column: control Sxgs-
F2-transduced or ntd cells. Red column: Sxgs-F2PrlR-transduced cells cultured in the presence of 
cytokines. Red dotted column: Sxgs-F2PrlR-transduced cells stimulated with AP20187. 
 
As demonstrated in Figure 4.4.16, the colony number from Sxgs-F2PrlR-transduced 
cells stimulated with AP20187 + mSCF increased from day 6 to day 22 (experiment A) and 
day 20 (experiment B), whereas those from non-selected and non-transduced cells decreased 
in this period. The total colony number from the cells cultured with AP20187 + mSCF for 2 
weeks was about 3.5-fold (experiment A) and 7-fold (experiment B) higher than that from the 
cells cultured for 2 weeks with the cytokine mix. No increase in colony number was observed 
for control Sxgs-F2-transduced or ntd cells under the same culture conditions. These results 
suggest that AP20187-stimulated, transduced Sca1+ cells contain more progenitor cells than 
the non-selected and ntd cells.  
In summary, as illustrated in Figures 4.4.15 and 4.4.16, the selective expansion of 
Sxgs-F2PrlR-transduced murine Sca1+ cells stimulated with AP20187 was significant, based 
on the proliferation of haematopoietic progenitor cells. 
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4.4.12 Polyclonal Provirus Integration of Genomic DNA in AP20187-Induced Selective 
Expansion of Murine HSCs Transduced with Sxgs-F2PrlR Retroviral Particles 
 
Ligation mediated (LM)-PCR is the technique available to map provirus integration 
sites in the genomic DNA of transduced cells. The polyclonal proliferation of transduced cells 
is an important pre-requisite for the use of retroviral vectors for gene therapy (see 
Introduction, chapter 1). To characterise the clonality and integration sites in the expanded 
transduced cells, the LM-PCR technique was adapted to the vector system used in this study.  
Special primers were designed to amplify a region of the 5’LTR-sequences in the retroviral 
vector. Genomic DNA was prepared from ex vivo-selected and non-selected mBM cells, and 
LM-PCR was performed with 250 ng genomic DNA, as described in chapter 3.4.4. The 
schematic representation of LM-PCR used in this study is shown in Figure 4.4.17.   
 
Ligation mediated PCR
5‘ LTR 3‘ LTR
Provirus
(Sxgs-F2PrlR)
genomic
DNA
genomic
DNA
5‘ LTR 3‘ LTR
one step PCR with biotinylated
primers and Pfu A1-RV-bio A1-RV-bio
5‘ LT
external bands
3‘ LT
internal band
cloning and sequencing of PCR products(Figure 4.4.18)
restriction enzyme
(Tsp 5091:AATT)
5‘ LT Adapter 3‘ LT Adapter
adapter ligation (blunt end)
sequence of 
interest
control
seq.
AP1
AP2
SL-R1
SL-R2
AP1
AP2
SL-R1
SL-R2 LM-PCR
(nested PCR)
INT 1
INT 2
5‘ LTR 3‘ LTR paramagnetic enrichment of 
biot. Fragments with 
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(reduction of internal band)
PCR products (Figure 4.4.18)
 
 
Figure 4.4.17: Schematic representation of LM-PCR: The genomic DNA was digested with four-cutter 
enzyme Tsp5091 and further combined with biotinylated special primer. The biotinylated fragments were 
enriched with strepavidin beads. A special adaptor was added into the sequence of interest and the expected 
bands were amplified with nested PCR. The details of this representation were described in chapter 3.4.3. 
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Genomic DNA from the samples was digested with the restriction enzyme Tsp5091, a 
four-cutter which should generate DNA fragments of an average length of ~300 bp. Digestion 
with the unique cutter HindIII reduced background by cutting the internal 3’LTR band, 
allowing specific amplification of the 5’LTR sequences. Polyclonal proliferation of expanded 
cells and identities of integration sites are shown in Figure 4.4.18 and Table 4.4.2. As shown 
in Figure 4.4.18, multiple bands representing different integration sites of Sxgs-F2PrlR 
provirus were observed by LM-PCR analysis of the AP20187-expanded mBM cells clearly. 
Most of the amplified DNA fragments ranged from 1000 to 100 bp. In contrast, only 4 
background bands were obtained from genomic DNA of wild type mBM cells. Furthermore, 
the genomic DNA from non-selected cells showed only 1 strong signal at ~ 230 bp. The DNA 
fragments from selected cells (Figure 4.4.18 A, lane 5) were transformed into the TOPO 
cloning vector, in order to sequence integration sites. As shown in Figure4.4.17 B, out of 13 
selected colonies, 12 showed a single band signal of variable size after colony PCR. The 
DNA fragments amplified from each single colony were purified and sequenced (Table 
4.4.2). Ten of the 12 sequenced integrations could be found in the mouse genome database 
(see Table 4.4.2). The location of genes within 100 kb and their distance to the integration site 
are listed. Genes containing integration sites are shown in bold type. 
  A
Marker 1              2 3                4             5
100 bp
200 bp
300 bp
400 bp
500 bp
1000 bp
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Marker   1        2        3        4        5        6         7        8        9       10      11       12      13 B 
 
 
Figure 4.4.18: Polyclonality of ex vivo selectively expanded murine HSCs shown by LM-PCR. A: Gel 
electrophoresis of 5’LTR integration site analysis of genomic DNA from wild type mBM cells (lane 1); Sxgs-
F2PrlR-transduced, Sca1-positive mBM cells, cultured ex vivo for 2 weeks in the presence of cytokines (lane 2), 
Sxgs-F2PrlR-transduced, Sca1-positive mBM cells, stimulated for 4 weeks with AP20187 (lane 4), and Sxgs-
F2PrlR-transduced, Sca1-positive mBM cells, stimulated for 2 weeks with AP20187 (lanes 3 and 5) Genomic 
DNA was digested with the restriction enzyme Tsp5091 and amplified with the LTR sequencing primer and the 
adapter primer at the end of the DNA fragments. The PCR products were cut with the restriction enzyme HindIII 
to digest the 3’LTR fragments. The 5’LTR DNA fragments were then amplified by nested PCR. B: Amplified 
PCR products from single picked colonies. The PCR product from lane 5 (A) was cloned into the TOPO cloning 
vector and positive colonies were picked directly for carrying out a colony-PCR with TOPO-primers (M13 rev, 
M13 for). Numbers correspond to the clone numbers in Table 4.4.2.  
 
Table 4.4.2: Insertion site analysis of selected clones from Sxgs-F2PrlR-transduced murine HSCs 
after 2 weeks stimulation with AP20187 
Clone 
number 
Genomic 
length(bp) 
Mouse chr.  Gene  Protein family  Distance & 
location 
1  88  4(qD3)  2610510H1Rik  nd  7.7 kb, 5’ 
     Padi4  Peptidylarginine 
deiminase, type IV 
70 kb, 5’ 
     Padi6  Peptidylarginine 
deiminase, type VI 
89 kb, 5’ 
2 232  15(qA1)  PrlR Prolactin  receptor  intron 
      A1987712  hypothetical protein  68 kb, 5’ 
3 188  non-random  Tmlhe  Trimethyl  hydroxylase 
epsilon 
38 kb,5’ 
4  164  9(qA5.2)  D630044F24Rik  Hypothetical protein LOC 
38273 
5.1 kb, 3’ 
      RP525  Ribosomal protein S25  71 kb, 3’ 
     Trappc4  Trafficking  protein 
particle complex 4 
98 kb, 5’ 
5 365  18(qE3)  no gene within 100 kb    
6,8  49  2(qA3)  Abca2  ATP-binding cassette sub-
family A 
1.1 kb, 5’ 
      Fut7  Fucosyltransferase 7  22 kb, 3’ 
7 148  17(qE4)  no gene within 100 kb    
9 nd  nd  nd  nd  nd 
10,11,12 247  6(qF2)  Grcc2f  Gene rich cluster c2f 
gene 
intron 
      Bcap37  B-cell receptor associated 
protein 37 
11 kb, 5’ 
      Grcc3f  Gene rich cluster c3f gene  5.7 kb, 3’ 
     Hcph  Hemopoietic  cell 
phosphatase 
2.2 kb, 5’ 
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All insertion site sequences detected in the different clones were aligned to the mouse genome using mouse 
genome Blast (http://genome.ucsc.edu). Length denotes the size of the genomic DNA part of the LM-PCR 
amplification without linker and LTR sequence; nd.: not determined; chr, chromosome. 
 
As indicated in Table 4.4.2, from the 12 selected and sequenced colonies, clones 10, 
11 and 12 have the same size and are located all on chromosome 6. Clones 6 and 8 also have 
the same size and are located on chromosome 2. All other clones are located on different 
chromosomes. Only clone 2 and clones 10–12 are located within genes, namely PrlR and 
Grcc2, respectively. The other indicated genes are located within 100 kb up- or downstream 
of the integration site. This result suggests that the ex vivo selectively expanded mBM cells 
transduced with Sxgs-F2PrlR have proliferated polyclonaly and show multiple, different 
integration sites. 
 
4.4.13  Expanded Cells Retain the Capacity to Repopulate the Bone Marrow of Lethally 
Irradiated Mice  
 
As shown earlier, the Sxgs-F2PrlR-transduced cells presented a clear selective 
proliferation after 2 weeks stimulation with AP20187 + mSCF ex vivo. This expansion 
seemed to be primarily due to proliferation of progenitor cells, as judged by standardised 
short-term colony assay and staining of the progenitor cells for Sca1 and c-kit expression. 
However, the identification of true HSCs, which have the ability both to durably repopulate 
myeloid and lymphoid lineages and to self-renew, has to be done using in vivo assays, i.e. 
mouse transplantation experiments (Benveniste et al., 2003; Matsuzaki et al., 2004). In order 
to clarify and extend the in vitro data, cells expanded ex vivo under different culture 
conditions were transplanted into sublethally irradiated C57BL/6 Ly 5.2 mice. As described in 
4.4.4, the Sca1-positive mBM cells from C57BL/6 Ly 5.1 mice were transduced with Sxgs-
F2PrlR retroviral particles. One day after transduction (on day 6 in culture), a first 
transplantation was carried out with transduced and non-transduced cells, as indicated in 
Figure 4.4.19. In addition, transduced cells were cultured under selective and non-selective 
conditions. After 2 weeks of selection, a second transplantation series was carried out with 
selected, non-selected and non-transduced cells (Figure 4.4.19). Eight to 10 weeks after 
transplantation, cells from the bone marrow (BM), peripheral blood (PB) and spleen of 
individual recipient mice were analysed. Figure 4.4.19 and Table 4.4.3 give an overview of 
the experimental outline and the results obtained from the transplantation study in terms of 
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engraftment level (% of CD45.1-positive cells) and transgene expression (percentage of 7D5-
positive cells). 
 
day 6
8,0 Gy
n=3
n=1
Between 30 % and 80 % of
cells positive for CD45.1 in
BM/spleen/ peripheral blood
CD45.2
n=3
all mice dead
day 21 n=3
one mouse alive, but no
CD45.1+ cells
cytokines
n=9
AP + mSCF
All mice transplanted with
transduced and AP-expanded
cells survived and repopulated,
whereas all cells expanded
with cytokines
did not engraft in the mice.
 
 
Figure 4.4.19: Study design of the transplantation with selected and non-selected cells. Day 6: One day 
after transduction, 1 × 10
6 transduced or non-transduced cells were administrated i.v. into preconditioned 
(8.0 Gy-irradiated) recipient mice. Day 21: After 2 weeks ex vivo expansion of transduced cells under 
different conditions, 1 × 10
6 selected or non-selected transduced cells, or non-transduced cells were 
transplanted into recipient mice. 
n: number of individual mice treated per condition. 
  
As shown in Figure 4.4.19, all mice transplanted with transduced cells (day 6) 
survived (8–10 weeks post-transplantation) until analysis. However, all mice transplanted 
with cytokine-stimulated, Sxgs-F2PrlR-transduced cells (day 21) died 12–16 days after 
transplantation. Two mice transplanted with non-transduced cells which had also been 
cultured for 2 weeks in cytokine medium died 14 days after transplantation. Unexpectedly, 1 
mouse in this group survived until analysis. In contrast, all mice transplanted with AP20187-
stimulated, Sxgs-F2PrlR-transduced cells survived until analysis 8–10 weeks post-
transplantation. This result suggests that the population of AP20187-stimulated cells 
contained high frequencies of progenitor cells which could repopulate irradiated recipient 
mice. Two lethally irradiated but non-transplanted mice were included in both transplantation 
experiments as a control for the efficiency of the irradiation dose. All non-transplanted mice 
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died 12–14 days after irradiation. The surviving recipient mice were used for multiple 
analyses 8–10 weeks after transplantation. The results are summarised in Table 4.4.3. 
 
Table 4.4.3: Repopulation efficiency and transgene expression in transplanted mice Cells from 
different tissues (BM, PB and spleen) were analysed by FACS with anti-CD45.1-PE antibody for detection 
of the Ly5.1 mouse cells (donor cells) and anti-7D5-PE antibody for detection of gp91
phox-positive cells. 
PB samples (10-20 µl) were stained after erythrocytes lysis using Pharmingen Lysis buffer (BD 
Pharmingen). For the BM and spleen, 1 × 10
5 cells were used for each staining after preparation of NH4Cl-
lysed cell populations. T1No.1: mouse number 1 from transplantation 1. No1: mouse number 1 from 
transplantation 2.  
 
A: Percentage of CD45.1-positive and 7D5-positive cells in PB, BM and spleen. 
             First transplantation on day 6 
Mouse 
no: 
Vector  Culture condition  PB cells  BM cells  Spleen cells 
     CD45.1  7D5  CD45.1  7D5  CD45.1  7D5 
T1No.1 F2PrlR  cytokines  54.8  3.2  11.1  0  41.1  3.2 
T1No.2 F2PrlR  cytokines  90.6  2.7  78.1  1.8  76.1  2.1 
T1No.3 F2PrlR  cytokines  79.4  3.0  41.5  3  69.5  3.0 
T1No.4 ntd.  cytokines  95.7  -  92.5  -  85.5  - 
 
 
B: Percentage of CD45.1 positive cells and 7D5 positive cells in PB, BM and spleen. 
             Transplantation on day 21 
Mouse 
no: 
Vector  Culture condition  PB cells  BM cells  Spleen cells 
     CD45.1  7D5  CD45.1  7D5  CD45.1  7D5 
No.1 F2PrlR  AP+mSCF  5.2  0  1  0  5.5  0 
No.2 F2PrlR  AP+mSCF  80.5  1.7  51.7  1.3  75.5  1.3 
No.3 F2PrlR  AP+mSCF  60.5  1.1  17.9  1.0  53.2  0.8 
No.4 F2PrlR  AP+mSCF  33.4  1.3  2.1  0  26.5  2.1 
No.5 F2PrlR  AP+mSCF  17.2  0  1.8  0.2  12.7  1.2 
No.6 F2PrlR  AP+mSCF  56.5  5.5  49.1  3.8  58.5  3 
No.7 F2PrlR  AP+mSCF  62.3  3.4  2.8  0.2  13.1  0.8 
No.8 F2PrlR  AP+mSCF  21.5  0  22.5  1.2  50.7  2 
No.9 F2PrlR  AP+mSCF  74.1  1.5  31.5  1.2  79.4  4.4 
No.10 ntd.  cytokines  0  0  0  0  0.7  0 
 
 
As illustrated in Table 4.4.3 A, all the surviving mice from the first transplantation 
had a clear engraftment ranging from 54 to 95.7% in PB cells, 11 to 92.5% in BM cells and 
41 to 85% in spleen. However, the percentage of transgene-expressing cells, that is 7D5-
positive cells, was very low (<4%). Interestingly, mouse that was transplanted with non-
transduced cells had a higher engraftment level in all organs than those transplanted with 
transduced cells. In contrast to these results, the transduced cells that had been cultured for a 
further 2 weeks with the cytokine combination could not repopulate recipient mice (Figure 
4.4.19 and Table 4.4.3 B). Nevertheless, the transduced cells stimulated with AP20187 for 2 
 132   Results 
weeks were able to establish a new haematopoiesis for the irradiated recipient mice. All mice 
in the group transplanted with dimerizer-expanded BM cells had a repopulation efficiency 
ranging from 1–80% in the 3 organs analysed. In addition, engraftment was usually much 
lower in BM cells than in PB and spleen cells. As in the first transplantation, gp91
phox 
transgene expression in this group of transplanted mice was very low (< 5% of the cells). 
 
4.4.14  Transgene Analysis of Genomic DNA from Recipient Mice Post-Transplantation 
 
After 2 weeks stimulation with AP20187, the transduced cells had a large transgene-
expressing population with 70% 7D5-positive cells. After transplantation, however, although 
the repopulation efficiency was over 50% in some organs, the number of 7D5+ cells was 
very low. These observations prompted us to use a more sensitive analysis method i.e. PCR, 
to determine transgene expression in transplant recipient mice. The human gp91
phox sequence 
was amplified from genomic DNA in different tissues and the results are shown in Figure 
4.4.20. 
No. 7
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No. 8
BM     Spl       PB
No. 9
BM     Spl       PB
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BM     Spl       PB
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No. 5
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N0. 6
BM     Spl       PB +- H2O
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mouse ß-actin
human gp91
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Figure 4.4.20: PCR analysis of the human gp91
phox sequence in different organs of transplanted mice. 
Genomic DNA was prepared from BM, PB and spleen cells of transplanted mice (No.4–No.10) 10 weeks 
post transplantation. PCRs were carried out with 100 ng genomic DNA. Human gp91
phox gene-specific 
primers were used to produce a 510 bp amplificate (see Figure 4.4.22). Mouse ß-actin sequences were 
amplified under the same PCR conditions as a control for the amount of DNA loaded. Genomic DNA for 
the positive control was prepared from SF71gp retroviral vector-transduced X-CGD cells containing 80% 
7D5-positive cells. The negative control was genomic DNA from BM cells of a wild type C57BL/6 mouse. 
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As shown in Figure 4.4.20, human gp91
phox sequences were observed in all samples 
(except BM from mouse No.4) from mice (No.4–No.9) that had been transplanted with Sxgs-
F2PrlR-transduced cells previously selected for 2 weeks with AP20187 and mSCF. No signal 
for human gp91
phox could be detected in all analysed organs of mouse No.10. This mouse had 
not received gp91
phox-expressing cells and served as a negative control. These results indicate 
that gp91
phox-containing cells may contribute to the reconstitution of haematopoiesis in 
transplanted mice. 
 
4.4.15 Ex vivo Restimulation of BM Cells from Recipient Mice Post-Transplantation 
 
For unknown reasons, the percentage of 7D5-positive cells in the BM cells of 
transplanted mice was found to be very low. We, therefore, investigated whether these cells 
can be reselected under stimulation with AP20187. To answer this question, BM cells from 
mice No.5–No.9 were cultured ex vivo for 2 weeks either with the cytokine combination or 
under stimulation with AP20187 + mSCF. The results are shown in Figure 4.4.21. 
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Figure 4.4.21: Ex vivo proliferation rate of mBM cells from transplanted mice under cytokine- and 
AP20187-stimulation conditions. BM cells were prepared from transplanted mice No.5–No.9 and 1 × 10
6 
cells from each mouse were cultured for 2 weeks with either the cytokine combination (A) or AP20187 + 
mSCF (B). The cell number was counted each week. The colours of the lines represent samples from 
different mice, as indicated in the figure. 
 
As indicated in Figure 4.4.21, the cytokine-stimulated cells from different mice 
proliferated within 2 weeks. In contrast, the number of cells cultured with AP20187 and 
mSCF strongly decreased during the first week. However, in the second week, the cells from 
mice No.6, No.8 and No.9 began to proliferate, in particular those from mouse No.6. The cells 
from mice No.5 and No.7 continued to decrease in number during the second week of 
stimulation with AP20187. These results suggest that a proportion of the BM cells from mice 
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No.6, No.8 and No.9 reacted upon stimulation with AP20187. Expression of the fusion 
protein F2PrlR most likely contributed to the proliferation of these cells. To verify this 
hypothesis, BM cells stimulated for 2 weeks either with cytokines or with AP20187 from 
mice No. 6, No.8 and No.9 were stained with anti-7D5 antibody for FACS analysis. In 
addition, PCR reactions for human gp91
phox and for the fusion protein F2PrlR were performed 
with genomic DNA. The results are shown in Figures 4.4.22 and 4.4.23. 
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Figure 4.4.22: FACS analysis of ex vivo-selected mBM cells from transplanted mice. 1 × 10
5 cells per 
sample were used for each staining. For double staining, cells were incubated with anti-7D5-APC and anti-
CD45.1-PE antibodies. After staining, cells were analysed in 3-colour mode with a FACS Calibur. The 
mouse number is indicated at the top of the figure. The upper plots show cells cultured with the cytokine 
combination and the lower plots show cells selected with AP20187. The percentage of 7D5/CD45.1 
double-positive cells is shown in each 
 
 As demonstrated in Figure 4.4.22, the cells stimulated with AP20187 + mSCF show 
high levels of 7D5-positive cells (over 70%) in donor cell populations (CD45.1-positive cells) 
from all analysed mice. In contrast, the cells from mice No.6, No.8 and No.9 that were 
stimulated with cytokines showed low levels of 7D5-positive cells (7.7, 4.2 and 19%). In the 
PCR analysis shown in Figure 4.4.23, significantly stronger signals for gp91
phox and F2PrlR 
were observed in AP20187-stimulated cells from mice No.8 and No.9 than in cells cultured 
 135   Results 
with cytokines. However, genomic DNA from the 2 populations of cells from mouse No.6 
gave rise to equal signal intensities for both gp91
phox and F2PrlR. 
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Figure 4.4.23: PCR analysis of gp91
phox and fusion protein F2PrlR sequences in ex vivo-cultured BM 
cells from mice No.6, No.8 and No.9. Genomic DNA was prepared from BM cells from mice No.6, No.8 
and No.9 cultured under different conditions, and 100 ng was used for each PCR reaction. The PCR 
reaction was carried out as described in chapter 3.4.2. The sample from mouse No.10 served as a negative 
control. The sizes and positions of the 2 PCR products are shown as red and blue arrows in the upper part 
of the figure. At the bottom of the figure, the PCR products for gp91
phox (left) and F2PrlR (right) are 
shown. C: Cells cultured with cytokines. A: Cells cultured with AP20187 + mSCF. PCR-reactions for ß-
actin sequences were performed as a control for equal DNA loading. 
 
4.4.16 Determination of Progenitor Cells in ex vivo-Cultured BM Cells from Recipient 
Mice using the CFU Assay 
 
As shown above, mBM cells from 3 transplanted mice could be selected for Sxgs-
F2PrlR-transduced cells for a second time ex vivo. As already shown, ex vivo-expanded cells 
cultured for 2 weeks under stimulation with AP20187 before transplantation contained high 
numbers of progenitor cells compared to cells stimulated with the cytokine combination. 
Therefore, we asked whether BM cells from the transplanted mice would show equally high 
numbers of progenitor cells after 2 weeks of ex vivo culture in selection medium. For this 
purpose, CFU-assays in methylcellulose were performed with ex vivo-cultured cells from 3 
transplanted mice. The results from the second plating are given in Figure 4.4.24. 
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Figure 4.4.24: CFU assay in methylcellulose: Second plating of ex vivo-cultured BM cells from mice 
No.6, No.8 and No.9. After 2 weeks of ex vivo culture of the BM cells under different conditions, 10000 
cells per sample were plated in methylcellulose as described in chapter 3.6.8. The total colony number of 
the first plating was very high. Thus, second plating was carried out with 5000 cells per sample. Ten days 
after plating, the total colony number in each dish was counted. A: Colony number from the second 
methylcellulose plating for all analysed mice. B: Typical morphology of one colony under the microscope. 
 
As observed in the second CFU assay, the total colony number from cells from mice 
No.8 and No.9, selected for 2 weeks with AP20187, was about 2-fold higher than that from 
cells stimulated with the cytokine combination. Despite the significance of the results 
obtained from mice No.8 and No.9, the colony numbers from BM cells from mouse No.6 did 
not show any difference between the 2 culture conditions. To determine whether the 
progenitor cells that generated the colonies, contained the transgene, we picked single 
colonies and performed PCR reactions with gp91
phox-specific primer pairs. As shown in Table 
4.4.5 and Figure 4.4.25 for the 3 mice No.6, No.8 and No.9, 100, 80 and 100% of colonies 
from the cells stimulated with AP20187 were gp91
phox-positive. However, only 60, 30 and 
10% positive colonies were found in cytokine-stimulated cells. The PCR analysis of colonies 
from mouse No.9 is shown in Figure 4.4.24. 
 
Table 4.4.4: Percentage of gp91
phox-positive colonies in picked colonies from mice No.6, No.8 and 
No.9. 
Mouse number  AP + mSCF  Cytokine 
No.6 100%  40% 
No.8 80%  30% 
No.9 100%  10% 
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Figure 4.4.25: PCR analysis of gp91
phox sequences in picked colonies from mouse No. 9. Ten 
colonies from each sample were picked for analysis and the PCR reaction was performed as described 
in chapter 3.4.2. The figure shows the results obtained from mouse No.9 as an example. The PCR 
reaction for mouse ß-actin was carried out with ß-actin
 primer pairs in the same reaction to ensure 
equal DNA levels.  
 
In summary of chapter 4.4, overexpression of Sxgs-F2PrlR retroviral construct led to a 
significant reversible selective expansion of transduced BAF/3 and primary mBM cells. In 
mouse transplantation experiments, ex vivo-expanded cells repopulated the bone marrow of 
lethally irradiated mice suggesting that the ex vivo expansion took place at the level of 
haematopoietic stem and/or progenitor cells. Genomic gp91
phox sequences were detected in 
the bone marrow, spleen and peripheral blood cells of transplanted animals, indicating that 
gp91
phox-containing cells most likely contributed to the reconstitution of haematopoiesis in 
these mice.  
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5. Discussion 
 
One of the main limitations of gene transfer into HSCs for the treatment of inherited 
disorders like X-CGD is the inefficiency of gene transfer into early haematopoietic progenitor 
and stem cells (Kume et al., 2003). Over many years, methods have been developed to 
improve the efficiency of gene transfer and expression in HSCs ex vivo and in vivo. The aim 
of this study was to develop a novel strategy to expand transduced murine HSCs. Strategies 
using different selection molecules, which play important roles in the maintenance of HSC 
self-renewal and proliferation, were investigated. 
The first strategy is based on the intrinsic transcription factor HOXB4, which can 
enhance self-renewal of human and murine HSCs, as observed in numerous in vitro and in 
vivo studies (Antonchuk et al., 2001, 2002; Sauvageau et al., 1995; Thorsteinsdottir et al., 
1999; Björnssen et al., 2002). A bicistronic vector derived from the backbone of the 
gammaretroviral vector SF71, coding for HOXB4 and the therapeutic gene gp91
phox, was 
designed. The second strategy used in the present study is based on an inducible dimerizer 
system consisting of an artificial drug-binding component and a signalling domain from either 
the EGFR or the PrlR. Addition or removal of the small molecular drug AP20187 controls 
activation of both constructs. To compare the efficiency and capability of each selection 
strategy, the following questions were examined throughout:  
  
   Does the appropriate selection system work in HSCs ex vivo? 
   Are ex vivo-selected HSCs able to repopulate lethally irradiated recipient mice? 
   Which of the strategies is most suitable for selective expansion of genetically 
modified murine HSCs? 
 
5.1 HOXB4  induced  ex vivo murine HSC proliferation but did not confer 
a growth advantage in vivo 
 
The first system used in the present study is based on the HOXB4 transcription factor. 
A large number of reports indicate that HOX genes act as key regulators for the balance 
between self-renewal and committed differentiation of haematopoietic stem/progenitor cells. 
In 1994, Sauvageau et al. reported that HOXB4 is expressed at high levels in primitive 
haematopoietic cells and becomes down-regulated in more mature cells. One year later, the 
same group published data showing that HOXB4 overexpression in murine BM cells resulted 
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in increased numbers of CFU-C (in vitro clonogenic progenitors), CFU-S12 (day 12 colony-
forming units in spleen) and long-term repopulating cells in primary and secondary recipients 
(Sauvageau et al., 1995). In competitive repopulation experiments, HOXB4-transduced cells 
outperformed control cells (Antonchuk et al., 2001). Recently, it was reported that transient 
expression of HOXB4 in mouse embryonic stem and yolk sac cells, which give rise to 
haematopoiesis, led to definitive haematopoietic potential and allowed stable and long-term 
haematopoietic engraftment of adult mice (Kyba et al., 2002). In the present study, 
overexpression of HOXB4 and gp91
phox from bicistronic retroviral vectors in primary BM 
cells led to a 3–4-fold increase in cell number compared to mock-transduced cells under the 
same culture conditions. The cell number increased from 2 × 10
5 to 86 × 10
5 within 2 weeks 
after transduction in culture under stimulation with the cytokine combination mIL-3, mIL-6 
and mSCF. Supporting these results, the proportion of transgene-expressing cells (7D5-
positive cells) clearly increased from 16%, one day after transduction, to 70%, 2 weeks later. 
These results are comparable to data from Humphries and colleagues (Antonchuk et al., 
2002). In their study, overexpression of a HOXB4-IRES-eGFP fusion construct led to a 2–3-
fold ex vivo proliferation advantage in 5-FU-treated mBM cells compared to mock (GFP)-
transduced cells. The percentage of GFP-positive cells increased 2.7-fold, from 30 to 80%, 
while that of mock-transduced cells increased only 1.3-fold, from 45 to 60%. In particular, the 
CFU from the HOXB4-transduced cells increased 2–3-fold after 14 days cultivation in both 
studies. However, Antonchuk et al. (2002) reported a significant 41-fold enhancement in CRU 
in vivo, compared to a 29-fold and 58-fold decrease for non-transduced and mock-transduced 
cells, respectively. In our case, after 7 days of ex vivo cultivation, HOXB4-transduced 
haematopoietic stem/progenitor cells did not have any selection advantage in irradiated 
recipient mice 8–10 weeks post-transplantation. Only 1% gp91
phox-positive cells could be 
detected in the PB via FACS analysis. Several circumstances could have contributed to our 
findings: First, the transduction efficiency of HSCs may be too low to achieve a functional 
selective effect in vivo. Only 11% of the transduced cell population were gp91
phox-positive. 
Secondly, the expression level of HOXB4 in the target cells is extremely important for its 
function. Too high an expression, such as in adenovirus-transduced cells, could lead to 
perturbation of the cells, whereas too low an expression might have no effect in vivo. In the 
vector used in this study, expression of the upstream therapeutic gene and downstream 
selective element HOXB4 are controlled by splice donor and acceptor sites. It has been 
reported that the transgenes are expressed at different levels with this vector system. When the 
expression levels of the therapeutic gene are high, the downstream gene for the selection 
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cassette is expressed at a much lower intensity (Hildinger et al., 1999). Similarly, our FACS 
analysis revealed that expression levels of the downstream protein (∆LNGFR) reached only 
40% after ex vivo selection, while therapeutic gene (gp91
phox) expression levels were 70% 
(data not shown). To clarify these observations western blot and genomic DNA PCR analysis 
should be carried out. Milsom and Fairbairn (2004) suggested that for certain selectable 
markers, such as drug-resistance-genes, HOXB4 and perhaps chemically inducible receptors, 
the level of expression required to achieve effective selection is likely to be high. Thirdly, an 
ex vivo cultivation and pre-selection (e.g. to about 20–30%) of the transduced cells may be 
required for a further sufficient selection in vivo. 
In the light of the intriguing report by Schiedlmeier et al. (2003), the use of HOXB4 as 
a selection molecule has to be re-discussed carefully. Schiedlmeier et al. provided data 
showing that high-level expression of HOXB4 in mice impairs myeloerythroid differentiation 
and further reduces the B-cell output of transduced human CD34-positive CB cells 
transplanted into NOD/SCID mice. In contrast, Buske et al. (2002) reported that 
overexpression of HOXB4 in human cells led to an increase in the number of progenitor cells, 
as shown by increased secondary plating capacity of colony-forming cells and an increased 
number of NOD/SCID repopulating cells. No evidence of any disruption in the differentiation 
potential of the engrafting human HSCs was observed, although an increased production of B-
cells was seen in vitro. These contradictory results and the poor expression levels in our 
transplanted mice prompted us to change the selection molecule. Furthermore, the effect of 
HOXB4 may be strongly influenced by the expression level of the protein. Definitive control 
of HOXB4 expression from the bicistronic Sxgs-HOXB4 retroviral vector cannot be 
controlled and we, therefore, focused our attention on approaches allowing an inducible 
action of another selection molecule. 
 
 
5.2  A Fusion Protein Containing the Intracellular Signalling Domain of 
the EGFR Constitutively Induced Proliferation of BaF/3 Cells  
 
As described in the introduction (chapter 1.5.1), constitutively active mutants or 
overexpression of EGF or its receptor play a crucial role in the development of numerous 
human tumours. EGF receptors are often constitutively stimulated in cancer cells in the 
presence of EGF ligands secreted by the cells themselves (Salomon et al., 1995). However, 
less evidence is available that overexpression of EGFR alone has oncogenic potential in 
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haematopoietic cells. In the present study, overexpression of the lentiviral dimerization 
construct S-NF2EGFR led to a huge proliferation advantage in transduced BaF/3 cells after 
stimulation by the dimerizer molecule AP20187. The cell number increased about 5 × 10
5-
fold, from 2 × 10
5 to 1 × 10
11, after 18 days of stimulation. This was the highest rate observed 
with any of the constructs used in this study. In the same experiment, the percentage of 7D5-
positive cells significantly increased from 20 to 99% after AP20187 stimulation. In opposition 
to the excellent selection capacity, the proliferation promoting effect could not be switched 
off after removal of AP20187 and it facilitated an uncontrolled proliferation of transduced 
BaF/3 cells for more than 12 days. Hence, cell proliferation induced by activation of the 
EGFR construct by AP20187 may be potentially oncogenic. The reasons for this are still not 
clear, although the following suppositions may have contributed. It has been reported that 
EGFR deletion mutants, which lack the extracellular domain, resemble the v-erb-B 
oncoprotein and have been detected in xenograft models derived from malignant human 
gliomas (Sugawa et al., 1990; Moscatello et al., 1995), breast carcinomas (Wilkstrand et al., 
1995), non-small-cell lung carcinomas (Garcia de Pallazzo et al., 1993) and ovarian tumours 
(Moscatello et al., 1995). These deletions represent receptor mutants that maintain 
constitutive active kinase function, thereby stimulating cellular proliferation in the absence of 
any ligands (Ekstrand et al., 1994). In our fusion construct, the extracellular domain sequence 
of the EGFR is completely replaced by a truncated LNGFR sequence. After AP20187-
induced dimerization, this structural alteration may lead to constitutive autophosphorylation 
of tyrosine residues in the intracellular kinase signalling domain, causing a further 
uncontrollable cell proliferation of transduced cells. Analysing the phosphorylation status of 
the EGFR after removal of AP20187 by western blotting experiments could prove this 
hypothesis. Furthermore, it is conceivable that the large number of EGFR proteins produced 
by overexpression leads to assembly and dimerization without the dimerizer AP20187, at least 
to some extent, which may be sufficient to propel cell proliferation. One could verify this 
mechanistic assumption by appropriate co-immunoprecipitation experiments in the presence 
and absence of AP20187. As a result of the observed oncogenic potential, I did not continue 
with the EGFR signalling domain construct. 
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5.3  Dimerizer-Induced PrlR Signalling Promotes Expansion of Murine 
HSCs  
 
In contrast to overexpression of the lentiviral vector S-NF2EGFR, overexpression of 
S-NF2PrlR, containing the intracellular domain of the PrlR as the selection cassette, led to 
inducible, and most importantly, reversible selective expansion of transduced BaF/3 cells. 
This result prompted us to investigate this system further using the backbone of a 
gammaretroviral vector that is currently utilised in clinical trials due to its safety and efficient 
transduction.  
 
The truncated LNGFR sequence is not an appropriate marker gene when fused to the 
2×FKBP dimerizer system 
 
As mentioned earlier, the bicistronic retroviral vectors used in this study contain splice 
donor and acceptor elements to control the co-expression of the therapeutic gene gp91
phox and 
a selection cassette. At first, vectors were designed with a truncated LNGFR (∆LNGFR) as a 
marker gene to be co-expressed with the selection cassette in order to allow detection of 
transduced cells by FACS analysis. Surprisingly, expression of the Sxgs-NF2 construct, 
which lacks any proliferation-conferring signalling domain, in primary BM cells led to 
significant expansion of transduced cells under stimulation with AP20187+mSCF. Under this 
treatment, cell numbers increased from 2 × 10
5 to 37 × 10
5 and the percentage of transgene-
expressing cells (7D5-positive) rose from 25 to 56%. The total Sxgs-F2PrlR-transduced cell 
number increased about 150-fold under selective conditions, from 2 × 10
5 to 296 × 10
5. 
Simultaneously, the percentage of 7D5-positive cells rose from 14 to 92%. Although the 
selective expansion of mock-transduced BM cells was not as strong as that of Sxgs-NF2PrlR-
transduced cells, the mock construct-driven proliferation was obviously too high. In addition, 
methylcellulose-based CFU assays indicated increased progenitor numbers in Sxgs-NF2-
transduced mBM cells after 2 weeks ex vivo stimulation with AP20187+mSCF. The colony 
number rose from 16 to 104 per 1000 plated cells. These numbers were even higher than those 
of Sxgs-NF2PrlR-transduced mBM cells. Here the colony numbers increased from 19 to 82 
per 1000 plated cells. Three independent experiments showed similar results. For unknown 
reasons, the ∆LNGFR element seems to contribute to the proliferation advantage of 
transduced mBM cells under stimulation with AP20187 and mSCF. Interestingly, this effect 
was never observed in Sxgs-NF2 transuced BaF/3 cells. ∆LNGFR was derived from the p75 
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neurotrophin receptor (p75NTR), which lacks the intracellular domain and juxtamembrane 
region of the LNGFR (Mavilio et al., 1994). The ∆LNGFR per se is broadly used as a marker 
gene for various gene therapy studies in haematopoietic cells (Junker et al., 2003; Sadat et al., 
2003) and other tissues (Ohkubo et al., 2001). To date, there is no evidence from those studies 
that overexpression of ∆LNGFR plays any role in proliferation. However data obtained in our 
laboratory from dimerizer constructs containing different deletions of the human 
thrombopoietin receptor (hmpl) showed similar auto-selective proliferation effects in 
transduced primary BM cells in serum-containing medium over about 99 days (Stefan Stein, 
personal communication). This may be due dimerization of ∆LNGFR/FKBP12 monomers 
induced by one of the numerous serum factors utilised for primary BM cell cultivation. It has 
also been reported that in cells expressing tyrosine kinase receptors for different neurotrophin 
ligands (NTs), association of p75NTR creates a heterodimeric receptor complex with 
increased ligand affinity that is not dependent on the presence of the cytoplasmic residues 
(Lee et al., 2001). More recently in one report, it was shown that retroviral overexpression of 
modified LNGFR may increase the risk of leukaemia development in mice (Li et al., 2002). 
However, no solid evidence for an increased incidence of leukaemia was observed in a large 
population of animals, or in patients transplanted with ∆LNGFR-modified cells (Bonini et al., 
2003). Apparently, the leukaemia observed by Li et al. may have been in part due to retroviral 
insertional up-regulation of the Evi-1 gene in haematopoietic cells, which has been implicated 
in the pathogenesis of human myelodysplastic syndrome and acute myeloid leukaemia (Baum 
et al., 2003). To minimise factors influencing our positive selection effect, derived from 
activation of the PrlR fusion construct, a new construct lacking the ∆LNGFR sequence was 
cloned and investigated. This was possible because 7D5 antibody was established to monitor 
gp91
phox expression, thus allowing the expression of the therapeutic gene also to be used as 
marker gene. 
 
Inducible and reversible selective proliferation effect achieved with the F2PrlR fusion 
protein  
 
The inducible dimerizer system used in the present study is based on the 
immunophilin FKBP12 and the CID AP20187. Certain properties of this system make it 
suitable for selective expansion of genetically modified haematopoietic cells. First, FKBP12 
is a small gene (180 bp cDNA), easily packaged into a retroviral vector together with the 
fusion signal domain and the therapeutic gene. Second, FKBP12 contains a cavity, engineered 
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by introducing a single phenylalanine-to-valine substitution at amino acid position 36 (F36V), 
thereby providing lock-and-key specificity for AP20187. Third, chemical modification of the 
CID AP20187 allows it to bind specifically to the adapted FKBP12. Together these 
modifications circumvent toxicity that might arise from binding to endogenous FKBP12. In 
addition, a fusion protein with 2 modified FKBP domains can enhance the binding activity of 
AP20187, thereby increasing the selective expansion effect of this system (Ariad 
www.ariad.com). For these reasons, the system was very attractive for the inducible selection 
system I was interested in. 
Deletion of the extracellular ∆LNGFR sequence in the novel Sxgs-F2PrlR construct 
led to loss of the membrane anchor amino acids. The assumption that the fusion protein would 
be located in the cytoplasm was verified by intracellular staining with specific antibody 
against FKBP. Results of confocal laser scanning studies indicate that the fusion protein 
F2PrlR located mainly in the cytoplasm. A. Blau and colleagues developed similar constructs 
with a mono- or oligo-FKBP12 fused to the intracellular domain of mpl (Jin et al., 1998, 
2000; Richard et al., 2003). This group showed that membrane localization is not required for 
the Mpl fusion protein (Otto et al., 2001). Our results demonstrate that the F2PrlR fusion 
protein localises mainly in the cytoplasm, in contrast to the wild type PrlR anchored in the 
plasma membrane. 
Examination of this truncated PrlR dimerizer system was performed in transduced 
BaF/3 cells, the growth of which is dependent on mIL-3 stimulation. The data show that PrlR-
construct-transduced BaF/3 cells proliferated very strongly in the presence of AP20187 
without mIL-3. The cumulative cell number increased about 100–4000-fold during 2 weeks 
AP20187 stimulation. In contrast, mock-transduced BaF/3 cells died within 4–6 days. Also, 
the number of gp91
phox-positive, Sxgs-F2PrlR-transduced cells, measured by FACS analysis, 
increased about 2.5–14-fold under AP20187 treatment, whereas the percentage of gp91
phox-
positive, mock-transduced cells decreased under the same conditions. Similar results have 
also been achieved with dimerizer systems containing signal domains derived from hmpl, G-
CSFR and Flt-3 (Jin et al., 1998; Zeng et al., 2001). Importantly, the proliferation potential of 
expanded BaF/3 cells in the present study could be switched off after removal of AP20187. 
This is a necessary condition for the utilisation of the CID-mediated dimerizer system. The 
fusion protein should not undergo constitutive dimerization and must be strictly dependent on 
the presence of CID for spatial convenience and therefore activation (Neff and Blau, 2001). 
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The ex vivo-expanded murine HSCs maintained stem/progenitor cell characteristics with 
polyclonal proliferation potential 
 
The CID-mediated expansion of primary haematopoietic cells has been well 
investigated using the mpl construct. Jin et al. (1998) reported that total mBM cells 
transduced with a vector encoding an FKBP12-mpl fusion construct failed to grow in the 
absence of dimerizer or growth factors, and died within –14 days. In contrast, the CID 
(FK1012) dramatically stimulated cell proliferation for up to nearly a year in culture. An 
initial brief phase of multilineage differentiation was followed by a longer phase of 
preferential megakaryocytic differentiation ex vivo. Instead of total BM cells, Sca1-positive 
mBM cells were employed in the present study for all ex vivo and in vivo experiments, 
because of the well established preparation method and high enrichment of murine early 
stem/progenitors. Our data showed that, after transduction and subsequent selection for 2 
weeks, Sxgs-F2PrlR-transduced cells cultured in the presence of AP20187 and mSCF 
expanded 50–60-fold, and showed 5–10-fold higher numbers than cells cultured with the 
cytokine combination. Additionally, 70% of the AP20187+mSCF-stimulated cells expressed 
the transgene, compared with only 12.5% of cytokine-stimulated cell populations. 
Furthermore, stem/progenitor capacities of the Sxgs-F2PrlR-transduced, AP20187+mSCF-
stimulated cells were analysed ex vivo by FACS using the stem cells markers Sca1 and c-kit. 
AP20187+mSCF-stimulated cells maintained high numbers of Sca1-positive cells (about 60–
78%), whereas the numbers in cytokine-treated, Sxgs-F2PrlR- or mock-transduced cell 
populations decreased (<10%) after 2 weeks culture. The same results were observed using c-
kit. Similar data were not provided in the study of Jin et al. described above. Further 
methylcellulose-based CFU assays showed significantly increased colony numbers from 
genetically modified cells after 2 weeks ex vivo CID stimulation, both in the study of Jin et al. 
and in the present approach. Thus, our data clearly demonstrate that Sxgs-F2PrlR-transduced 
cells maintained stem/progenitor cell capabilities after 2 weeks ex vivo selection with 
AP20187+mSCF. In addition, multilineage differentiation of AP20187+mSCF-stimulated 
cells was verified by FACS analysis of the lineage markers Gr-1 for myeloid cells, B220 for 
B-cells and CD3 for T-cells. The percentage of Gr-1
+, B220
+ and CD3
+ cells in gp91
phox-
positive cell populations were 2.7, 24 and 1.2%, respectively. The percentages in cells 
cultivated with cytokines were significantly higher, 30, 70 and 17.8%, respectively. These 
results provided further evidence for a high proportion of lineage-negative stem and/or 
progenitor cells in AP20187+mSCF-stimulated BM cells. In this aspect, multilineage 
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differentiation in AP20187-stimulated cells is comparable to data from Jin et al. (2001). In 
their study, the CID stimulated the expansion of multiple cell lineages, including granulocytes 
and macrophages, during the first 2 weeks of culture. After 6 weeks of selection, the 
megakaryocytes emerged as the dominant phenotype. Long-term ex vivo culture of 
AP20187+mSCF stimulation was not investigated in the present study. The cells cultured ex 
vivo for 2 weeks were transplanted into mice.  
Elevated expression levels of Prl and its receptor have been observed in 
lymphohaematopoietic cells, granulocytes, macrophages and stroma cells, which support 
haematopoiesis (Welniak et al., 2001). Clevenger et al. (1998) reported that the PrlR plays an 
important role in the immune system by stimulating both cell proliferation and survival. This 
was verified by determining the activity of PrlR-induced signal transduction pathways. 
Among them, STAT5, Src family kinase and c-myc were found to be activated in T-, B-, 
mono- and polymorphonuclear cells (Dominguez-Caceres et al., 2004; Dogusan et al., 2001, 
2003). However, no clear evidence was found that the PrlR plays a direct role in stem cell 
proliferation and maintenance. The present study demonstrates for the first time that 
activation of a PrlR construct is able to stimulate murine haematopoietic stem and/or 
progenitor cell proliferation ex vivo. A similar effect was observed for the mpl dimerizer 
system (Jin et al., 1998; Richard et al., 2003) and the steroid-based selective proliferation 
system (Kume et al., 2003). 
For the matter of safety, polyclonality is an important condition for the administration 
of selected HSCs to patients. LM-PCR represents a well-established method to determine the 
position of provirus integration after gene delivery. In the present study, integration-site 
analysis by LM-PCR indicated that the AP20187 response was followed by proliferation and 
selection of various provirus-containing transduced mBM cell clones. Subsequently, through 
the analysis of the DNA fragments using Mouse Genome BLAST, the integration positions of 
the 13 colonies investigated were determined. Proviral sequences of the retroviral vector were 
found to be integrated into 8 different chromosomes at diverse positions in various genes. 
This clearly ruled out a monoclonal, eventually oncogenic, expansion of PrlR-construct-
transduced cells. Recently, Du et al. (2005) reported that defective oncogenic retroviruses 
induce leukaemia in part through insertional mutagenesis of cooperating cancer genes. A few 
genes, relevant to the development of mouse leukaemia, have been identified (Du et al., 
2005). None of the eight genes identified in the present study have been found to play a role 
in leukaemia development compared with the identified genes in Du’s study. To answer the 
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question of whether integration of the retroviral vectors activated genes with oncogenic 
potential, a higher number of samples should be examined.   
 
AP20187 induced selective expansion of haematopoietic cells by activation of the truncated 
PrlR construct and subsequently STAT5 phosphorylation 
 
Normally, growth factor receptor-induced cell signal transduction depends on 
membrane anchored receptor proteins. Ligand binding to the extracellular domain of the 
receptor activates intracellular signal cascades. Prolactin activates three important pathways 
termed the JAK/STAT, the Ras/Raf/MAPK and the Fyn/Sos/Vav pathways (Clevenger et al., 
1998). The present study demonstrated that the PrlR construct is mainly localised to the 
cytoplasm. In order to test whether AP20187-induced activation of the cytoplasmic PrlR 
construct leads to activation of the same signal transduction pathways as wild type membrane 
anchored PrlR, I investigated the JAK/STAT pathway, particularly the activation status of 
STAT5. This was because the JAK/STAT pathway, especially STAT5, has fundamental roles 
in apoptosis, differentiation and proliferation of haematopoietic cells. The results showed that 
enhanced phosphorylation of STAT5 can be detected in the cell lysates of PrlR-construct 
transduced BaF/3 cells under AP20187 stimulation. In addition, enhanced binding activity of 
STAT5 to the promoter of its target gene ß-casein could be clearly verified by EMSA assay in 
AP20187-stimulated cell populations. Most likely, AP20187-induced PrlR-construct-
signalling activates the same signal transduction pathways as the natural ligand Prl in 
haematopoietic cells. However, a weak signal for STAT5 phosphorylation and STAT5-DNA 
binding activity were obtained from starved transduced cells without AP20187 stimulation. It 
is possible that the effect of AP20187 could not be completely turned off due to the short 
starving period of 28 hours after a long stimulation period of 2 weeks. For various reasons, 
such as the half-life of AP20187, ending PrlR-construct activity takes some time, but the cells 
finally stopped proliferating about 2 weeks after removal of AP20187. Over the past few 
years, the STAT5 transcription factor has been recognised as a key transcription factor for 
proliferation and survival of haematopoietic cells. Most recently, Kato et al. (2005) reported 
that activated forms of STAT5 led to a dramatic expansion of multipotential progenitors and 
promoted HSC self-renewal ex vivo; however, they induced a foetal myeloproliferative 
disease in vivo. Proleukaemia effects of activated STAT5 have also been reported by other 
groups (Mulloy et al., 2005; Morrigl et al., 2005). In our system, the advantageous effect of 
STAT5 activation in expanding HSCs can be switched on by AP20187 treatment, while long-
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term, leukaemia-promoting effects can avoid by removing AP20187, resulting in inactivation 
of PrlR-construct-driven STAT5 activity. The other signal transduction pathways were not 
investigated in the present study. It will be helpful to assess the phosphorylation status of 
MAPK, MAPKK and other transcription factors (such as c-myc, SOS and Ras/Raf), which 
may also influence PrlR-construct-induced cell activation. Activation of the PrlR construct 
may exert its effect through activation of STAT5. Experiments in STAT5-deficient murine 
HSCs could clarify a key role of STAT5 in PrlR-construct-induced proliferation.  
 
PrlR-construct-expanded HSCs can repopulate myeloablated recipient mice  
 
Sxgs-F2PrlR-transduced mBM cells maintained stem and/or progenitor cell 
characteristics during 2 weeks stimulation with AP20187+mSCF ex vivo. To answer the 
question of whether these expanded cells are still able to contribute to repopulation of lethally 
irradiated recipient mice, AP20187-selected and unselected cells were injected directly into 
such mice. The donor and recipient strains are phenotypically distinguishable on the basis of 
allelic differences at the Ly5 locus. Donor mice are Ly5.1 homozygous, whereas recipient 
mice are Ly5.2 homozygous. All the recipients that were transplanted with cells one day after 
transduction (i.e. 6 days in culture) survived until analysis. In contrast, all recipient mice that 
were injected with cells cultured for a further 2 weeks with cytokines died 12–14 days post-
transplantation. On the other hand, all mice transplanted with mBM cells stimulated for 2 
weeks with AP20187 survived until analysis. Clearly, there were enough progenitor cells in 
selected cell populations for rescue of myeloablated mice, whereas non-selected cells lost 
their stem/progenitor cell ability after 2 weeks cultivation with cytokines. The repopulation 
efficiency (Ly5.1-positive cells) of 9 analysed transplanted mice ranged between 5.2 and 
80.5% in PB cells, 1 and 51.5% in BM cells, and 5.5 and 79.4% in spleen cells. Nevertheless, 
transgene-expressing cells were detected at very low level (<5%) in all organs. These results 
were quite unexpected, since 30% of the AP20187-stimulated mBM cells were 7D5 - and 
Sca1-double positive before transplantation. Therefore, theoretically at 50% engraftment there 
should be 15% 7D5-positive cells in the peripheral blood of recipient mice. The reasons for 
these results are not clear. One explanation could be that the number of early stem cells in 
AP20187-selected cells was much lower than 30%. FACS analysis of transgene expression 
from the inducible hmpl-dimerizer system showed over 15% GFP
+ cells in mice 3 months 
post-transplantation (Jin et al. 1998, 2001; Richard et al 2003). However, in this system, the 
cell growth switch was induced by a fusion protein containing the marker gene GFP. In the 
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present study, the marker gene and selection cassette were expressed from a bicistronic 
vector, with unequal expression levels. Constructing a gp91
phox fusion protein including a 
selection cassette did not solve this problem. The gp91
phox selection marker fusion protein was 
not expressed properly. In contrast to our approach, in the study of Jin et al., AP20187 
treatment was performed in vivo. Another possibility could be due to limitations of the 
analysis method. Human gp91
phox expression in our recipient mice was measured with the 
specific 7D5 antibody. This antibody allows good detection of human gp91
phox by FACS 
analysis in a few murine cell lines, such as the mouse fibroblast cell line SC1, but not in 
others, such as NIH3T3 cells. The reasons for this difference are not clear. gp91
phox 
expression can also be determined in transduced primary BM cells ex vivo. The sensitivity of 
this method for samples collected from PB, BM and spleen is not known. Practically, 
handling of the samples e.g. lysing the red cells with NH4Cl, may also have an influence on 
the sensitivity of the 7D5 antibody. Determination of gp91
phox protein expression in cell 
lysates from different organs by western blotting with anti-gp91
phox antibody could be useful. 
Another reason for low numbers of gp91
phox-expressing cells may be gene silencing in vivo. 
Gene silencing is a limitation for retroviral vectors, arising as a consequence of random 
integration into the genome. Transgene expression is influenced by chromosomal sequences 
adjacent to the integration site and is inversely correlated with CpG methylation. Vector 
integration into heterochromatin may induce inhibition of transcription (position-dependent 
silencing) or may result in varying expression in progeny cells (position-effect variegation) 
(Karpen, 1994). It is commonly agreed that gene silencing tends to occur in undifferentiated 
cells like HSCs that go through a long differentiation process (Baum et al., 2003). In order to 
clarify whether the gene-modified HSCs contributed to the repopulation of recipients, PCR 
analysis with primers pairs specific for gp91
phox was carried out with genomic DNA from 
BM, spleen and PB cells. The results showed a strong gp91
phox signal in all analysed tissues, 
with one exception in BM cells from mouse No.4. Therefore, gene-modified HSCs did 
contribute to the repopulation of irradiated recipient mice. Furthermore, BM cells from 3 
recipient mice could be re-stimulated with AP20187+mSCF ex vivo. In two analysed mice, 
stimulated cells showed stronger signals with gp91
phox or F2PrlR fusion protein primers than 
the non-stimulated cells in PCR analysis, and also higher colony numbers in the CFU assay. 
In contrast, samples from stimulated and non-stimulated cells from one mouse showed equal 
signals in PCR analysis and the same colony numbers in the CFU assay. Gene silencing may 
possibly have occurred in this mouse. It would be very interesting to determine whether this 
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increase in gp91
phox expressing cells is due to a reselection of few gp91
phox expressing cells or 
to a possible inactivation of the silencing process by the restimulation with the dimerizer. 
Transplantation of ex vivo-stimulated mBM cells into recipient mice demonstrated that 
the selectively expanded BM cells contained sufficient stem/progenitor cells to repopulate 
irradiated recipients. However, no clear increase in early HSC numbers after AP20187 
stimulation was seen. Most importantly, the number of early HSCs should be estimated with 
CRU assays. As described in the introduction, the CRU assay is considered to be the best 
available method for analysing early murine HSCs. To compare HSC numbers in Sxgs-
F2PrlR-transduced cells before and after selection, CRU assays should be carried out one day 
after transduction and 2 weeks after selection with AP20187+mSCF. We expect an increased 
number of CRUs in AP20187-stimulated cells. The CFU-S assay could then be used to 
determine the number of myeloid progenitor cells. 
 
5.4 Perspectives   
 
In the development of gene transfer approaches targeting HSCs, methods allowing 
selective expansion of genetically modified cells could improve their performance in clinical 
trials. As seen in this and various other studies, the HOXB4 transcription factor acts as an 
important positive regulator of HSC self-renewal. However, high-level of HOXB4 
overexpression may have a negative effect on the output of mature blood cells by preventing 
or perturbing differentiation. Recently, new findings suggest that HOXB4 per se, when 
delivered directly as an oligopeptide, has the ability to expand murine and human HSCs, and 
to retain their in vivo potential for differentiation and long-term repopulation (Krosl et al., 
2003; Amsellem et al., 2003). These findings boost the potential clinical application of 
HOXB4 oligopeptides for expansion of HSCs. gp91
phox-transduced cells could be isolated by 
FACS cell sorting and stem cells could then be expanded ex vivo by treatment with HOXB4 
oligopeptides before re-infusion into X-CGD patients. This strategy would allow removal of 
the HOXB4 selection molecule from the retroviral transduction vector, thus limiting toxicity 
issues and perturbation of differentiation.  
Recently, the Poly comb group (PcG) gene Bmi-1 has been implicated in the 
maintenance of haematopoietic and leukemic stem cells (Ohta et al., 2002; Park et al., 2003, 
Iwama et al., 2004). A progressive postnatal decrease in the number of early HSCs has been 
observed in Bmi-1 knockout mice (Park et al., 2003, Iwama et al., 2004). Retroviral 
overexpression of Bmi-1 in murine HSCs clearly mediated cell proliferation, which was 
largely restricted to the primitive haematopoietic cells. A net 56- to 80-fold CFU-GMEM 
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expansion and 15- to 35-fold higher repopulation activity were obtained in the Bmi-1 
transduced cultures (Iwana et al., 2004). Therefore, Bmi-1 could be used as a novel molecular 
target for the selective expansion of gp91
phox gene transduced HSCs. 
 
In the presented experiments, the signalling domain of the PrlR was employed for the 
first time as a cell growth switch contributing to the selective expansion of genetically 
modified HSCs. The findings in this study demonstrate the feasibility of conditionally 
enlarging the gp91
phox gene-modified progenitor cell population ex vivo, and, as such, provide 
a new strategy for gene and cell therapy of stem cells. This approach may circumvent some of 
the major difficulties of stem cell gene therapy, among which is the extremely low efficiency 
of gene transfer into low cycling early stem cells. Whether the ex vivo selection induced by 
the signalling domain from the PrlR led to high numbers of early stem cells remains to be 
determined. AP20187 administration for in vivo selection appears to be the next step for 
investigation. In vivo administration of AP20187 has been established using selection vectors 
based on the hmpl cell-growth switch, for both mice and large animals (Jin et al., 2000; 
Richard et al., 2002), and a JAK2 cell-growth switch in mice (Zhao et al., 2004). The hmpl 
construct demonstrated a clear selective proliferation advantage in dimerizer construct-
transduced cells throughout a 7-day course of AP20187 treatment (Jin et al., 2000), albeit an 
apparent preference for differentiation along the megakaryocytic lineage was observed. Since 
gene therapy of x-CGD patients would require a proliferation advantage in the macrophage 
lineage, a therapeutic approach using the selective cassette with the hmpl construct is not 
suitable. The biological responses to AP20187 treatment in vivo could be kept within a 
desired range by titrating the dose. Trangene-expressing cells in different organs could be 
easily detected by FACS analysis. Further experiments should investigate the possibility of in 
vivo positive selection of gene-modified stem cells to the desired range. AP20187 lacks 
apparent toxicity and, therefore, could potentially be used repeatedly over time. In vivo 
administration could avoid some of the unexpected effects of ex vivo culturing, such as culture 
conditions, quality of the cytokines and microorganism contamination. 
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6. Summary   
 
 
Selective Expansion of Gp91
phox Gene-Modified Murine Haematopoietic 
Stem Cells 
 
Haematopoietic stem cells (HSCs) are regarded as the prime target for gene therapy of 
inherited and acquired disorders of the blood system, e.g. X-linked chronic granulomatous 
disease (X-CGD). The major reason for this is that HSCs posses the ability to self renew as 
well as the potential to differentiate into all lineage-specific cell types. However, the need to 
reach and to maintain sufficient therapeutic levels of genetically modified stem cells and their 
progeny after gene delivery still presents major challenges for current HSC gene therapy 
approaches. In particular, one of the main limitations for most genetic defects is the lack of a 
selective growth advantage of gene-modified cells after engraftment. In vitro and in vivo 
methods have been developed that focus on either positive or negative selection of HSCs. An 
artificial selection advantage can be conferred to transduced HSCs by incorporating a 
selection marker in addition to the therapeutic transgene. In the present study, two novel 
strategies for positive selection of murine gp91
phox gene-modified haematopoietic stem cells 
were developed and tested, bearing in mind that with selective growth advantage, the 
possibility of uncontrolled proliferation arises.  
The first strategy to be investigated was based on the homeobox transcription factor 
HOXB4, which plays an important role in the control of haematopoietic stem cell 
proliferation and differentiation. Overexpression of a retroviral bicistronic construct 
containing the therapeutic gene gp91
phox and HOXB4 in murine primary bone marrow cells 
led to a significant 3–4-fold expansion of transduced cells ex vivo. The numbers of transgene-
expressing cells increased 2–3-fold after 2 weeks cultivation under cytokine stimulation. 
Furthermore, the clonogenic progenitor cell assay (CFU assay) demonstrated that the number 
of colony-forming cells had increased to levels 2-fold higher than those of mock-transduced 
cells after 1 week of culture, thereby augmenting the presence of a significant number of 
stem/progenitor cells in the selected cell population. However, in our experiments, HOXB4-
overexpressing murine HSCs did not show any repopulating advantage in transplanted 
recipient mice over control construct-transduced HSCs. These results indicate that selective 
expansion of gp91
phox gene-modified HSCs can be induced by the HOXB4 transcription 
factor ex vivo but not in vivo. This is possibly dependent on HOXB4 expression levels, which 
are too low in vivo to achieve selection. 
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The second strategy made use of a chemically inducible dimerizer system consisting 
of the therapeutic gene gp91
phox and a fusion protein, containing sequences from a growth 
factor receptor signalling domain (epidermal growth factor receptor, EGFR, or prolactin 
receptor, PrlR) and the drug binding protein FKBP12, as the selection cassette. This strategy 
aimed to allow inducible selection that could be easily switched off. The activity of these 
fusion proteins is controlled through the small molecular dimerizer AP20187. Transduction of 
BaF/3 cells with lentiviral vectors expressing the EGFR construct induced proliferation and 
led to complete selection within 18 days (99%). However, removing AP20187 could not turn 
off proliferation. This construct is, therefore, not suitable as a selection cassette for the 
expansion of gene-modified HSCs due to its oncogenic potential. Transduction of the 
construct containing the intracellular domain of PrlR caused significant selective expansion of 
AP20187-treated BaF/3 cells. Following expression in cells, the fusion protein, which lacks 
membrane-anchoring sequences, mainly localized to the cytoplasm. Evidence was found to 
indicate that activated STAT5 might be responsible for this effect. Upon expression of the 
prolactin construct, phosphorylation of STAT5 and its DNA-binding activity to a ß-casein 
promoter sequence was strongly increased. Importantly, the induced proliferation was 
reversible after removal of AP20187. Transduced Sca1
+ bone marrow cells obtained from 
C57BL/6-CD45.1 mice could be expanded about 20–100-fold ex vivo in the presence of 
AP20187 and mSCF without losing progenitor cell features and the capability to contribute to 
all lineages of the haematopoietic system. To exclude oncogenic outgrowth of one single 
clone, the polyclonality of selected cells was proven by ligation-mediated PCR (LM-PCR) 
analysis. In mouse transplantation experiments, ex vivo-expanded cells repopulated the bone 
marrow of lethally irradiated mice suggesting that the ex vivo expansion took place at the 
level of haematopoietic stem and/or progenitor cells. Genomic gp91
phox sequences were 
detected in the bone marrow, spleen and peripheral blood cells of transplanted animals, 
indicating that gp91
phox-containing cells most likely contributed to the reconstitution of 
haematopoiesis in these mice.  
 
 154   Zusammenfassung 
 
7.  Selektive Expansion von gp91
phox Gen-modifizierten murinen 
hämatopoetischen Stammzellen 
 
Stammzellen stellen die entscheidenden Zielzellen bei Gentherapie-Strategien zur 
Behandlung von erworbenen und angeborenen Krankheiten des Blutsystems, wie zum 
Beispiel der X-chromosomal vererbten chronischen Granulomatose, dar. Diese Stammzellen 
können später in alle verschiedenen Blutzellreihen differenzieren und gleichzeitig den 
Stammzellpool erhalten (Selbsterneuerung). Allerdings bereitet es immer noch große 
Probleme, eine genügend große Anzahl dieser Stammzellen genetisch zu modifizieren. Dies 
stellt eines der Hauptprobleme aktueller Gentherapie Studien dar. Des weiteren bedeutet der 
Gentransfer vieler therapeutischer Gene für die Zelle kein Vorteil in Bezug auf das 
Zellwachstum, nachdem sich die gen-modifizierten und transplantierten Zellen im Körper 
angesiedelt haben. Ein zusätzliches Selektions-Molekül könnte der Zelle einen 
Proliferationsvorteil verschaffen und so zur Expansion der wenigen gen-modifizierten Zellen 
führen. In der vorliegenden Arbeit wurden für eine selektive Expansion von genetisch 
modifizierten murinen hämatopoetischen Stammzellen zwei neue Selektionssysteme 
entwickelt. 
 
In der ersten Strategie wurde die Funktion des intrinsischen Transkriptionsfaktors HOXB4 
genutzt, der eine zentrale Rolle in Zellvermehrung und Differenzierung von hämatopoetischen 
Stammzellen spielt. Zunächst wurde ein bicistronisches gammaretrovirales Vektorkonstrukt, 
bestehend aus dem therapeutischen Gen gp91
phox und HOXB4, kloniert. Wachstumskurven 
haben gezeigt, dass die Überexpression dieses retroviralen Vektors in murinen 
hämatopoetischen Stammzellen ex vivo in einem signifikanten 3 bis 4-fachen Zellzahl-
Anstieg resultierte. Die FACS-Analyse dieser Zellen hat ergeben, dass, nach zwei Wochen 
unter Stimulation mit den Stammzellzytokinen IL-6, IL-3 und SCF, die Anzahl der gp91
phox 
Transgen exprimierenden Zellen ebenfalls 2 bis 3-fach anstieg. Des weiteren zeigt der auf 
Methylcellulose basierende Colony forming units (CFU) - Assay, dass die Anzahl der 
koloniebildenden Zellen nach einer Woche auf das zweifache anstieg, verglichen mit 
Kontroll-Vektor transduzierten Zellen. Dies belegt eine signifikante Anzahl an Stamm- 
und/oder Vorläuferzellen in der selektierten Zellpopulation. Allerdings haben diese 
selektionierten Zellen nicht die Fähigkeit, in bestrahlte, myeloablatierte Empfängermäuse 
transplantiert das hämatopoetische System wieder aufzubauen. Der prozentuale Anteil der 
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gp91
phox exprimierenden Zellen im Knochenmark dieser Mäuse betrug 8 bis 10 Wochen nach 
Transplantation deutlich weniger als 5%. Diese Ergebnisse belegen, dass gp91
phox Gen-
modifizierte hämatopoetische Stammzellen zwar ex vivo mittels Überexpression von HOXB4 
selektioniert und vermehrt werden können, in vivo aber keinen Vorteil gegenüber nicht 
modifizierten Zellen besitzen. Möglicherweise beruht diese Diskrepanz auf einem zu 
niedrigen Expressionslevel von HOXB4 in dem murinen in vivo - Modell. 
 
Die zweite Strategie beruht auf einem induzierbaren Dimerisierungs-System. Dazu wurden 
zunächst lentivirale Fusionskonstrukte, bestehend aus FKBP12 und einer Signaldomäne 
entweder des EGF-Rezeptors oder des Prolaktin-Rezeptors, kloniert. FKBP12, eine 
modifizierte Form des für das Immunsystem wichtigen FK506-binding Proteins, fungiert hier 
als induzierbare, durch Zugabe des kleinen Dimerisierungsmoleküls AP20187, anschaltbare 
Dimerisierungsdomäne. Dimerisierung von zwei Fusionprotein-Monomeren sollte die 
jeweilige Signaltransduktionskaskade anschalten. Die chemische Substanz AP20187 kann 
sowohl in Zellkultur als auch in in vivo Mausmodell-Experimenten ohne toxische 
Nebenwirkungen verwendet werden. Durch dieses System sollte die selektionierende 
Wirkung der Signaldomäne kontrollierbar an- und abschaltbar gemacht werden. Die Aktivität 
des Fusionsproteins ist also durch Zugabe und Wegnahme des chemischen Moleküls 
AP20187 steuerbar. Lentivirale Vektoren, die das EGFR-Konstrukt exprimierten, induzierten 
in BaF/3 Zellen deutlich gesteigertes Zellwachstum und führten zu einer kompletten Selektion 
gen-modifizierter Zellen innerhalb von 18 Tagen von 20% transduzierter auf 99% gp91
phox 
tragender Zellen. Diese induzierte Proliferation ließ sich jedoch nach Wegnahme des 
Moleküls AP20187 nicht abschalten. Auch nach 2 Wochen AP20187 Entzug teilen sich die 
Zellen mit fast ungeminderter Schnelligkeit weiter. Aufgrund dieser unkontrollierbaren und 
möglicherweise onkogenen Eigenschaften schien uns dieses Selektionsmodell als nicht 
anwendbar. Das weitere Konstrukt, welches anstelle der EGF-Rezeptor-Signaldomäne  die 
komplette intrazelluläre Phosphotyrosinkinase-Domäne des Prolaktin-Rezeptors enthält, 
verursachte nach AP20187 Stimulation ebenfalls eine deutliche Proliferationssteigerung und 
eine Selektion von 19% zu 96% gp91
phox positiver BaF/3 Zellen. Dieser Proliferationsvorteil 
konnte durch Entnahme des AP20187 wieder ausgeschaltet werden. Bereits 2 Tage nach 
Entzug der AP20187 Stimulation nimmt die Zellzahl deutlich ab. Nach diesem Test in BaF/3 
Zellen wurde ein neuer bicistronischer retroviraler Vektor kloniert, bestehend aus dem 
therapeutische Gen gp91
phox und dem selektionsvermittelndem Prolaktinrezeptor-
Fusionskonstrukt (PrlR-Konstrukt). Nach Überexpression des Konstruktes in transduzierten 
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murinen SC1 Zellen haben konfokale Lasermikroskopiestudien gezeigt, dass dieses PrlR-
Fusionsprotein, welches keine membranverankernden Sequenzen des Prolaktinrezeptors mehr 
besitzt, hauptsächlich im Zytoplasma der Zelle lokalisiert ist. Von den wesentlichen 
Prolaktin-aktivierten Signalwegen, dem Jak/Stat-Signalweg, dem Ras/Raf/MAP-Kinase-
Signalweg und dem Fyn/Sos/Vav-Signalweg, wurde der Jak/Stat-Signalweg untersucht, da er 
eine zentrale Rolle in der Hämatopoese spielt. Möglicherweise verursacht das aktivierte PrlR-
Konstrukt gesteigerte Proliferation und Stammzellselektion durch Aktivierung des STAT5-
Signalweges. Es wurde bereits in STAT5 Knockout Maus-Modellen gezeigt, dass STAT5 
eine wichtige Rolle für den Erhalt der hämatopoetische Stammzellen spielt. Die vorgelegten 
Ergebnisse zeigen, dass nach Expression des PrlR-Konstruktes und Stimulation mit AP20187 
ein gesteigerter STAT5-Phosphorylierungsstatus und eine vermehrte Bindung von STAT5 an  
Promotorsequenzen des STAT5 Zielgens ß-Casein in BaF/3 Zellen resultieren. AP20187 
induzierte Aktivität des PrlR-Konstruktes vermag auch gänzlich ohne IL-3 Stimulation 
STAT5 in vergleichbarer Stärke zu phophorylieren. In Kontroll-Vektor transduzierten Zellen 
waren hingegen kein Signal detektierbar. In dieser Zelllinie vermag die Expression des PrlR-
Konstruktes nach zwei Wochen AP20187 Stimulation die Proliferation um den Faktor 1.500 
bis 27.000 zu steigern. Simultan wurde in FACS- Analysen eine Zunahme der gp91
phox 
Expression von 3% auf 70% beobachtet. Dieser proliferationssteigernde Effekt ist, wie auch 
zuvor für das lentivirale Konstrukt beobachtet, nach Wegnahme des AP20187 reversibel, was 
eine wichtige Eigenschaft im Hinblick auf weitere Anwendungen, möglicherweise in 
humanen Studien, darstellt. Auf Proteinebene kann in den transduzierten BaF/3 Zellen nach 
Selektion mit AP20187 ein deutlich stärkeres Signal für das PrlR-Konstruktes nachgewiesen 
werden. Auch gen-modifizierte murine Stammzellen können unter AP20187 Stimulation ex 
vivo um den Faktor 20 bis 100 expandiert werden, ohne ihre Stammzelleigenschaften und die 
Fähigkeit zu allen Blutzellen der verschiedenen Reihen beizutragen, zu verlieren. In der 
FACS-Analyse wurde deutlich beobachtet, dass PrlR-Konstrukt modifizierte Stammzellen 
unter AP20187 Stimulation wichtige Stammzell-Oberflächenmarker wie Sca1 und c-kit über 
einen Zeitraum von 2 Wochen in hohen Levels exprimieren. Während in der Abwesenheit 
von AP20187 die Stammzellen in die Differenzierung eintreten, behalten AP20187 
stimulierte Zellen den Stammzellphänotyp bei. Hier nimmt die Zahl der Sca1- und c-kit-
positiven Zellen von 20% auf 70% und von 12% auf 40% zu. In Methylcellulose basierten 
Assays (CFU-Assays) können diese Stammzellen, ähnlich wie im Knochenmark, Kolonien 
von Vorläuferzellen aller Blutzellreihen bilden. Die selektionierten murinen Zellen wurden 
auf die Fähigkeit, Kolonien zu bilden, hin untersucht. Nach 14-tägiger Inkubation bildeten 
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AP20187 stimulierte PrlR-Konstrukt gen-modifizierte primäre Mause-Knochenmarkzellen 
deutlich mehr Kolonien aus. Während Kontrollzellen ohne AP20187 Stimulation lediglich 15 
Kolonien pro 1.000 ausplattierten Zellen bilden, liegt die Zahl unter AP20187 Stimulation bei 
75 Kolonien. In weiterführenden FACS-Analysen dieser Zellen wird ersichtlich, dass PrlR-
Konstrukt transduzierte Zellen unter AP20187 Stimulation dennoch zu einem kleinen Ausmaß 
in die verschiedenen Blutzell-Richtungen differenzieren können. Sie sind  zu einem geringen 
Teil positiv für die Oberflächenmarker Gr-1 (myeloische Zellreihe) mit 2,7%, B220 (B-
Zellen) mit 24% und CD3 (T-Zellen) mit 1,2%. Allerdings ist die Oberflächenmarker-
Expression deutlich schwächer als in PrlR-Konstrukt-transduzierten Zellen unter alleiniger 
Zytokin-Stimulation ohne AP20187. Der prozentuale Anteil der Gr-1, B220 und CD3 
positiven Zellen beträgt hier 30%, 70% und 17,8%. Vermutlich veranlassen die Expression 
des PrlR-Konstruktes und die gleichzeitige Aktivierung durch AP20187 die Stammzelle zur 
ständigen Selbsterneuerung. Simultan wird dabei die Differenzierung hin zu den 
verschiedenen Vorläuferzellen unterdrückt. Dies würde erklären, warum es zu einer 
Anreicherung der Stammzellpopulation kommt. Um ferner eine mögliche onkogene 
Eigenschaft der PrlR-Konstrukt-Aktivierung auszuschließen, wurden die zweiwöchig 
selektionierten Mause-Knochenmark-Zellen auf ihre Klonalität mit der Ligation-vermittelnde 
PCR (LM-PCR)-Methode hin untersucht. Es kann klar gezeigt werden, dass es innerhalb der 
selektionierten Zellen zahlreiche hervorgegangene Klone gibt und die retrovirale 
Vektorsequenz auf unterschiedlichen Chromosomen in verschiedenen Gen-Abschnitten 
integriert wurde. Diese polyklonale Situation spricht gegen eine mögliche onkogene Potenz 
des PrlR-Fusionsproteins. 
In anschließend durchgeführten Maus-Transplantationsexperimenten können ex vivo 
expandierte Knochenmarkzellen das Knochenmark von tödlich bestrahlten Mäusen wieder 
herstellen. Während die Kontroll-Mäuse, die mit unselektionierte Zellen transplantiert 
wurden, 12-14 Tage nach der Transplantation gestorben sind, haben Mäuse, die mit AP20187 
stimulierten Zellen transplantiert wurden, bis zum Abschluss der Versuche (8-10 Wochen 
nach Transplantation) überlebt. Dieses Ergebnis zeigt, dass es eine ausreichende Anzahl an 
frühen Stammzellen in der AP20187 stimulierten Zellenpopulation gab, um das Blutsystem 
der tödlich bestrahlten, myeloablatierten Empfängermäuse wiederherzustellen. Das 
Engraftment der Spenderzellen lag, gemessen in peripheren Blutzellen bei 5% bis 80%, bei 
1% bis 50% in Knochenmarkzellen und bei 5,5% bis 80% in Milz-Zellen. Allerdings war die 
transgene Experessionsrate, gemessen als gp91
phox  Expression in der FACS-Analyse, im 
Bereich von 5%, in allen Mäusen sehr niedrig, sogar in Mäusen mit hohem Entgraftment. 
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Möglicherweise stellt ein großer Anteil der ex vivo selektionierten Zellen zwar Sca1 positive 
Vorläuferzellen, aber keine frühen, pluripotenten Stammzellen, dar und geht durch 
Differenzierung verloren. Die Tatsachen, dass diese Mäuse überlebt haben und Gen-
modifizierte Zellen in Knochenmark, Milz wie auch peripherem Blut gefunden wurden, legt 
nahe, dass die ex vivo Selektion auch auf früher Stammzellebene stattgefunden haben muss. 
In genomischer DNA aus Zellen von Knochenmark, Milz und peripheren Blut der 
transplantierten Mäuse konnten mittels PCR Sequenzen von gp91
phox nachgewiesen werden. 
Somit tragen die gen-modifizierten murinen Stammzellen zur Rekonstitution der 
Hämatopoese bei. Weiterhin wurden von 5 Mäusen, transplantiert mit PrlR-Konstrukt 
transduzierten und ex vivo AP20187 selektioneierten Stammzellen, 10 Wochen nach 
Transplantation Knochenmarkzellen entnommen und wieder ex vivo unter AP20187 
Stimulation kultiviert. Knochenmarkzellen von 3 der 5 Mäuse konnten ex vivo wieder unter 
AP20187 Stimulation deutlich vermehrt und selektioniert werden. Der prozentuale Anteil der 
gp91
phox exprimierenden Zellen stieg von anfangs weniger 5% auf über 70%. In Gegensatz 
dazu haben die nur mit Zytokinen kultivierten Knochenmarkzellen nach zwei Wochen 
Kultivierung lediglich einen Anteil von 10% gp91
phox exprimierender Zellen. Diese ex vivo 
unter AP20187 wieder re-stimulierten versus unstimulierten Knochenmark-Zellen wurden 
ebenfalls in Methylzellulose-Assays auf Koloniebildung hin untersucht. AP20187 stimulierte 
Zellen von 2 Mäusen zeigten signifikant höhere Kolonie-Anzahlen als die der 
unselektionierten Zellen. Die PCR-Analysen mit Primer-Paaren sowohl für das gp91
phox 
Transgen als auch für das PrlR-Selektionsmolekühl zeigten, dass 100% der Kolonien aus 
AP20187 stimulierten Zellen für beide Gene starke Signale aufweisen. Dagegen ist dies bei 
lediglich 10% der Kolonien aus unselektionierten Zellen nachgewiesen worden.  
 
Zusammengefasst konnte gezeigt werden, dass selektive Expansion von murinen 
hämatopoetischen Stammzellen mit Hilfe von verschiedenen aktivierten Signalmolekülen  ex 
vivo erreicht werden kann. Als besonders vielversprechend hat sich das in seiner Aktivität 
regulierbare PrlR-Konstrukt erwiesen. Zum einen kann es nach erfolgter positiver Selektion 
abgeschalten werden, zum anderen können die Gen-modifizierten Stammzellen zur 
Rekonstitution der kompletten Hämatopoese beitragen. Weitere Versuche und 
Verbesserungen können die Sicherheit und Effizienz dieses System steigern. Insgesamt 
bekräftigen die gezeigten Ergebnisse die Strategie, Gen-modifizierte Zellen zusätzlich zum 
therapeutischen Gen mit einem Selektionsmolekül für eine ex vivo und/oder in vivo Selektion 
auszustatten.  
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  185   Zusammenfassung 
 
Selektive Expansion von gp91
phox Gen-modifizierten murinen 
hämatopoetischen Stammzellen 
 
Hämatopoetische Stammzellen stellen die entscheidenden Zielzellen für Gentherapie-
Strategien zur Behandlung von erworbenen und angeborenen Krankheiten des Blutsystems, 
wie zum Beispiel der X-chromosomal vererbten chronischen Granulomatose, dar. Diese 
Stammzellen können später in alle verschiedenen Blutzellreihen differenzieren und 
gleichzeitig den Stammzellpool erhalten (Selbsterneuerung). Allerdings bereitet es immer 
noch große Probleme, eine genügend große Anzahl dieser Stammzellen genetisch zu 
modifizieren. Des weiteren bedeutet der Gentransfer vieler therapeutischer Gene, nachdem 
die gen-modifizierten und transplantierten Zellen sich im Körper angesiedelt haben, für die 
Zelle kein Vorteil in Bezug auf das Zellwachstum. Ein zusätzliches Selektions-Molekül 
könnte der Zelle einen Proliferationsvorteil verschaffen und so zur Expansion der wenigen 
gen-modifizierten Zellen führen. In der vorliegenden Arbeit wurden für eine selektive 
Expansion von genetisch modifizierten murinen hämatopoetischen Stammzellen zwei neue 
Selektionssysteme entwickelt. 
In der ersten Strategie wurde die Funktion des intrinsischen Transkriptionsfaktors HOXB4 
genutzt, der eine zentrale Rolle in Zellvermehrung und Differenzierung von hämatopoetischen 
Stammzellen spielt. Die Überexpression eines bicistronischen gammaretroviralen Vektors, 
kodierend für das therapeutische Gen gp91
phox und HOXB4, in murinen hämatopoetischen 
Stammzellen ex vivo resultierte in einem signifikanten 3 bis 4-fachen Zellzahl-Anstieg. 
Zugleich stieg die Anzahl der gp91
phox Transgen exprimierenden Zellen 2 bis 3-fach an. CFU-
Assays zeigten eine signifikante Anzahl an Stamm- und/oder Vorläuferzellen in der HOXB4-
selektierten Zellpopulation. Allerdings haben diese selektionierten Zellen nicht die Fähigkeit, 
in bestrahlte, myeloablatierte Empfängermäuse transplantiert, das hämatopoetische System 
wieder aufzubauen. Diese Ergebnisse belegen, dass gp91
phox gen-modifizierte 
hämatopoetische Stammzellen zwar ex vivo mittels Überexpression von HOXB4 selektioniert 
und vermehrt werden können, in vivo aber keinen Vorteil gegenüber nicht modifizierten 
Zellen besitzen. Möglicherweise beruht diese Diskrepanz auf einem zu niedrigen 
Expressionslevel von HOXB4 in dem murinen in vivo - Modell. 
Die Zweite Strategie beruht auf einem induzierbaren Dimerisierungs-System. Dieses umfasst  
das therapeutische Gen gp91
phox und ein Fusionkonstrukt bestehend aus einer „Drug-
binding“-Domäne (FKBP12) und einer Signaldomäne entweder des EGF-Rezeptors oder des 
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Prolaktin-Rezeptors. Durch dieses System sollte die selektionierende Wirkung der 
Signaldomäne kontrollierbar an- und abschaltbar durch Zugabe bzw. Wegnahme des 
chemischen Moleküls AP20187 gemacht werden. Es hat sich gezeigt, dass die   
Überexpression von EGFR-lentiviraler Vektoren zu unkontrollierbaren Vermehrung von 
transduzierten  murinen BaF/3 Zellen führte. Deshalb wurde dieses Selektionsmodell als nicht 
anwendbar erachtet. Im Gegensatz dazu führte die Transduktion des PrlR-lentiviralen 
Konstruktes zu einer deutlichen Proliferationssteigerung der AP20187-behandlten BaF/3 
Zellen. Darüber hinaus konnte dieser Proliferationsvorteil durch Entnahme des AP20187 
wieder abgeschaltet werden. Weiterhin wurde ein neuer bizistronischer retroviraler Vektor, 
bestehend aus dem therapeutische Gen gp91
phox und dem selektionsvermittelndem PrlR-
Konstrukt, kloniert. Es wurde nachgewiesen, dass dieses PrlR-Fusionsprotein, welches keine 
membranverankernden Sequenzen des Prolaktinrezeptors mehr besitzt, hauptsächlich im 
Zytoplasma der Zelle lokalisiert ist. Möglicherweise verursacht das aktivierte PrlR-Konstrukt 
gesteigerte Proliferation und Stammzellselektion durch Aktivierung des STAT5-Signalweges. 
Die vorgelegten Ergebnisse zeigen, dass nach Expression des PrlR-Konstruktes und 
Stimulation mit AP20187 ein gesteigerter STAT5-Phosphorylierungsstatus und eine 
vermehrte Bindung von STAT5 an Promotorsequenzen des STAT5 Zielgens ß-Casein in 
BaF/3 Zellen resultieren. Auch Gen-modifizierte murine Stammzellen können unter AP20187 
Stimulation  ex vivo um den Faktor 20 bis 100 expandiert werden, ohne ihre 
Stammzelleigenschaften und die Fähigkeit, zu allen Blutzellen der verschiedenen Reihen 
beizutragen, zu verlieren. Um ferner eine mögliche onkogene Eigenschaft der PrlR-
Konstrukt-Aktivierung auszuschließen, wurde Polyklonalität der selektionierten Zellen durch 
LM-PCR-Methode nachgewiesen. In anschließend durchgeführten Maus-Transplantations-
experimenten konnten ex vivo expandierte Knochenmarkzellen das Knochenmark von tödlich 
bestrahlten Mäusen wiederherstellen. Diese Ergebnisse zeigen, dass eine ausreichende Anzahl 
an frühen Stammzellen in der AP20187 stimulierten Zellenpopulation vorhanden war, um das 
Blutsystem der tödlich bestrahlten, myeloablatierten Empfängermäuse wiederherzustellen. 
Die Tatsache, dass diese Mäuse überlebt haben und Gen-modifizierte Zellen in Knochenmark, 
Milz wie auch peripherem Blut gefunden wurden, legt nahe, dass die ex vivo Selektion auch 
auf früher Stammzellebene stattgefunden haben muss. Außerdem konnten 
Knochenmarkzellen von 3 der 5 Mäuse ex vivo wieder unter AP20187 Stimulation deutlich 
vermehrt und re-selektioniert werden. Somit tragen die Gen-modifizierten murinen 
Stammzellen zur Rekonstitution der Hämatopoese bei.  
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